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ABSTRACT 
Colorectal cancer (CRC) is the third most common cancer amongst South 
Koreans. Indirect evidence suggested CRC can be prevented, if not cured 
through the early detection and the subsequent removal of the precursor of CRC 
using colonoscopy (COL), the colorectal adenoma (polypectomy). The main aim 
of this thesis is to identify cost-effective strategies in the follow-up of people with 
confirmed colorectal adenomas (COL surveillance) for the prevention and early 
detection of colorectal cancer in the colorectal cancer screening (CRCS), 
National Health Insurance in Korea. To fulfil the main aim of this study, the 
following specific objectives were carried out: Estimation of adenoma recurrence 
post-polypectomy, identification of resources used in the CRCS and CRC 
treatment and the mapping of common pathways in the CRCS – this was 
achieved through a collaboration with a researcher in Korea by constructing a 
CRC cohort utilising the NHI data (2009-2012); Examination of the relevant cost-
effectiveness evidence of COL surveillance in individuals with adenomas – this 
was achieved by conducting a review of the cost-effectiveness evidence in the 
prevention and early detection of CRC; A literature review of the Health State 
Utility Values (HSUVs) was conducted to identify methodologically robust 
HSUVs with health states of interest, this information was used for economic 
evaluation of COL surveillance; Identification of cost-effective strategies for COL 
surveillance utilising the findings from previous objectives. Results from a de 
novo cost-utility analysis indicated that a 0LR3HR (a COL 3 years post- 
polypectomy for high-risk) strategy is expected to be the most cost-effective in 
the follow-up of people with confirmed adenomas in the CRCS, NHI. The findings 
of this study will inform the COL surveillance policy in the CRCS, NHI. 
Approaches taken in this study and the findings can provide a foundation for 
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further comparative policy analyses in other Asian countries where similar rates 
of CRC are observed. 
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1 INTRODUCTION, AIMS AND OBJECTIVES  
 
South Korea (hereafter, Korea) is mostly urban with more than 50% of 50,977,027 
Koreans concentrated in and around Seoul, the capital city [1]. The population is 
ethnically homogeneous with approximately 98% Koreans and life expectancy at 
birth was 81.3 years in 2010-2013 [2]. In 2015, 13.1% of the Korean population 
was 65 years and older and this proportion is projected to be 40.1% by 2060. 4 
in 10 Koreans are going to be 65 years and older by 2030 [2]. The population 
projection implies a rapidly increasing demand for health services, and increasing 
incidence and prevalence of age-related chronic conditions including CRC. 
In order to have a better understanding of the research questions posed, this 
chapter provides background information concerning an overview of the health 
care system in Korea with regard to financing and operational structure health 
care service delivery, and health service provider payment and overviews of 
national cancer screening programmes (NCSPs) and CRCS are in introduced. 
Also presented are the identified challenges and opportunities in the current 
CRCS followed by the aims and objectives of this thesis. 
 
1.1 Financing and operational structure  
The Ministry of Health and Welfare (MoHW) has overall responsibility for the 
National Health Insurance (NHI), it produces strategies and policies concerning 
the health system including financing, insurance, benefits systems, health care, 
traditional medicine, long-term care and oversees the operation of the NHI. 
National Health Insurance Service (NHIS), formerly known as National Health 
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Insurance Cooperation (NHIC), as a single insurer manages the NHI membership, 
collects NHI contributions, provides health insurance benefits, health check-ups 
and CRCS as part of the NCSP and provides access to a range of services and 
cost containment [3]. Health Insurance Review & Assessment (HIRA) is 
responsible for the reviews and assessments of health service fees [4-6]. The 
overview of NHIS associated with MoHW and HIRA is presented in Figure 1.1.  
MoHW and NHIS specify the list of benefit packages covered by NHI and 
determine the fee schedule for insured health services each year [5, 7].  Health 
care institutions (mainly hospitals and clinics) submit reimbursement requests to 
HIRA, and HIRA undertakes the evaluation of the health care service fee, sends 
the review results to NHIS and the requesters. HIRA also conducts the evaluation 
of the quality of health care institutions and adequacy of health care services [8].  
A new health technology assessment (HTA) committee was set up in 2007 where 
the new and existing technologies were reviewed for a reimbursement decision 
at HIRA. The National Evidence-based healthcare Collaborating Agency (NECA) 
leads the HTA research on pharmaceutical products, medical devices and 
diagnostics; however, the review and recommendations have been made by 
HIRA which supports the decision making process of the MoHW. There is an 
increase in demand for the reviews of health technologies in the NHI from the 
stakeholders with the rapidly rising health care expenditure and ageing 
population in Korea coupled with finite resources in the NHI, economic evaluation 
was introduced to aid the decision making process for pharmaceutical products 
in the NHI led by HIRA [9].  
However, HIRA’s guidelines for economic evaluation do not indicate a specific 
cost-effectiveness threshold but the implicit willingness-to-pay (WTP) is said to 
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be Korean Won (KRW) 30,000,000 per quality-adjusted life years (QALY) gained 
(This personal communication was in confidence and the person wishes to 
remain anonymous). The lack of a cost-effectiveness threshold communicated to 
stakeholders often creates myths and mistrust about the reimbursement 
decisions made by MoHW among stakeholders in Korea [10].  
There are three health security programmes – Medical Aid Programme (MAP), 
long-term care insurance (LTCI), and National Health Insurance (NHI) – in the 
Korean health care system [8]. MAP, introduced in 1979, is a government initiated 
medical benefit programme for low-income households unable to afford health 
care. About 2% of Koreans whose income falls below the minimum standard of 
living are covered by MAP [4, 6]. MAP coverage was recently expanded to those 
with rare, intractable and chronic diseases and to children up to 18 years of age 
[8, 11].  
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Figure 1.1 NHI at a glance (www.nhic.or.kr) 
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The LTCI was introduced in 2008 to provide support to individuals 65 years and 
older and their informal carers. Individuals aged 65 years and older with ‘age-
related’ physical and cognitive conditions were eligible for LTCI through an 
assessment of physical and cognitive function. Table 1.1 presents the population 
coverage of LTCI. Since its introduction, the service usage of LTCI went up from 
53% in 2008 to 99% in 2012 [6, 12].  
 
Table 1.1 LTCI population coverage 
 2008 2009 2010 2011 2012 
Number of people eligible for 
LTCI (% of the elderly) 
146,643 
(2.9%) 
268,000 
(5.2%) 
308,000 
(5.7%) 
318,000 
(5.8%) 
327,766 
(5.7%) 
Number of used services  
(% of those eligible for LTCI) 
78,000 
(53%) 
184,000 
(69%) 
245,000 
(79%) 
280,000 
(88%) 
318,266 
(99%) 
LTCI Long-term care insurance 
 
NHI, founded in 1977, is a public not-for-profit organisation and a single 
purchaser of health services in Korea [4, 6]. Strong political will coupled with rapid 
economic growth enabled an achievement of universal coverage following the 
initial patchy coverage of social health insurance in 1977, coverage was 
expanded to 98% of Korean by 1987 [5, 13]. As a compulsory social insurance, 
NHI is funded through beneficiaries’ contributions, government subsidies and 
substantial out-of-pocket (OOP) payments and is regulated by the MoHW and 
NHIS [5, 6]. The insured (health service users) pay a monthly premium 
contribution (NHI contribution) and a co-payment at the point of health service 
use as presented in Table 1.2 [4]. NHI contribution rates are determined by ability 
to pay: calculated using the beneficiaries’ wage (if employed, equally shared 
 
 
22 
 
between employers and employees) or self-reported income and property (if self-
employed) [4, 14].  
 
Table 1.2 NHI user charges and protection mechanisms for cancer patients   
(Unit: KRW; KRW 1,000=GBP 0.56) 
Health 
service 
Inpatient Outpatient 
Co-payment 
rates for 
service users 
In general, 20% of total 
treatment cost 
5% for registered cancer patients 
10% for registered rare/incurable 
disease 
Ceiling on OOP payment for 6 
months  
- for lower income* percentile 
50%, KRW 2 million  
- for middle income* percentile 
30%, KRW 3 million  
- for higher income* percentile 
20%, KRW 4 million 
Exemptions/ 
discounted 
rates 
Tertiary (specialist general) 
hospital - 60% of total treatment 
cost and other expenses 
General hospital - 45-50% 
(depending on administrative 
districts in rural areas: Eup, 
Myeon or Dong) of total care 
benefit expenses 
Pharmacy for outpatient 
prescriptions - 35-40% 
(depending on administrative 
districts: Eup/Myeon or Dong) of 
total care benefit expenses 
Hospital - 30% of total care 
benefit expenses 
Physicians’ clinic (primary 
care), public health centre - 
30% of total care benefit 
expenses 
Ceiling on OOP payment for 6 
months  
- for lower income* percentile 
50%, KRW 2 million  
- for middle income* percentile 
30%, KRW 3 million  
- for higher income* percentile 
20%, KRW 4 million 
Protection 
mechanisms 
Age 6 years and younger, fixed 
rate: 10% 
Reduced co-payment rate for 
severe diseases including 
cancer, chronic renal failure, 
severe burns, rare and incurable 
disease 
Pharmacy for outpatient 
prescriptions - 65 and older, 
fixed amount (KRW 1,200) if 
total < KRW 10,000 
Physicians’ clinic (primary care), 
public health centre - 65 and 
older, fixed amount (KRW 
1,200) if total < KRW 10,000 
Reduced co-payment rate for 
severe diseases including 
cancer, chronic renal failure, 
severe burns, rare and 
incurable disease 
*Calculation based on average monthly household income and assets; GBP Great 
British Pound; KRW Korean Won; NHI National Health Insurance; OOP out-of-pocket 
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CRCS and other NCSPs are funded through NHI and central and local 
government taxes, see Table 1.3 [15]. CRCS and other NCSPs are typically 
performed at outpatient clinics. For those whose income level falls within the top 
50 percentile, 90% of the fee for CRCS is paid by NHI and 10% by the insured. 
CRCS is offered free for those with income in the lowest 50 percentile, including 
MAP recipients [16].  
 
Table 1.3. Financing of CRCS  
  NHI insured (%) MAP beneficiaries (%) 
Central government 5 50 
Local governments 5 50 
NHIS 90 - 
CRCS colorectal cancer screening programme; MAP Medical Aid Programme; NHI 
National Health Insurance; NHIS National Health Insurance Service 
 
The estimated total spending on the NCSP in 2011 was KRW 4.45 trillion [13, 17]. 
Total health spending as a share of gross domestic product (GDP) was 7.5% in 
2012 below the Organisation for Economic Co-operation and Development 
(OECD) average of 9.3%, however health spending is increasing at a faster rate 
than GDP in Korea [18]. Since 2002, tobacco tax is used exclusively as additional 
funds for the NHI scheme to help keep the financial balance of the NHI [4]. NHIS 
revenues and expenditures from 2002 to 2012 are presented in Figure 1.2 [17].  
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Figure 1.2. Financial indicators of NHIS 2002-2012  
(Unit: KRW; KRW 1,000=GBP 0.56)
 
GBP Great British Pound; KRW Korean Won; NHIS National Health Insurance Service 
 
All Koreans are covered by either NHI or MAP, however, public expenditure as a 
proportion of total health expenditure is 55.3%, lower than the OECD average of 
72.5% indicating limited protection against catastrophic medical expense 
spending for the insured [18]. The government introduced financial benefits for 
cancer patients, including a recently introduced maximum cap on OOP payment 
by cancer patients in a given period to ease ongoing problems of limited benefit 
coverage and catastrophic expenses paid through OOP payments as presented 
in Table 1.2 [19, 20]. The reported total economic burden of CRC was KRW 3.1 
trillion in 2010 which makes CRC the third largest economic burden among all 
cancers in Korea [15, 21]. Therefore, the importance of preventive measures 
through screening and structured management of follow-up is considerable [19, 
20, 22].  
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1.2 Health care service delivery 
Approximately 90% of health care is delivered by private practitioners or 
organisations, in other words, in Korea most health care institutions are for-profit 
owned by physicians [7]. Primary care institutions include clinics, dental hospitals 
and general hospitals [4]. Secondary care services provide primary care and 
complex specialised services at clinics/hospitals. Forty-four tertiary care 
institutions (specialised general hospitals), typically university hospitals with high-
tech medical equipment, are located in the capital and metropolitan cities. For the 
purpose of cost control and financial sustainability of NHI patients, referrals to 
secondary care services made by primary care institutions are covered by NHI, 
otherwise, all expenses are borne by service users except for child birth and 
emergencies [4].  NHIS outlines the minimum coverage and minimum standards 
for health care services/facilities [8]. Guidelines for CRCS and other NCSPs are 
set out by the National Cancer Centre (NCC) which often conflict with various 
clinician-led guidelines for CRCS [8, 23, 24]. Individuals are dependent on the 
clinicians’ advice on the modality and intensity of CRCS, this results in frequent 
screening tests leading to OOP payments [25]. Some clinicians prefer to be 
cautious thus recommend additional tests outside the CRCS to individuals while 
it is also seen as the compensatory behaviour for the lower reimbursement fee 
for a COL by NHI. Under the strict control of the health service fee by the 
government, unnecessary use/delivery of health care services was reported 
among for-profit hospitals and clinics [7, 19, 26]. The deregulation of health care 
institutions in 1990 resulted in an increasing number of beds in hospitals for acute 
care service, this triggered the increasing number of health care institutions over 
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the period of 2000-2013 leading to fierce competition and marketing among 
health services providers. [4, 8].   
The characteristics of NHI include a short waiting time and a comprehensive NHI 
electronic data system [19, 27]. NHI service users have the right to choose their 
preferred health service providers, facilities, specialists and general practitioners 
within the health institutions for outpatient clinics visits, as well as the type of 
inpatient facilities (namely, ‘high class’ versus ‘normal class’ ward). Such 
privileged users’ choices come with additional premium charges. Furthermore, 
NHI service users often choose the methods of treatments for themselves to a 
certain degree, profoundly based on their clinicians’ advice which seem to have 
conflict of interests as clinicians have their own interests for their for-profit private 
practice [4, 6, 27]. Although primary care institutions (clinics, dental hospitals and 
general hospitals) are the recommended first point of contact in the NHI, 
secondary care institutions are preferred by service users. In theory, one should 
obtain a referral letter from a primary care physician in order to access secondary 
care, however, there is no such gate-keeping in the NHI. Service users tend to 
prefer a university hospital in a major city to a primary clinic despite the higher 
co-payment fee schedule. Some opt for opportunistic health screening outside 
the NCSPs in order to obtain a second opinion or ‘double-check’ their CRCS 
results with their preferred specialists/hospitals outside the CRCS [13]. The 
average number of visits to health care institutes per person per year was 
reported to be 11.8 compared with the OECD average of 6.8 in 2006 [4].  
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1.3 Health service provider payment  
Since 1977, outpatient based health care services, including colonoscopy, is 
primarily reimbursed through fee-for-service (FFS) methods, which is the 
payment of actual costs incurred per unit of service delivered retrospectively. This 
fee has been regulated by the government which has been a source of ongoing 
friction between the government and health care institutes [7]. Approximately, 90% 
of health services are delivered by private health institutes with a strong profit 
orientation under the FFS payment system [4]. Consequently, current FFS 
payments for outpatient based health service give health service providers strong 
financial incentives to deliver more units of complex interventions/service at 
outpatient clinics [7]. For example, a typical outpatient visit for a minor condition 
would entail 2-3 separate visits for the repeat prescriptions every other day [28]. 
Most health care service providers tend to add non-insured items (that are not 
regulated by the government) into tailored health screening packages, or provide 
a comprehensive CRCS package that includes both insured and non-insured 
items [28]. A number of comprehensive health screening packages are fiercely 
marketed, starting from KRW 626,000 for a basic package to an undisclosed 
amount for a ‘First Class’ package which includes providing over-night stays with 
a limousine and valet parking services in a designated unit [29, 30]. A COL 
procedure is reimbursed  at KRW 74,240 (average) in the CRCS [31]. On the 
other hand, the reimbursement of COL was reported to be 9 to 95 times higher in 
the US, 28 times higher in the UK and 7-14 times higher in Singapore than in the 
CRCS, Korea [32]. 
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In 2002 the diagnosis-related groups (DRGs) were introduced for the in-hospital 
stays for selected conditions/diseases in an attempt to control ‘overuse of medical 
services’ that are reimbursed through a FFS [7]. State-regulated medical fees 
have long been recognised as insufficient to cover the basic costs of health 
service, and insufficient to ensure the effectiveness, efficiency and financial 
sustainability of NHI [5, 7, 11, 32]. With the rapidly increasing health care 
expenditure the government attempts to move towards evidence-informed 
decision-making for health care, the use of economic evaluation of existing CRCS 
and NCSPs would provide a better alternative to stage-regulated cost control for 
the NHI in the long term [19, 26]. 
 
1.4 Colorectal adenomas and CRC in Korea 
Colorectal adenoma (henceforth, adenoma) is a type of polyp, abnormal tissue 
growth in the rectum or the colon which can be either pre-cancerous or benign 
[33]. Polyps can be categorised by the major histological groups of 
hyperplastic/metastatic polyp, neoplastic polyp and adenomastous polyp 
(adenoma). Adenomas are classified as tubular, villous or tubulovillous based on 
histological examinations [34, 35].  
Although CRCS and COL are widespread, the natural history of adenoma-
carcinoma remains understudied. COL surveillance studies indicate that 
individuals who did not have COL surveillance have a three- or fourfold risk of 
CRC compared to individuals who had COL surveillance [36]. Indirect and non-
randomised controlled trial evidence indicate the potential benefits of 
polypectomy (that is the removal of polyps and adenomas) associated with a 
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reduction in CRC mortality and morbidity [33]. Transformation of adenomas into 
carcinomas is said to take on average 10-15 years [37]. The number and 
estimated size of adenomas are positively related to the potential future risk of 
developing CRC [38]. People who have adenomas removed, require lifetime 
follow-up in order to detect and prevent CRC [39].  
Direct measurement of the adenoma-carcinoma sequence or the true incidence 
of adenomas is not possible due to ethical reasons and CRCS being widely 
offered to everyone in many countries. Therefore, consideration should be given 
to commissioning more research on the natural history of adenoma-carcinoma by 
utilising registry and reimbursement datasets in order to fill the gaps in the 
evidence-base, as not all questions can be answered through RCTs because of 
practical or ethical issues.  
In Korea, the incidence rate of adenomas is increasing in proportion to the rapid 
increase in CRC incidence [40]. In a retrospective COL study comprised of 2,435 
Korean adults, over the period of 1998-2004, the prevalence of polyps was 30.2%, 
of which 4.1% was advanced adenomas [41]. The prevalence of adenoma was 
33.3% and advance adenoma 2.2% in a prospective study of 2,307 asymptomatic 
average-risked Koreans in 2003-2004 (mean age ± SD, 52.1±11.6) [21]. For 
people at average risk (that is without a history of adenomas or a family history 
of CRC) the prevalence of adenomas was comparable to western countries [21, 
24, 42-45]. Age, male gender and a history of adenomas are known risk factors 
for CRC among Koreans [46, 47]. Individuals with previous adenomas are three 
times as likely to develop CRC as people with no previous colorectal adenomas 
[46]. Therefore, structured management of people with confirmed adenomas is 
priority in the current CRCS that aims to detect and prevent CRC.  
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Figure 1.3 Trends in selected cancer incidence rates, 1999-2012 in Korea [48] 
(Unit: per 100,000)
  
Cancer, in general, has been the primary cause of death over decades, with 1 in 
3 people dying of cancer in Korea [15]. CRC is the third most commonly 
diagnosed cancer in Korea and the reported CRC incidence in 2012 and mortality 
rates continued to rise every year whilst stomach and liver cancer incidence rates 
steadily decreased over the period of 1999-2012 as presented in Figure 1.3 [48]. 
A total of 28,988 new CRC cases and 8,135 deaths due to CRC were reported 
during the year of 2012. Of all cancer deaths in 2012, the main sites of cancers 
in the lung, liver, stomach, and colon and rectum accounted for about 61.6% of 
the total [18]. 
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Figure 1.4 Trends in the 5-year relative survival rates (%) by the year of cancer 
diagnosis in Korea, 1993-2012 [48, 49] 
 
 
The relative 5-year survival rate of CRC improved by 20% from 1993-1995 to 
2008-2012 in conjunction with the widened population coverage of CRCS and 
technological advances in treatments of CRC (see Figure 1.4) [48, 49].  
 
The direct cost of CRC was reported to be KRW 1.97 trillion (KRW 1,000=Great 
British Pound (GBP) 0.56) and the reported indirect cost was KRW 1.16 trillion in 
2010 [49]. Koreans perceive cancer as a serious threat, thus many people are 
willing to spend on opportunistic cancer screenings that is 100% not covered by 
the NHI. NHI spending on NCSP reached KRW 71,200,000,000 with the number 
 
 
32 
 
of providers of the screening programme rising to 8,514 in April 2011 [13]. Of the 
reported KRW 3.1 trillion total economic burden of CRC in 2010, KRW 1.97 trillion 
(63%) was spent on direct costs. Therefore, the true costs of CRC treatment 
would be much greater when OOPs are accounted for. The estimated economic 
burden of CRC was 3.122 trillion KRW in 2010 compared with 1.4 trillion KRW in 
2005 [49]. 
 
Table 1.4 Distribution of CRC stage at diagnosis in 2011 [50] 
CRC stage Definition Approximate 
proportion at 
CRC diagnosis 
(%) 
Number of 
patients 
diagnosed 
by stage of 
CRC 
Stage I Cancer localised within the bowel 
wall 
22.2 4,073 
Stage II Cancer penetrating the bowel 
wall 
28.6 5,237 
Stage III Cancer in lymph nodes 35.8 6,571 
Stage IV Distant metastases (commonly in 
the liver) 
11.8 2,169 
Unknown Disease stage not recorded 1.4 260 
CRC colorectal cancer 
 
Of the estimated proportions of patients with different stages of CRC, 
approximately 47% of CRC was detected at stages III and IV in 2011 as 
presented in Table 1.4 [50]. A total of 73, 759 deaths were caused by all cancers 
in Korea in 2012 accounting for 27.6% of all deaths, and, in this year, the age-
standardised CRC mortality rate was 9.7 per 100,000 [48]. Localised CRC (stage 
I) was treatable with a 5-year relative survival of 91% when the disease was 
detected and treated in the period between 2007-2011 [15].  
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CRC progresses slowly from adenomas which gives a window of opportunity to 
have the precursor of CRC removed or CRC detected at an earlier stage to 
improve prognosis through COL surveillance post-polypectomy (henceforward 
COL surveillance) and CRCS [38, 51]. CRC causes significant economic burden 
and the opportunity cost of COL surveillance within the current CRCS needs to 
be estimated in order to achieve the aim of CRCS: the prevention and early 
detection of CRC in the NHI, Korea [46, 49, 52, 53].  
 
1.5 NCSPs and CRCS 
The great socioeconomic impact of cancer, including CRC, prompted the rapidly 
introduced policy initiative, the NCSP in 1998 [15].  
Table 1.5 Establishment and expansion of NCSP  
 NCSP coverage  Offered NCSPs Comments 
 MAP NHI 
1999 Yes No Stomach, breast, 
cervical cancers 
 
2002 Yes *Low 20% Stomach, breast, 
cervical cancers 
Coverage expanded 
2003 Yes *Low 30% Stomach, breast, 
cervical, liver cancers 
Liver cancer added to 
NCSPs, coverage 
expanded 
2004 Yes Limited to 
*low 30% 
Stomach, breast, 
cervical, liver and 
colorectal cancers 
CRCS added to NCSPs 
2005 Yes Limited to 
*low 50% 
Stomach, breast, 
cervical, liver and 
colorectal cancers 
Coverage expanded to 
the 50% income bracket 
*Low 20-50% NHI contribution rates are calculated based on reported household income 
and assets every year for the following year’s contribution rates. For the household 
income that falls lower than 20-50% of all the NHI insured, NCSPs are offered for free in 
the following year; CRCS colorectal cancer screening programme; MAP Medical Aid 
Programme; NCSP National Cancer Screening Programme; NHI National Health 
Insurance  
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The aim of the NCSP is to promote the awareness of cancer prevention and offer 
free screening to those unable to afford opportunistic screening or who were not 
screened during regular occupation-based health checks [13]. 
In 2004 CRCS was added to the existing NCSPs (cervical, breast, stomach and 
liver) that initially offered a faecal occult blood test (FOBT) to MAP beneficiaries, 
then gradually expanded to the general population by 2007/2008 as summarised 
in Tables 1.5 and 1.6 [8]. 
 
Table 1.6 Current National Cancer Screening Programmes  
 Target 
population 
Modalities 
reimbursed by 
NHI 
Interval Started 
year 
Percentage 
paid by  
(NHIS/ 
service 
users) 
Breast 
Cancer 
Age 40 and 
older female  
Mammography 
and breast 
clinical 
examination  
2 yearly 1999 (90/10) 
Stomach 
cancer 
Age 40 and 
older  
Gastric contrast 
x-ray or gastric 
endoscopy 
2 yearly 1999 (90/10) 
Cervical 
cancer 
Age 30 and 
above female  
Cervical smear 2 yearly 1999 (90/10) then 
(100/0) 
Liver 
cancer 
Age 40 and 
above with 
confirmed  
liver cirrhosis 
or Hepatitis B 
or C positive 
Liver ultrasound 
sonogram and 
plasma alpha-
feto protein test 
6 
months 
2008 (90/10) 
Colorectal 
cancer 
Age 50 and 
above 
COL or DCBE if 
FOBT positive  
yearly 2004 (90/10) 
COL colonoscopy; DCBE double-contrast barium enema; FOBT faecal occult blood test; 
NHI National Health Insurance; NHIS National Health Insurance Service  
 
Following the establishment and expansion of NCSPs as the main focus of the 
1st 10-year Plan for National Cancer Control (NCC) (1996-2005), the 2nd 10-year 
Plan for NCC (2006-2015) aimed to reduce the incidence of cancer and cancer 
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mortality through systematic cancer management, follow-up strategies and 
management of cancer risks [54]. The MoHW announced targets for 5-year 
cancer survival increased from 54% to 67% by 2015 in the 2nd Cancer Control 
Plan. The main objectives of the 2nd Plan included raising the level of awareness 
in the prevention of cancer, increasing the level of compliance in cancer 
screening and encouraging innovation in cancer treatment. Guaranteed access 
to the NCSPs and improved compliance rates remain as priorities [54]. Areas for 
further evaluation including economic evaluation or the structured management 
of follow-up strategies of the NCSPs remain under-studied [11, 52, 55].  
 
The main aim of CRCS is to detect and remove the precursor of CRC, 
adenoma(s), to interrupt the adenoma-carcinoma sequence. Figure 1.5 outlines 
the process (in black) and the flow of funding (in blue) of CRCS. The centrally 
allocated funding for CRCS to each city or region is deposited at the NHI, and 
NHI pays for the CRCS service to the health service providers [56]. Each year a 
database of individuals eligible for CRCS is generated from the central database 
at the NHI, this information is shared with NCC. These eligible individuals receive 
an invitation to annual FOBT from NHI. FOBT is offered to individuals 50 years 
and older and the results are notified to participants within 15 days. For those 
with positive FOBT results, further information on a recommended follow-up test 
is included in the notification.  
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Figure 1.5 Process and management of CRCS  
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Stool tests are used to detect blood from adenoma/polyps or cancerous tumours. 
Guaiac FOBT (gFOBT) or immunochemical FOBT (iFOBT) are recommended as 
a primary CRCS owing to their relatively low cost and convenient administration 
which allow a wider population to be reached. iFOBT is widely used in the current 
CRCS [31, 40]. Individuals eligible for CRCS (age 50 and older) are sent a stool 
test kit with a return address by post, with instructions on how to collect and return 
the stool sample. Results are usually notified to individuals with advice of further 
testing by either COL or double-contrast barium enema (DCBE) for those with a 
positive FOBT result [15]. 
COL enables the examination of the lining of the whole large bowel using a long 
flexible tube with a light and a camera at the end of the tube. This method is 
commonly used as a ‘gold standard’ in CRCS because it provides a full view of 
the colon and rectum with the option of the removal of foreign benign or 
cancerous bodies during the procedure [57]. COL is an invasive procedure and 
has rare but potentially fatal complications such as perforation and bleeding from 
the removal of adenomas. COL requires a thorough bowel preparation 24-48 
hours prior to the procedure and may require light sedation during the procedure 
[15].  
Sigmoidoscopy (SIG), an invasive technique visualising the distal colon, alone or 
with the combination with DCBE is reimbursed by NHIS for people with positive 
FOBT results. In contrast, SIG is relatively under-utilised in the clinical practice 
because of the need for further COL in case of positive findings such as 
neoplasms or polyps [40]. 
DCBE is less invasive than COL, but DCBE is not as sensitive as COL in 
detecting adenomas that are smaller than 9 mm in diameter [40, 58-60]. As 
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evidence suggests DCBE is less effective than COL in detecting adenomas, 
DCBE is not recommended in CRCS [24, 40]. 
Computerised tomography colonography (CTC) is an advanced diagnostic 
imaging technology. CTC requires pre-test bowel preparations by the patient 
ingesting radiopaque contrast media and colonic distension which causes 
discomfort post-procedure [40]. CTC usually takes about 10 minutes in the 
scanner with no sedation therefore no additional resources for recovery are 
required post-procedure. In the event of positive findings from CTC, patients 
require a COL for further investigation. Some expressed concerns on the 
potential harms caused from additional exposure to low-dose radiation from CTC, 
but specialist radiologist-led studies reported that the minimum level of health 
effects from low-dose radiation exposure is outweighed by the greater potential 
benefits gained [61-63]. Clinical effectiveness of CTC in CRCS remains uncertain 
[63, 64]. CTC is currently outside CRCS thus is paid predominantly by OOP or 
3rd party payment.  
 
1.6 Challenges and opportunities in CRCS and COL 
surveillance 
Early detection and prevention of CRC are feasible through CRCS and COL 
surveillance due to the slow transformation of adenomatous polyps into 
carcinoma, and the relatively long sojourn time before presenting symptoms [38, 
39]. Existing guidance recommends post-screening management through 
planned follow-up COL in order to prevent interval cancers and CRC related 
mortality in several countries [39, 51, 59, 65, 66]. The economic burden of CRC 
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is considerable in line with the increasing CRC incidence among the aging 
Korean population [49]. The need for Korean evidence on the cost-effectiveness 
of COL surveillance based on Korean evidence has not been addressed [67].  
 
Current CRCS policy ends with the results notified to individuals by post within 
15 days of screening, and as a follow-up measure telephone advice and/or 
individual visits are offered to those with positive results depending on available 
resources [15]. Individuals with positive FOBT results are given full responsibility 
for deciding to seek further medical opinion and/or help. There is no formal 
network or data system where continuity of care could be provided related to 
clinical conditions identified through CRCS [13]. Clear guidance and structured 
management of positive FOBT results is lacking within the existing CRCS [68]. 
Significant resources have been committed to the CRCS over a decade, yet there 
are no recommendations on the structured management of people with identified 
risk of developing CRC or economic evaluation of structured COL surveillance 
[26]. An individual with CRC diagnosis or adenomas continues with an annual 
invitation of FOBT within the current CRCS in the NHI (see Figure 1.6). Identified 
gaps related to COL follow-up strategies (marked with a red-dotted line) and the 
focus of economic evaluation of this thesis (marked with the green-dotted circle) 
in the existing CRCS are presented in Figure 1.7. 
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Figure 1.6 Outline of current CRCS in NHI, Korea 
 
  
START 
CRCS – FOBT invitation 
FOBT 
Follow-up COL or  
DCBE then COL 
Post-polypectomy: 
return to START for 
next CRCS 
COL colonoscopy; CRC colorectal cancer; CRCS colorectal cancer screening; DCBE 
double-contrast barium enema; FOBT faecal occult blood test 
Negative: return to 
START for next CRCS 
Positive 
Suspected or confirmed 
CRC:  return to START 
for next CRCS 
Polyps/adenomas 
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Figure 1.7 Gaps in the current CRCS NHI 
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Correlation between the level of CRC disease stage at diagnosis and survival 
indicates that early detection and prevention of CRC through timely screening 
and COL surveillance of those at a high risk of developing the recurrent precursor 
of CRC, can reduce CRC mortality and morbidity [33, 40]. The number of 
adenomas is said to be positively correlated with the increased risk of advanced 
neoplasia [69].  
Index COL, defined as the most recent COL performed by an experienced 
specialist colonoscopist, is performed in order to remove detected 
polyps/adenomas and to establish risk status [24, 67, 69, 70]. Adenomas are 
categorised by size, type (pathology test results) and the number present [40, 67]. 
Based on the findings from an index COL, people with 3 or more adenomas, any 
adenoma > 10 mm, or any tubulovillous or villous adenoma(s), any adenoma(s) 
with high-grade dysplasia or any serrated polyp(s) larger than 10 mm are 
considered to be at a high risk of developing subsequent advanced adenomas 
and/or CRC, therefore COL surveillance is recommended 3 years after 
polypectomy in the first COL surveillance guideline in Korea [40].  
Clinicians/practitioners recommended a follow-up COL according to the risk 
stratification based on the findings from the index COL [24, 40]. Repeated COLs 
within the CRCS or within NHI are reimbursed by current NHIS regardless of the 
interval between COLs because there is no clear guideline or ceiling set within 
the current reimbursement for CRCS. A COL performed outside CRCS in the NHI 
is defined as health care service utilisation, HCSU). In addition, each 
reimbursement claim of COL is treated as a separate episode in the current 
reimbursement and review of CRCS. Multi-society guidelines recommend COL 
surveillance 3 years after the index COL in the HR group and 5 years in the LR 
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group [24]. COL surveillance at a 3 year interval is recommended after removal 
of adenomas smaller than 10 mm, 1 year after removal of adenomas greater than 
10 mm or more than one [15]. However, such recommendations lack the details. 
What should be done if there are 2 or 3 consecutive negative findings from COL 
surveillance in the HR group? Or will the assigned risk status based on the index 
COL remain unchanged? Atkins and Saunders [39] outlined the required steps of 
down-grading and ceasing COL surveillance post-polypectomy.  
Notably, more than 50% of practitioners did not follow recommended COL 
surveillance or chose different guidelines in a survey [71, 72]. This suggests that 
the state-regulated reimbursement of COL is not agreed with 
clinicians/practitioners, but presenting clear costs and consequences of COL 
surveillance in the form of economic evaluation would probably facilitate 
convincing stakeholders [73]. Koreans are exposed to opportunistic screening, 
and multiple national health checks and screening programmes which may 
provide further opportunities of having COL repeated. Repeated and duplicated 
COL become a barrier to establishing an accurate index COL that acts as the 
basis of risk stratification for COL surveillance [24, 74]. There is a number of 
CRCS guidelines but the COL surveillance guidelines remain limited. 
Discrepancies between CRCS guidelines and the implementation of guidelines 
were widespread [75].  CRCS programmes are offered in the USA, Canada, 
Australia, Europe, Japan and Korea, but COL surveillance is only recommended 
in the NHS UK and in the US [76].  
Table 1.7 summarises the discrepancies in the risk stratifications of COL findings 
and the recommendations for COL surveillance post-polypectomy in CRCS, NHI 
in Korea. 
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Table 1.7 Discrepancies in the risk stratification of adenomas and identified gaps 
in the recommendations and current practice 
Low risk High risk  COL interval (year) 
post-polypectomy  
References 
Without any 
high-risk 
findings at 
index COL 
 
3 or more adenomas or any 
adenoma larger than 10 mm 
or any tubulovillous  or villous 
adenoma or any adenoma 
with HGD or any serrated 
polyps larger than 10 mm  
5LR3HR  
(5 years for LR, 3 
years for HR) 
Yang (2012) 
[24] 
Hong (2012) 
[67] 
 
Not specified In patients with alarming 
symptoms or with a high risk 
of interval cancer 
5LR 
HR ≤5 (less than 5 
years) 
Lee BI (2012) 
[40] 
Any 
adenomas 
without high 
risk  
3 or more adenomas or 
adenomas > 10 mm or HGD 
or any tubulovillous or villous 
adenoma 
1HR Jung (2012) 
[77] 
6 mm tubular 
adenoma or 
two 6 mm 
tubular 
adenomas 
12 mm tubular adenoma with 
HGD 
12 mm tubulovillous 
adenoma 
LR ≤1 (less than 1 
year) 
3LR; 5LR 
HR≤1; 3HR; 5HR 
Sohn (2014) 
[72] 
COL colonoscopy; HGD high-grade dysplasia; HR high risk; LR low risk 
 
In any screening programme potential harm should be considered in order to 
minimise unintended consequences such as complications of screening 
interventions while maximising health benefits given the limited resource [25]. 
Duplication of screening activities within CRCS and NHI need to be reduced to 
improve cost-effective use of finite health care resources [13]. User access to 
health care institutions has been the ongoing focus of the cancer control plan and 
expansion of subsidies for cancer treatments has resulted in steadily increasing 
resource use in the NHI [7, 19].   
 
A better understanding of and structured management of CRCS have been 
suggested in order to improve the efficiency [68]. The estimated proportion of the 
Korean population needing COL will increase from 29% in 2010 to and 60% in 
 
 
45 
 
 
 
2050 [1]. Thus, careful forward planning for COL as part of CRCS is vital, training 
for the relevant specialists, investments for appropriate level of facilities within the 
budget constraints are examples that would be of high priority in Korea. Kim et al. 
(2014) suggested specific indicators should be developed for the future 
evaluation of CRCS including cost per CRC detected and cost per CRCS per 
person [52]. 
The benefits of CRCS can be accrued over a long period due to the long lead-
time of adenoma-carcinoma, therefore CRCS should be linked to CRC treatment 
in order to get a fuller picture of CRCS [78, 79]. The feasibility and sustainability 
of NHI against the return of investment in health terms need to be reviewed 
without any delay [11, 13]. Although spending on CRCS has been increasing over 
the years, the current CRCS lacks evidence regarding the cost-effectiveness of 
COL surveillance, which could not only minimise clinical practice variations but 
also promote efficient use of scarce resources in the NHI Korea. In addition, 
unnecessary COL would be discouraged thus promoting best clinical practice 
among practitioners [52, 53, 80-82]. Furthermore, COL following a positive FOBT 
results continues to be reimbursed without specific restriction/caps by the NHI. 
Clinicians/practitioners recommend COL at different intervals with different 
starting ages [40, 64, 80]. The importance of COL surveillance is further 
emphasised through meta-analyses of evidence and the final decision on the 
COL surveillance interval is said to be best made by clinicians [40].  
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1.7 Conclusion 
The NHI is characterised by the state-regulated fees for health services, 
predominantly for-profit health service providers and the co-payments paid for by 
service users in the NHI. NHIS collects data related to all health checks, NCSPs 
including CRCS of the population in Korea. Although a comprehensive electronic 
data system pools demographic and health data in the NHI, this wealth of data is 
not being utilised to inform the decision making process of CRCS to make the 
best use of resources in the NHI, Korea. Current clinical practice of CRCS is 
difficult to map out due to various health care service delivery and reimbursement 
systems including NHI and 3rd party private insurance. With the rapidly increasing 
health care expenditure, the government attempts to move towards evidence-
informed decision-making for health care, thus the use of economic evaluation of 
existing CRCS and NCSPs would provide a better alternative to state-regulated 
cost control for the NHI in the long term [9, 83].  
Recommended guidance and clinicians own practice on the follow-up COL vary 
markedly in the intervals of COL in the current CRCS [24, 67, 72, 74, 77]. 
Furthermore, there is no cost-effectiveness evidence of COL surveillance among 
people with confirmed colorectal adenomas in the CRCS, NHI in Korea. Given 
the increasing economic burden of CRC and limited resources for the provision 
of COL surveillance, examining the cost-effective strategies should be a logical 
next step. Therefore,  cost-effective strategies for COL surveillance will be 
identified through an economic analysis in order to promote cost-effective use of 
resources in the early detection and prevention of CRC in CRCS NHI [68]. 
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1.8 Aims and objectives 
This study aims to identify the most cost-effective strategies, based on the best 
available evidence, in the COL surveillance for individuals who had confirmed 
adenomas in the prevention and early detection of CRC in the CRCS, NHI. During 
the course of this research a rare opportunity arose to form a collaboration with 
a Korean researcher, this enabled access to NHI data. The specific objectives to 
fulfil the main aim of this study are:  
1) Identification of resources used in CRCS and CRC treatment, and mapping of 
the current clinical practice and common CRCS pathways in the prevention and 
early detection of CRC and the estimation of adenoma recurrence rates post-
polypectomy in the CRCS, NHI – achieved by collaboration with a researcher 
from Korea, a cohort dataset utilising NHI reimbursement data was constructed.  
2) Review of the relevant cost-effectiveness evidence of COL surveillance in 
people with colorectal adenomas – achieved by conducting a literature review of 
published cost-effectiveness evidence in the prevention and early detection of 
CRC. 
3) Estimation of health outcomes relevant to CRCS in order to populate economic 
model(s)- achieved by conducting a literature review of relevant HSUVs for 
economic evaluation.  
4) Identification of cost-effective strategies for COL surveillance for the prevention 
and early detection of CRC – achieved by developing an economic model and 
identifying the most cost-effective strategy of COL surveillance by utilising findings 
from objectives 1) to 3).  
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2 SHORT-TERM ANALYSIS OF COLORECTAL 
CANCER SCREENING IN NHI, KOREA, 2009-2012 
 
 
2.1 Preamble to Research Paper I  
Chapter 2 contains the identification of resources used in CRCS and CRC 
treatment, and a mapping of current clinical practice and common CRCS 
pathways in the prevention and early detection of CRC in the NHI. As highlighted 
in the previous chapter, although CRCS has been offered in Korea since 2004, 
there is no evidence on the current practice, average costs of CRCS, the 
breakdown of COL surveillance costs, the average costs of CRC diagnosis and 
the treatment of CRC in the NHI. A unique opportunity to collaborate with a 
Korean researcher enabled the establishment of a Korean CRC cohort, utilising 
NHI reimbursement data. In this research paper the current clinical practice in the 
CRCS is mapped out based on NHI data by using indicators for the CRCS 
evaluation including the cost per CRC detected using COL and the average cost 
of CRC treatment [52]. Subgroup analyses were carried out to estimate the 
adenoma recurrence rates post-polypectomy and the CRC-free survival time 
among people with low-risk (LR) or high-risk (HR) of developing CRC who 
required follow-up COL post-polypectomy (COL surveillance). Also reported were 
the gaps in CRCS reporting, the variations of CRC staging information collected 
by different institutes/organisations and the risk stratification through the analysis 
of the CRC cohort. 
 
 
49 
 
 
 
Findings from the CRC cohort analysis including the average costs of CRCS, the 
average costs of CRC diagnosis and the treatment of CRC, and a further 
breakdown of COL surveillance costs, are used to estimate expected costs and 
benefits of COL surveillance in CRCS, NHI (Chapter 5). 
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2.2 Research Paper I Short-term analysis of colorectal cancer 
screening in South Korea, 2009-2012 
 
2.2.1 Abstract 
As a single purchaser of health services in Korea, the National Health Insurance 
Service (NHIS) manages the health care service costs and the reimbursement of 
colorectal cancer screening (CRCS) in the National Health Insurance (NHI), 
Korea. There has been only limited evaluation of the costs and benefits of CRCS 
despite the considerable resources committed for over a decade. The aim of this 
study is to provide information for economic evaluation of CRCS. Specific 
objectives include the identification of common pathways in CRCS with relevant 
resources used in the NHI. A retrospective cohort study was constructed by 
utilising reimbursement data from the NHI, the single public purchaser of health 
services, 2009-2012. Four CRCS pathways were mapped including CRCS only, 
HSCU (health care service utilisation within the NHI) only, non-compliant to 
CRCS (NC) and CRCS combined with HCSU. The highest average cost of CRC 
detection was in the CRCS only group and lowest in the NC group. The highest 
average cost of CRC treatment was in the NC group. Estimates of adenoma 
recurrence rates post-polypectomy were derived from the subgroup analysis, 
which can inform the future economic evaluation. This short-term analysis is the 
first study utilising the detailed NHI data including costs and benefits of CRCS 
and the utilisation of relevant health care services at a Korean population level 
from the NHI perspective. From our knowledge, this short-term analysis of CRCS 
is the first study to highlight differences between CRCS reimbursement policy 
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and the current clinical practice by utilising the detailed NHI data at a population 
level in Korea.  
Further studies concerning risk-based CRC-free survival post-polypectomy 
utilising CRCS and NHI data are warranted to inform decision making in the 
CRCS NHI. 
 
KEY WORDS 
Colorectal cancer; screening; surveillance; colonoscopy; adenoma 
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2.2.2 Introduction 
CRC is the third most common cancer in Korea [48]. The National Health 
Insurance (NHI) is the single public purchaser of health services covering 97.1% 
of the population [17]. The remaining 2.9% of Koreans with below minimum 
income levels are covered by the Medical Aid Programme (MAP). NHI and MAP 
are operationalised by the National Health Insurance Service (NHIS) [17].  
CRC screening (CRCS) as part of the National Cancer Screening Programmes 
(NCSP) was first implemented in 2004 for MAP beneficiaries and was gradually 
rolled out to Koreans aged 50 years and older [8]. Previously, people who were 
50 years and older were invited to a biennial FOBT [8, 52]. Colonoscopy (COL) 
or double-contrast barium enema (DCBE) followed by COL are recommended 
follow-up tests after a positive FOBT result [31]. However, evidence indicated that 
FOBT and COL are not always carried out as per CRCS policy and there are 
many opportunistic screening programmes outside CRCS that are not insured by 
NHI [13, 84].  
Despite the huge amount of efforts and resources being spent on CRCS over a 
decade, the need for structured follow-up strategies from CRCS remains unmet 
despite gaps reported by several studies [11, 52, 80, 81]. Clinicians and experts 
have highlighted the costs per CRC detected and costs per early CRC detected 
as priorities in the evaluation of CRCS [52]. 
The cost of COL surveillance, of diagnosis and of treatment of CRC are crucial 
parameters to inform an economic evaluation; however, such information is not 
readily available in the CRCS and NHI. The aim of this study was to elaborate 
and exemplify a pragmatic approach to estimate costs of COL surveillance, 
diagnosis and treatment of CRC based on reimbursement data from the NHI, 
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2009-2012 CRC cohort. The findings from this analysis would provide evidence 
for the cost-utility analysis of COL surveillance for people with confirmed 
colorectal adenomas in the CRCS, from the NHI perspective in Korea (Chapter 
5). The main objectives were to: 1) provide costing information of CRCS and COL 
surveillance and the costs of CRC diagnosis and CRC treatments by utilising 
CRCS reimbursement data in the NHI; 2) to map common pathways in CRCS.  
The primary purpose of this short-term analysis was to provide costing 
information for the COL surveillance in this thesis and future economic evaluation 
of CRCS by utilising CRCS reimbursement data in the NHI. In addition, this study 
aimed to map out common pathways in CRCS with relevant resources by utilising 
reimbursement NHI data at a Korean population level for the period 2009-2012. 
Based on  the pathways identified, the secondary endpoints included CRCS 
compliance rates and the estimation of the total costs of diagnosis and treatment 
of CRC [52]. People with confirmed colorectal adenomas who required COL 
surveillance were further considered in a subgroup analysis in order to estimate 
the adenoma recurrence rates post-polypectomy according to risk status and 
CRC-free survival post-polypectomy for the economic evaluation of COL 
surveillance in the CRCS.  
 
2.2.3 Methods 
Ethics approval 
This study and the waiver of the requirement to obtain informed consent were 
approved by the Institutional Review Board (IRB) of Seoul National University 
Bundang Hospital (IRB No. X-1411/276-902, see Appendix Figure A2.1).   
 
 
56 
 
 
 
CRC cohort data and NHIS routine data collection 
The CRC cohort comprised 6,658,551 Korean individuals aged 50 and over with 
no previous history of CRC or current CRC on 1 January 2009. People with 
previous or current CRC were identified and excluded through tracking CRC 
related ICD-10 codes and Special Cancer Fund V193 [85]. Index COL, defined 
as the most recent COL performed by an experienced specialist colonoscopist, 
was performed as part of follow-up testing for those with a positive FOBT result 
in the CRCS. In addition, people who had a COL procedure in 2007-2008 were 
also excluded from the CRC cohort 2009-2012. NHIS routinely collects data 
associated with NCSPs. NHIS collects NHI contributions (premiums) based on 
reported household income levels [31]. NHI pays health care service providers 
based on the submitted reimbursement forms. Follow-up COL results are 
recorded as normal, inflammatory or hyperplastic polyps, low grade 
adenoma/dysplasia, high grade adenoma/dysplasia, suspected CRC or CRC 
(see Appendix Figure A2.2) [8]. These routinely collected data and CRCS results 
were anonymised and linked with the relevant health care service utilisation 
(HCSU) for the NHIS 2009-2012 (see Figure 2.1). 
 
Direct costs were considered including NHI reimbursed items, co-payments 
made by service users for the NHI insured items and other health service usages 
for non-CRC related conditions in the NHI. The analysis of cost was from the best 
use of health care resources among different COL surveillance strategies in the 
CRCS, Korea. Direct costs including NHI reimbursements, co-payments made by 
service users for NHI insured items in all mapped pathways including HCSU and 
NC from the perspective of providing health care services. CRCS costs included 
the costs of COL and pathology in the case of adenoma. CRC diagnostic costs 
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were costs incurred from the date of ‘suspected CRC’ to the day before the first 
CRC treatment. Active CRC treatment costs included outpatient clinic visits, 
hospital admission episodes and visits to the emergency department. CRC 
treatment costs were calculated from the first day of CRC treatment to 6 months 
including any health care service utilised by individuals with CRC diagnosis. CRC 
follow-up costs included the costs of any health care service utilised by individuals 
with a CRC diagnosis in the period from day 1 after the CRC treatment to 6 
months.  
 
Figure 2.1 CRC cohort, 2009-2012 
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Definitions and assessment of risk variables 
Adenomas found during any COL surveillance after index COL are defined as 
recurrent adenomas. The findings of the index COL were stratified according to 
the number and size of adenomas and histology results. The size of adenomas 
(mm) detected was recorded in the CRCS. However, the number of adenomas 
removed at the index or follow-up COL is not currently reported (see Appendix 
Figure A2.2). Therefore, the number of biopsies, derived from the number of 
histology and the number of biopsy results, was used as a proxy for the number 
of polyps/adenomas removed during the COL surveillance. Reported histology 
results included low- or high-grade dysplasia from adenoma biopsies. The 
number/size and the degree of dysplasia of adenomas were used to decide the 
risk status of the individual at the index COL post-polypectomy [24, 39, 40]. 
 
Statistical analysis 
Descriptive analysis was carried out to understand the cohort characteristics and 
to map out pathways. Kaplan Meier survival analysis and a range of functions for 
the model were estimated to examine the cumulative risk of developing CRC 
post-polypectomy (subgroup COL surveillance) in order to extrapolate the risk of 
developing CRC beyond the short-term follow-up period [86]. Data analysis was 
performed using STATA®/SE14.  
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2.2.4 Results 
Characteristics of the CRC cohort and compliance to CRCS 
In 2009, of 6,658,551 eligible individuals for CRCS, the mean age was 60.45 
years (SD 9.52, male 47.2%). The majority were female in all age groups (except 
<55), and the number of female individuals was more than twice as many as male 
in the 80 year and older age groups (see Table 2.1).  
 
Table 2.1 Characteristics of CRC cohort (N=6,658,551) 
 Male Female 
 3,143,697 (47.21%) 3,514,854 (52.79%) 
Mean age (SD) 60.45 (±9.52) 
Age (years)    
50 ≤ age <55  1,164,699 1,143,797 
55 ≤ age <60 642,243 660,810 
60 ≤ age <65 435,025 444,536 
65 ≤ age <70 446,766 521,877 
70 ≤ age <75 234,998 311,948 
75 ≤ age <80 142,616 249,589 
80 ≤ age < 85 46,863 101,585 
85 < age 30,487 80,712 
CRC colorectal cancer; SD standard deviation 
 
Of the 6,658,551 individuals who were eligible for CRCS in 2009, approximately 
29.5% were compliant with the FOBT invitation, and 6.16% of participants had 
positive FOBT results. Participation in the follow-up test for those with positive 
FOBT remained between 35-45% during 2009-2012 (see Table 2.2). Everyone 
in the CRC cohort (starting from 1 January 2009) was eligible for CRCS in 2009 
and 2011 under the biennial CRCS policy, and again in 2012 following the 
introduction of the annual invitation policy as a consequence of the move from 
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biennial to annual CRCS implemented from 2012 [87]. Compliance rates to 
biennial FOBT invitation was approximately 29-31% in 2009 and 2011, and a 
lower compliance rate (17.1%) in 2012, the first year of annual FOBT (see Table 
2.2).  
 
Table 2.2 CRCS compliance CRC cohort, 2009 and 2011-2012  
Description [interval of FOBT within 
CRCS policy] 
*2009 
[biennial]  
*2011 
[biennial] 
$2012 
[annual] 
a) Number (% of CRC cohort) of people who 
had the FOBT 
1,963,874 
(29.49%) 
2,080,837 
(31.25%)  
1,138,299 
(17.10%)  
b) From those who had the FOBT in (a), the 
number (%) of individual positive FOBT 
results 
121,131 
(6.16%) 
 128,816 
(6.19%)  
 66,489 
(5.84%)  
c) From those with a positive FOBT result in 
(b), the number of people compliant to follow-
up   
53,992 
(44.57%) 
 45,336 
(35.19%)  
 25,059 
(37.69%)  
CRC colorectal cancer; CRCS colorectal cancer screening; FOBT faecal occult blood 
test; *Biennial CRCS offered until 2011, changed to annual CRCS from $2012 
 
Mapping common pathways in CRCS 
Four common pathways (CRCS, HCSU, NC (non-compliant), CRCS combined 
with HCSU) were identified when considering compliance, reported results, 
additional tests outside CRCS within NHI and CRC incidence as presented in 
Table 2.3 and Figure 2.2. Further detailed steps taken to mapping CRCS 
pathways are reported in Appendix Figure A2.3 and Appendix Table A2.1.  
Results highlight varying pathways outside the current CRCS policy. Further 
COLs were performed after a FOBT positive result indicating possible duplication 
of COLs in and outside the CRCS and NHI. 
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Table 2.3 Mapping common pathways in the CRCS 
Description Pathway 
Compliant to CRCS (FOBT positive then follow-up test (COL or 
DCBE then COL)) (CRC detected) 
CRCS only 
Compliant to CRCS (FOBT negative), then CRC treatments after 
*90 days (missed CRC) 
CRCS only 
Compliant to CRCS (FOBT positive then COL negative), then 
CRC treatment after *90 days (missed CRC) 
CRCS only 
Compliant to CRCS (FOBT positive then follow-up test negative, 
no CRC) 
CRCS only 
NC to CRCS and xTests, then CRC treatments received (CRC) HCSU only 
NC to CRCS  and xTests, and no CRC HCSU only 
NC and CRC treatments received  NC 
NC and no CRC treatment received (no CRC) NC 
Compliant to CRCS FOBT positive and xTest (COL) then CRC 
treatments 
CRCS combined 
with HCSU 
Compliant to CRCS (FOBT positive and follow-up test positive) 
and xTest (COL) then CRC treatment 
CRCS combined 
with HCSU 
Compliant to CRCS (FOBT positive), then HCSU (no CRC) CRCS combined 
with HCSU 
Compliant to CRCS (FOBT negative), then CRC treatments 
(missed CRC) 
CRCS combined 
with HCSU 
Compliant to CRCS, FOBT negative, then HCSU (no CRC) CRCS combined 
with HCSU 
COL colonoscopy; CRC colorectal cancer; CRCS colorectal cancer screening; DCBE 
double-contrast barium enema; FOBT faecal occult blood test; Follow-up test COL or 
DCBE then COL; HCSU health care service utilisation outside the CRCS but still within 
NHI when xTests were performed; NC non-compliant to CRCS; xTests screening tests 
(FOBT, COL, or DCBE) performed outside the CRCS within NHI; *90 days [52] 
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Figure 2.2 Identified common pathways in CRCS in 2009 
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Identified common pathways in the CRCS and the corresponding numbers of 
individuals in each pathway from 2009 to 2012 are presented in Figure 2.3.  
 
Figure 2.3. Mapped common pathways in the CRCS in the CRC cohort, 2009-2012  
 
CRC Colorectal cancer; HCSU Health care service utilisation outside CRCS within NHI;  
CRCS colorectal cancer screening; NC Non-compliant to CRCS 
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Costs of diagnosis and treatment of CRC per CRCS pathway 
The highest average cost of new CRC diagnosis was in the CRCS only group 
and lowest in the NC group in 2009. Estimated average costs of CRC diagnosis 
per pathway are presented in Tables 2.4.1-2.4.2. For a summary of unit costs 
associated COL surveillance and CRC diagnosis in the CRCS see Table 2.4.3.  
 
Table 2.4.1 Average costs of CRC diagnosis per pathway  
 (Unit: KRW; KRW 1,000=GBP 0.56) 
Pathway Number 
of new 
CRC  
Average costs 
of CRC 
diagnosis 
Min Max SD Cost per 
CRC 
diagnosis   
CRCS only 1,203 18,251,733,608 143,504 37,353,240 992 15,171,848  
HCSU only 4,842 16,701,708,000 123,435 31,243,434 935 3,449,341  
NC 1,031 124,596,350 103,524 29,235,354 933 120,850  
CRCS 
combined 
with HCSU 
1,232 8,541,531,425 124,354 32,343,258 774 6,933,061  
CRC colorectal cancer; CRCS colorectal cancer screening in the National Health 
Insurance (NHI); HCSU Health care service utilisation outside CRCS within NHI; KRW 
Korean Won; GBP Great British Pound; NC Non-compliant to CRCS; SD standard 
deviation 
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Table 2.4.2 Breakdown - average costs of CRC diagnosis per pathway 
(Unit: KRW; KRW 1,000=GBP 0.56) 
Pathway Breakdown Unit cost Number 
Average min max SD Average min max SD 
CRCS 
only 
Outpatient clinic visits  39133 12343 93212 87 3.9 1 7 1.3 
Treatments including surgical 
procedures 
86232 0 423241 123.2 3.4 0 8 2.1 
Diagnostic  tests  623433 0 1423146 231.5 4.1 1 12 3.4 
Diagnostics: imaging technologies 1931740 0 9514319 214.4 6.3 1 10 1.4 
HCSU only Outpatient clinic visits  31234 12381 53432 76.5 2.4 1 6 1.5 
Treatments including surgical 
procedures 
43432 0 194312 95.6 2.3 0 13 3.1 
Diagnostic  tests  234353 0 643243 234.1 2.9 1 22 4.2 
Diagnostics: imaging technologies 632893 0 8314324 423.2 4.1 1 34 1.3 
NC Outpatient clinic visits  12323 11213 54324 54.6 1.8 1 14 5.2 
Treatments including surgical 
procedures 
13434 0 564323 434.1 1.6 0 6 2.1 
Diagnostic  tests  23243 0 332149 234.2 1.3 1 23 3.5 
Diagnostics: imaging technologies 39131 0 8599513 1353.1 1.2 0 16 2.4 
CRCS 
combined 
with 
HCSU 
Outpatient clinic visits  24356 9421 64342 132.1 2.3 1 27 5.6 
Treatments including surgical 
procedures 
23453 0 732143 323.5 3.5 0 13 2.4 
Diagnostic  tests  873221 0 1415314 231.3 3.2 1 23 5.2 
Diagnostics: imaging technologies 975768 0 6452341 435.2 4.1 1 19 4.1 
CRC colorectal cancer; CRCS colorectal cancer screening in the National Health Insurance (NHI); HCSU Health care service utilisation 
outside CRCS within NHI; KRW Korean Won; GBP Great British Pound; NC Non-compliant to CRCS; SD standard deviation 
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Table 2.4.3 Summary of unit costs associated COL surveillance and CRC 
diagnosis in the CRCS  
(Unit: KRW; KRW 1,000=GBP 0.56) 
Description Reimbursement 
NHI (2015) [8] 
COL  74,240  
Bowel preparation for COL 8,400  
Biopsy during COL 12,740  
Pathology 
1-3 pieces  
4-6 pieces  
7-9 pieces  
10-12 pieces  
13 and more  
 
20,390  
27,470  
34,560  
42,530  
49,620  
Outpatient clinic visits for consultation  9,479  
Histopathology 40,437 
Routine blood tests, complete blood count with platelet, 
chemistry and CEA 
16,255 
Colonoscopy repeated  74,240 
PET-CT when metastasis is suspected 260,135 
Abdomen (MRI)  277,018 
Bone scan 76,062 
Ultrasound sonography 44,120 
CEA carcinoembryonic antigen; COL colonoscopy; CRC colorectal cancer; CT 
computed tomography; GBP Great British pound;  KRW Korean Won; MRI magnetic 
resonance imaging; PET position emission tomography 
 
Estimated average costs of CRCS treatment was highest in the HCSU group 
followed by the CRCS combination with HCSU group. Details of recommended 
chemotherapy agents for CRC treatment, treatment costs and radiation costs of 
CRC are summarised in Table 2.5.1. Average treatment costs per CRC pathway 
and the breakdown of treatment costs per pathway are presented in Tables 2.5.2- 
2.5.3. 
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Table 2.5.1 Summary costs of chemotherapy and radiotherapy for CRC in the NHI 
(NHIS 2015) 
(Unit: KRW; KRW 1,000=GBP 0.56) 
NHI Code Description Average  cost 
KK 153, KK154  Chemotherapy Administration-Continuous 
Intravenous 
4,170  
HE427, HE 427001, 
HE427006, HE427007, 
HE427300, HE427306, 
HE427307 
Abdomen MRI (limited) in deciding 
therapeutic range and location of 
radiotherapy 
86,605  
 
Q2671, Q2672, Q2673, 
Q2679, Q2680, Q2921-
Q2927  
Surgeries relevant to CRC treatment: total 
colectomy, colectomy – segmental resection, 
rectal and sigmoid resection, intestinal 
anastomosis, hemi-colectomy, colectomy 
with proximal colostomy and distal stump, 
colonoscopic operation of colonic tumor-
mucosal resection and submucosal resection 
373,038 
L01010101 Intravenous general anaesthesia 62,159 
HD051-HD056 Teletherapy 28,378 
HD057-HD059 Rotational irradiation 38,845 
HD061 3-dimensional conformal therapy 152,490 
HD071-HD073 Unsealed sources 36,265 
HD080-HD088 Brachytherapy 2,097,480 
HD091-HD092 Total body irradiation 233,060 
HD093 Total skin electron beam therapy 403,665 
HD110 Fractionated stereotactic radiotherapy 547,915 
HD111, HD112, HD212 Body stereotactic radiosurgery 529,565 
HD121 Proton therapy 513,235 
HZ271 Intensity modulated radiation therapy 297,645 
CRC colorectal cancer; KRW Korean Won; GBP Great British pound; MRI magnetic 
resonance imaging 
 
Table 2.5.2 Average treatment costs of CRC per pathway  
(Unit: KRW; KRW 1,000=GBP 0.56) 
Pathway Number 
of new 
CRC 
Average costs 
of CRC 
treatment 
Min Max SD Cost per 
CRC 
treatment 
CRCS only 1,203 1,306,587,293 365,154  8,561,871  945  1,086,107 
HCSU only 4,842 15,197,271,881 410,587  9,515,847  892  3,138,635 
NC 1,031 124,596,350 298,515  7,920,518  958  120,850 
CRCS 
combined 
with HCSU 
1,232 1,971,024,554 358,154  8,154,955  934  1,599,858 
CRC colorectal cancer; CRCS colorectal cancer screening in the National Health Insurance 
(NHI); GBP Great British Pound; HCSU Health care service utilisation outside CRCS within 
NHI; KRW Korean Won; NC Non-compliant to CRCS; SD standard deviation 
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Table 2.5.3 Breakdown - Average treatment costs of CRC per pathway   
Pathway Breakdown Unit KRW (KRW 1,000=GBP 0.56) Number 
Average min max SD Average min max SD 
CRCS 
(Colorectal 
Cancer 
Screening in 
the National 
Health 
Insurance 
(NHI)) only 
Outpatient: clinic visits 18,321  9,123  43,213  91.2  2.6 1  14  5.4  
Inpatient stay: diet, single-room 29,334  0  312,411  231.3  2.5 1  21  5.9  
Medications 32,321  0  534,123  217.1  2.6 1  32  9.4  
Infusions, injections 23,432  0  335,153  951.2  2.3 1  31  6.8  
Anaesthetics for surgical procedures 32,491  0  321,215  321.5  1.5 1  5  3.5  
Care, physiotherapy 21,343  0  94,342  343.7  1.6 1  32  7.5  
Surgical procedures 437,598  0  1,542,452  832.9  1.2 1  18  7.8  
Diagnosis: blood tests, biopsies 76,231  0  150,231  231.1  1.9 1  25  6.2  
Diagnostics and therapeutics using  imaging technologies 32,334  0  53,312  143.5  2.3 1  21  9.9  
HCSU (Health 
Care Service 
Utilisation 
outside CRCS 
in the NHI) 
only 
Outpatient: clinic visits 35,123  11,232  41,321  87.1  4.5 1  16  5.8  
Inpatient stay: diet, single-room 32,143  0  432,159  214.2  3.2 1  23  6.1  
Medications 54,321  0  832,141  256.1  2.9 1  29  10.4  
Infusions, injections 32,459  0  589,312  732.1  2.7 1  28  8.2  
Anaesthetics for surgical procedures 37,432  0  736,414  431.8  3.1 1  8  4.2  
Care, physiotherapy 42,532  0  143,115  531.2  4.3 1  23  6.9  
Surgical procedures 1,018,431  0  5,341,233  873.2  2.4 1  19  8.2  
Diagnosis: blood tests, biopsies 91,420  0  913,213  321.5  1.8 1  23  5.9  
Diagnostics and therapeutics using  imaging technologies 54,123  0  154,121  43.2  2.5 1  21  10.5  
NC (Non-
Compliant to 
CRCS) 
Outpatient: clinic visits 13,212  8,321  98,321  76.5  1.2 1  14  6.1  
Inpatient stay: diet, single-room 10,231  0  94,155  398.2  1.3 1  12  9.1  
Medications 8,434  0  73,211  743.1  1.1 1  32  13.4  
Infusions, injections 9,431  0  31,412  219.5  1.3 1  22  6.9  
Anaesthetics for surgical procedures 9,424  0  42,131  532.1  1.1 1  5  4.2  
Care, physiotherapy 12,322  0  213,145  313.3  1.1 1  22  9.1  
Surgical procedures 18,190  0  1,593,132  985.8  1.1 1  18  7.9  
Diagnosis: blood tests, biopsies 11,321  0  51,321  321.3  1.4 1  22  8.7  
Diagnostics and therapeutics using  imaging technologies 9,435  0  59,321  431.4  1.1 1  20  15.1  
CRCS 
combined with 
HCSU 
Outpatient: clinic visits 28,311  14,232  421,321  98.4  2.8 1  12  9.4  
Inpatient stay: diet, single-room 32,421  0  553,241  184.4  2.4 1  15  7.4  
Medications 34,542  0  431,951  315.6  2.5 1  31  16.3  
Infusions, injections 42,532  0  983,232  643.1  2.6 1  22  8.3  
Anaesthetics for surgical procedures 31,342  0  873,214  315.6  1.7 1  6  8.5  
Care, physiotherapy 28,323  0  423,124  458.3  1.9 1  21  8.0  
Surgical procedures 659,436  0  7,433,151  873.3  1.3 1  19  6.3  
Diagnosis: blood tests, biopsies 87,321  0  983,123  74.3  1.7 1  21  5.3  
Diagnostics and therapeutics using  imaging technologies 53,212  0  632,141  439.5  2.5 1  23  15.8  
CRC colorectal cancer; GBP Great British Pound; KRW Korean Won; SD standard deviation 
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Subgroup analysis - COL surveillance post-polypectomy 
Of the four identified pathways, there was a group of people who required regular 
follow-up post-polypectomy (COL surveillance; n=131,422) as part of the CRCS 
pathway based on findings from FOBT. The COL surveillance group (marked by 
a green dotted line in the in Figure 2.2) was considered in a subgroup analysis.  
The number of biopsies during the COL was submitted for the NHI reimbursement, 
however, the number of adenomas detected/removed per COL procedure was 
not recorded within the current reporting structure of the CRCS NHI. Therefore, 
it is assumed that the number of biopsies is positively correlated with the number 
of polyps/adenomas detected during COL, as the practitioners are reimbursed by 
the number of biopsies per COL under current CRCS, thus this assumption is 
reasonable (expert opinion). In addition, the reported number of biopsies during 
the COL is divided into 5 groups [8].  
Based on the reported findings of follow-up COLs in the CRCS, the subgroup is 
divided into two risk groups as outlined in Table 2.6. 
 
Table 2.6 Subgroup COL surveillance post-polypectomy (n=10,092), 2009-2012 
Subgroup COL surveillance  Male 53.88% 
Mean age (years, SD) 58.95 (SD 7.455) 
Number of people with adenomas detected 
at index COL, 2009 (% of CRC cohort) 
Low risk (LR) 8,832 (6.7%) 
High risk (HR) 1,260 (0.96%) 
COL colonoscopy; CRC colorectal cancer; HR 4 or more adenomas/polyps or one 
adenoma ≥10 mm or high-grade adenoma/dysplasia; LR 1-3 adenomas <10 mm or low-
grade adenoma/dysplasia; SD standard deviation 
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Table 2.7 Reported COL findings from CRCS and risk stratification for economic 
model 
Reported COL findings from CRCS (CRC cohort) *Approximated risk 
stratification for the 
economic model 
Reported size of adenomas  
<10 mm LR 
≥10 mm HR 
Reported numbers of adenomas  
Number of 
adenomas 
Reported number of 
biopsies taken for 
pathology/ histology 
Reported 
numbers of 
biopsies  
 
Not reported 1-3 Group 1 LR 
Not reported 4-6 Group 2 HR 
Not reported 7-9 Group 3 HR 
Not reported 10-12 Group 4 HR 
Not reported 13 or more Group 5 HR 
Reported degree of dysplasia in 
adenomas 
LGD LR 
HGD HR 
COL colonoscopy; CRC cohort short-term analysis of the CRCS in NHI, Korea, 
2009-2012; CRCS colorectal cancer screening; HGD high-grade dysplasia; HR 
high risk LGD low-grade dysplasia; LR low risk; * approximated risk stratification 
was carried out using the CRC cohort data for the economic model in Chapter 5 
 
Reported findings from CRCS and the approximation of risk stratification for the 
economic model are presented in Table 2.7. For risk stratification, the number of 
biopsies was assumed to be the number of adenomas considering the 
reimbursement would be made based on the number of biopsies reported in the 
CRCS (expert opinion). Table 2.8 presents adenoma recurrence post-
polypectomy by risk groups 
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Table 2.8 Adenoma recurrence at follow-up COL by presence of adenomas at the 
index COL in 2009 (n=10,092), 2009-2012 
  LR (n=8,832; 87.5% of 
subgroup) in 2009 
HR (n=1,260; 12.5% of 
subgroup) in 2009  
  LR HR LR HR 
COL in 2010 85 1 6 4 
COL in 2011 282 1 17 8 
COL in 2012 79 3 7 3 
COL colonoscopy; HR 4 or more adenomas/polyps or one adenoma, ≥10 mm or high-
grade adenoma/dysplasia; LR 1-3 adenomas, <10 mm or low-grade 
adenoma/dysplasia 
 
 
Kaplan-Meier analysis was used to estimate CRC-free survival following 
polypectomy as presented in Figure 2.4. Clear steps are observed in the Kaplan-
Meier curve that is likely to be due to the clustering of events around the 
scheduled COL surveillance visits. Around 76-77% of this subgroup remained 
alive in 2012.  
 
 Figure 2.4 Survival estimate post-polypectomy, CRC cohort 2009-2012 
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Of several methods available for undertaking extrapolation, Weibull and 
Gompertz functions provide the best overall fit for undertaking extrapolation 
beyond the data points of the COL surveillance subgroup following the Akaike 
information criterion (AIC) and Bayesian information criterion (BIC)  test results 
as presented in Table 2.9 [86].  
 
Table 2.9 AIC and BIC test results for assessing the suitability of survival models, 
COL surveillance subgroup 
Model  AIC BIC 
Weibull 149.7909 157.5687 
Exponential 160.362 164.2509 
Log -normal 151.6438 159.4216 
Log-logistic 150.0665 157.8442 
Gompertz 149.6093 157.3871 
Generalised gamma 151.5258 163.1924 
AIC Akaike information criterion; BIC Bayesian information criterion; COL colonoscopy 
 
The cumulative risk of CRC diagnosis was estimated in the subgroup with 
polyp/adenoma in order to extrapolate the risk of developing CRC beyond the 
short-term CRC cohort, 2009-2012. A survival function was estimated from CRC 
originating from adenoma leading to CRC death, for the subgroup, indicating 
approximately 80% of individuals in the subgroup would die due to CRC in the 
next 10 years as presented in Figure 2.5.  
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Figure 2.5. Extrapolated CRC-free survival curve post-polypectomy, subgroup  
 
Ideally, the LR and HR follow-up COL dates at the individual level would have 
enabled the calculation of the transformation of adenoma into carcinoma by risk 
status. Estimates of adenoma recurrence rates post-polypectomy are derived 
from subgroup analysis; however, it is not feasible to estimate the risk of 
developing CRC from recurrent adenomas in different risk groups leading to CRC 
deaths because of the incomplete information on the timings of subsequent COL 
surveillance with the corresponding results in the CRC cohort. 
 
2.2.5 Discussion 
Current clinical practice can be established and the costs and benefits of CRCS 
can be estimated by utilising the rich CRCS dataset, thus the approaches taken 
in this short-term analysis can be utilised for future economic evaluation of CRCS 
[88]. Some insist that a randomised controlled trial (RCT) is the only way to prove 
the effectiveness of CRCS and the NCSP [89]. However, given the complexity of 
setting up randomised controlled trials related to ethical implications, this may not 
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be feasible, in addition, CRCS has long been implemented at a population level 
in Korea. Instead, a cohort comparison by creating a synthetic cohort from the 
abundant individual-level NHI data would be more appropriate and feasible in 
assessing the effectiveness of CRCS and the NCSPs [90].  
Four common pathways were mapped in the CRCS based on the compliance to 
FOBT invitation, FOBT results, compliance to follow-up tests and their results and 
the different routes to CRC diagnosis using the CRC cohort data (2009-2012): 
CRCS only, HCSU only, CRCS combined with NHSU and NC. Improved 
compliance to CRCS is a priority in order to improve detection of early CRC and 
the subsequent reduction in CRC mortality. Findings from the CRC cohort 
indicate the current practice in CRCS varies substantially from the CRCS policy 
including HCSU only and CRCS combined with HCSU groups, and it is crucial to 
have consensus in the clinical guidelines and relevant reimbursement policies in 
CRCS, NHI.  
The subgroup analysis indicated that adenomas recurrence was more frequent 
in the LR group compared to the HR group that might have been partly caused 
from the biennial CRCS changes to annual from 2011. Risk-based (LR or HR) 
extrapolation of CRC-free survival post-polypectomy beyond the short-term 
period of CRC cohort (2009-2012) was not possible due to the limited information 
on the dates of follow-up COLs linked to their outcomes in the subgroup. A CRC 
cohort with a longer-term follow-up will provide further evidence of the adenoma-
carcinoma sequence and the movements between the CRC disease states, this 
will be crucial to improving the robustness of the results of future economic 
evaluations. 
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The consensus around the reporting of CRC stages is of paramount importance 
as staging determines the most appropriate treatment thus improving survival. 
Staging of CRC disease is reported to differ across the practitioners and relevant 
organisations, and thus lacks comparability [91]. There are different staging or 
classification of CRC including Surveillance, Epidemiology and End Results 
(SEER), Dukes’ system and Tumour-Node-Metastasis (TNM), but there are no 
universally agreed terms regarding different stages of CRC as reported in Table 
2.10.  
 
Table 2.10 CRC staging information submitted/used in CRCS 
 Providers [8] HIRA [50] NHI [8] KCCR [15] KAMS [92] 
SEER 1,2,7,9 ✓   ✓  
TNM     ✓ 
Stages  ✓    
No stage 
information  
✓  ✓   
CRC colorectal cancer; CRCS colorectal cancer screening; HIRA Health Insurance 
Review & Assessment; KAMS Korean Academy of Medical Science; KCCR Korean 
Central Cancer Registry; NHI National Health Insurance; SEER Surveillance, 
Epidemiology and End Results; TNM Tumour-Node-Metastasis 
 
Therefore, in this short-term analysis of the CRC cohort, CRC stages were 
estimated based on the comparison of SEER, Dukes’ system and TNM (see 
Table 2.11) [91-93]. 
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Table 2.11 Comparison of CRC stage using different classification system [91-93] 
CRC stage   T N M SEER code Dukes Estimated 
CRC stages, 
CRC cohort 
0 Tis N0 M0 LOC 0 - DA 
I T1 N0 M0 LOC 1 A DA 
I T2 N0 M0 LOC 1 A DA 
IIA T3 N0 M0 REG 2 B DB 
IIB T4a N0 M0 REG 2 B DB 
IIC T4b N0 M0 REG 2 B DB 
IIIA T1-2 N1/N1c M0 REG 3 C DC 
 T1 N2a M0 DIS 3 C DC 
IIIB T3-4a N1/N1c M0 REG 4/5 C DC 
 T2-T3 N2a M0 REG 5 C DC 
 T1-T2 N2b M0 REG 5 C DC 
IIIC T4a N2a M0 REG 5 C DC 
 T3-T4a N2b M0 DIS 7 C DC 
 T4b N1-N2 M0 DIS 7 C DC 
IVA Any T Any N M1a DIS 7 - DD 
IVB Any T Any N M1b DIS 7 - DD 
CRC colorectal cancer; DA Dukes A; DB Dukes’ B; DC Dukes’ C; DD stage D CRC; 
DIS distant cancer; DIS distant cancer; LOC localised cancer; M distant metastasis; 
M0 no distant metastasis; M1 distant metastasis; M1a metastasis confined to one 
organ or site (for example, liver, lung, ovary, nonregional node); M1b metastases in 
more than one organ/site or the peritoneum; T primary tumour; N regional lymph 
nodes; N0 no regional lymph node metastasis; N1 metastasis in 1-3 regional lymph 
nodes; N1a Metastasis in one regional lymph node; N1b metastasis in 2–3 regional 
lymph nodes; N1c tumuor deposit(s) in the subserosa, mesentery, or 
nonperitonealized pericolic or perirectal tissues without regional nodal metastasis; N2 
metastasis in 4 or more regional lymph nodes; N2a metastasis in 4–6 regional lymph 
nodes; N2b metastasis in 7 or more regional lymph nodes; NCC National Cancer 
Centre; REG regional cancer; SEER Surveillance, Epidemiology, and End Results; 
Tis carcinoma in situ; T1 tumour invades submucosa; T2 tumour invades muscularis 
propria; T3 tumour invades through the muscularis propria into the pericolorectal 
tissues; T4 tumour penetrates to the surface of the visceral peritoneum or directly 
invades or in adherent to other organs or structures 
SEER code 0 In situ; 1 Localized only; 2 Regional by direct extension only; 3 
Regional lymph nodes involved only; 4 Regional by BOTH direct extension AND 
lymph node involvement; 5 Regional, NOS (Not Otherwise Specified); 7 Distant 
site(s)/node(s) involved; 9 Unknown if extension or metastasis (unstaged, unknown, 
or unspecified); Death certification only case 
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There are limitations in this analysis; the use of NHI reimbursement data lacks 
the continuity of collection in the case of changes in the report form and possible 
reporting errors. CRCS policy changed from biennial (2009-2011) to annual 
(2012), the results of this short-term analysis should be interpreted with caution.  
Colorectal adenomas is a type of polyp, abnormal tissue growth in the rectum or 
the colon, which can be either pre-cancerous or benign [33]. Polyps can be 
categorised by the major histological groups of hyperplastic/metastatic polyp, 
neoplastic polyp and adenomatous polyp (adenoma). Adenomas can be 
classified by number, size (diameter), histologic type (tubular, villous or 
tubulovillous), dysplasia and location [94]. The number and size of adenomas 
are said to be positively correlated with the increase risk of advanced neoplasia 
[33, 39]. 
In the current reporting of CRCS results, adenomas are categorised by size, 
type (pathology test results) and the number present [40]. Based on the findings 
from an index COL, people with 3 or more adenomas, any adenoma > 10 mm, 
any tubulovillous or villous adenoma(s), any adenoma(s) with high-grade 
dysplasia or any serrated polyp(s) larger than 10 mm, are considered to be at a 
high risk of developing subsequent advanced adenomas and/or CRC, therefore 
COL surveillance is recommended 3 years after polypectomy in the first COL 
surveillance guideline in Korea [40, 67]. Despite the reported changes in the 
adenoma location related to age [95]  the proportion of individuals who only had 
adenomas in the proximal colon remained unchanged significantly by age [96]. 
COL is a recommended follow-up test modality which enables the visualisation 
of the bowels, therefore, the specific location of adenomas was not considered 
important in the risk stratification of adenomas for this thesis. 
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The reporting of COL results did not include the number of adenomas 
detected/removed during the follow-up COL in the CRCS, therefore the number 
of biopsies taken during the follow-up COL was used as a proxy for the number 
of adenomas in the risk stratification for the economic model. The approximation 
of risk status of the COL subgroup highlighted the discrepancies in the risk 
stratifications in the current clinical guidelines and the reported CRCS results. 
The production of high quality data requires data collection procedures that are 
standardised over time with dedicated training of data collectors and appropriate 
tools for data collection leading to the future studies utilising comprehensive 
CRCS data to inform decision making in the NHI  [88].  
For the purpose of mapping common pathways in the CRCS it was necessary to 
define mutually exclusive pathways. Individuals must be in only one pathway 
group each year for the compliance and reported test results. The mapped 
pathways did not consider additional tests performed after CRC diagnosis or 
those individuals who dropped out of the CRCS but later returned to CRCS via 
separate pathways. Therefore, estimated resources used in the CRCS and CRC 
might have been under-estimated in this analysis. Furthermore, additional 
resources used and costs associated with the NC group were outside the current 
CRCS and NHI, thus lead to a possible under-estimation of resources used in the 
NC pathway. Insufficient evidence around the costs and benefits of CRCS has 
long been acknowledged.  
Findings from the CRC cohort suggest that further diagnostic tests are performed 
after a positive FOBT or a positive COL result in the CRC combined with HCSU 
pathway. There is no mechanism to capture the duplication of diagnostic tests in 
the current reporting system in CRCS, leading to a potential under-estimation of 
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the diagnostic costs, thus the results should be interpreted with caution. There is 
no record of opportunistic screening activities; therefore, the potential pathway of 
‘cross-over’ between CRCS in NHI and opportunistic screening was not included 
in this analysis. 
 
This short-term analysis of CRCS highlights potential advantages of utilising NHI 
reimbursement data in population health research and confirms that it is a 
feasible alternative to clinical trials in the evaluation of costs and benefits of 
existing programmes in NHI. NHI data capture information about each episode of 
care across health services and enable the estimation of the cost of interventions 
on the population and for sub-groups. This analysis of CRCS not only provides 
information relevant for the economic evaluation of CRCS and follow-up COL but 
also demonstrates how the current clinical practice of other NCSPs can be 
mapped out in order to inform the decision making process. Further studies 
related to the role of the NHI reimbursement data in population health research 
and risk-based COL subgroup over a longer term in the CRCS, NHI are warranted. 
 
2.2.6 Conclusion 
Results from the CRC cohort analysis revealed varying pathways outside current 
CRCS policy including CRCS combined with HCSU, HCSU and NC. Reported 
resources used in the CRCS COL surveillance provide invaluable information for 
the future economic evaluation of CRCS in the NHI. Despite the short-term 
analysis (2009-2012) and the changes in CRCS policies from biennial to annual 
2011, results from the subgroup analysis indicated that individuals would develop 
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CRC over the 15 year post-polypectomy. Therefore, a risk-based COL 
surveillance that is seamlessly linked with CRCS is needed in order to minimise 
double-running costs of CRC diagnostics between CRCS and HCSU in the NHI. 
Furthermore, a CRC cohort with a longer-term follow-up will provide further 
evidence of the adenoma-carcinoma sequence and the movements between the 
CRC disease states, this will be crucial to improving the robustness of the results 
of future economic evaluations. Results from this short-term analysis of CRCS 
provide the basis for the cost-effectiveness analysis of the COL surveillance in 
the CRCS, NHI.  
  
 
 
81 
 
 
 
3 REVIEW OF ECONOMIC EVIDENCE IN THE 
PREVENTION AND EARLY DETECTION OF 
COLORECTAL CANCER  
 
 
3.1 Preamble to Research Paper II  
It is important to understand how other researchers have modelled CRCS in order 
to inform the economic evaluation of COL surveillance in the CRCS, NHI. 
Common modelling approaches used, modelled follow-up strategies, chosen 
interventions and comparators, the source of parameter inputs, the source of 
quality of life data for the health states of interest, health states and the details of 
down-stream effects of CRCS in the model were systematically reviewed. Also, 
reported limitations and uncertainties addressed in the literature were critically 
appraised [97, 98]. Please see the numerical summary of searches for the review. 
 
 
82 
 
 
 
 
 
 
A review of the cost-effectiveness evidence carried out in a systematic manner 
for this thesis is presented in 3.2.  
Since the publication of Research Paper II updates of the cost-effectiveness 
evidence were conducted (until 31 March 2015) as presented in 3.3. A report 
Initial hits (n=2,452) 
Excluded duplicates 
(n=609)  
Excluded after title and 
abstract review 
(n=1,736) 
Included studies (n=68)  
Full economic evaluations 
that considered costs and 
health outcomes of CRCS  
 
Studies included for 
full text review (n=107)  
Excluded: no access (n=2) 
Excluded after full text review 
(n=37)  
- Burden of disease studies  
- Non-comparative costing studies 
- Any studies which did not assess 
costs and related health outcomes  
- Clinical investigation or 
therapeutic interventions for 
suspected CRC or conditions 
other than colorectal 
adenoma/polyp  
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Numerical summary of the searches for the review  
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relevant to this topic [99] was not captured in the original search because the 
report was indexed as a book in the database at the time of original search [100]. 
Therefore, the search was broadened to include the National Institute for Health 
and Care Excellence (NICE) website (www.nice.org.uk) to minimise the chance 
of missing relevant studies in the update.  
Based on a published checklist [97] included studies were critically appraised. Of 
68 studies reviewed from the original review [100] and 10 from search updates, 
approximately 227 different comparisons of the CRCS tests made were reported 
to be cost-effective compared to no CRCS. Mostly, stool-based CRCS strategies 
were cost effective compared to no CRCS or endoscopy-based screening 
strategies in an average risk group.  
The evidence for the importance of colorectal polyps in the development of CRC 
was largely indirect, but nonetheless extensive and convincing and has been 
described in detail [101]. The structure of model was adequately reflecting the 
nature of the adenoma-carcinoma with the time horizon that was sufficiently long 
to reflect costs and health outcomes [76, 79, 96, 101, 102]. On the other hand, a 
shorter time horizon (10 years) was considered in estimating costs and outcomes 
of screening and/or surveillance strategies that was not sufficiently long enough 
to capture potential gains from the prevention of CRC [103, 104]. Estimated 
resource use was reasonable and up-to-date within 1-4 years except for one 
study [103]. For estimating costs and benefits of early detection and prevention 
of CRC through CRCS and COL surveillance, differentiated CRC disease states 
would be better suited than a single health state of CRC [105, 106], however 
more attention needs to be paid to report search methods in identifying model 
input parameters. 
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The review found consistent methodological flaws: 1) lack of clear descriptions of 
adenoma-carcinoma, justification of modelling approach [107-109]; 2) lack of 
clear description of perspective of  analysis [105, 107-122]; 3) lack of 
description/justification  of discounting of future costs and outcomes [107-109, 
113, 123-125]; 4) the lack of exploration of uncertainty associated with important 
input  parameters through  sensitivity analysis [106-110, 112, 113, 120, 121, 123, 
126-130].  
Additional filters related COL surveillance strategies for people with confirmed 
adenomas and CUA were added in order to identify highly relevant studies for 
the CUA (Chapter 5). COL surveillance strategies were nested in a CRCS model 
structure [79, 96, 102]. Risk-based COL surveillance strategies were cost-
effective in two previous studies [76, 99]. First, Saini (2010) [76] reported COL 
surveillance every 3 years in HR (> 2 adenomas or adenomas ≥ 10 mm in size, 
villous or containing high-grade dysplasia) and every 10 years in LR (1-2 
adenomas < 10 mm) were cost-effective. Second, NICE (2011) [99] reported COL 
surveillance every 3 years in HR (5 or more adenomas smaller than 10 mm or 3 
or more adenomas if one is 10 mm or larger), every 3 years in intermittent risk (3 
or 4 adenomas smaller than 10 mm or 1-2 adenomas if one is 10 mm or larger), 
and every 5 years in LR (one or two adenomas smaller than 10 mm) were cost-
effective.  
Utility loss from harm done by surveillance was not modelled except for Saini 
(2010) and NICE (2011) where disutility associated with COL was assumed to be 
0.0025 [76, 99]. Therefore, a COL related disutility of 0.0025 was considered in 
the base-case of model. 
Screening outcomes estimated by the model were validated against UK trial data 
[79]. Predicted outcomes from a natural history of adenoma-carcinoma (no COL 
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surveillance) in an average cohort were compared to observed data from 1975 
SEER registry [76]. 
Findings from the review informed the modelling approach adopted in the 
economic evaluation of COL surveillance in the CRCS, NHI (Chapter 5).  
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3.2 Research Paper II Review of economic evidence in the 
prevention and early detection of colorectal cancer 
 
3.2.1 Abstract 
This paper aims to systematically review the cost-effectiveness evidence and to 
provide a critical appraisal of the methods used in the model-based economic 
evaluation of CRC screening and subsequent surveillance. A search strategy was 
developed to capture relevant evidence published in the period between January 
1999 and November 2012. Databases searched were MEDLINE, EMBASE, 
National Health Service Economic Evaluation Database (NHS EED), EconLit and 
Health Technology Assessment (HTA). Full economic evaluations that 
considered costs and health outcomes of relevant interventions were included. 
Sixty-eight studies which used either cohort simulation or individual-level 
simulation were included. Follow-up strategies were mostly embedded in the 
screening model. Approximately 195 comparisons were made across different 
modalities, however, the strategies modelled were often simplified due to 
insufficient evidence and the chosen comparators in the model insufficiently 
reflected current practice or recommendations. Studies used up-to-date evidence 
on the diagnostic test performance combined with outdated information on CRC 
treatments. Quality of life relating to follow-up surveillance is rare. Quality of life 
relating to CRC disease states was largely taken from a single study. Some 
studies omitted to say how identified adenomas or CRC were managed. Besides 
deterministic sensitivity analysis, probabilistic sensitivity analysis (PSA) was 
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undertaken in some studies, but the distributions used for PSA were rarely 
reported or justified. 
The cost-effectiveness of follow-up strategies among people with confirmed 
adenomas are warranted to aid evidence-informed decision making in response 
to the rapidly evolving technologies and rising expectations.   
 
KEYWORDS 
Colorectal cancer; Screening; Polyp; Adenoma; Cost-effectiveness; Cost-utility  
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3.2.2 Introduction 
Colorectal polyps are small benign growths in the inner layer of the colon and 
rectum that can be either pre-cancerous or non-precancerous. Neoplastic 
colorectal polyps, known as adenomas, can be further divided into non-advanced 
and advanced dependent on the size, degree of villous features or grade of 
dysplasia [51, 131]. The number and size of adenomas are positively related to 
the risk of developing colorectal cancer (CRC) over 10 years or longer [37, 38, 
131]. Evidence suggests that early detection and removal of colorectal adenomas 
(polypectomy) reduces the risk of developing CRC [37]. 
Several screening modalities are currently used in different sequences and with 
different intervals ranging from stool tests, barium enema (BE), colonoscopy 
(COL), sigmoidoscopy (SIG) to computerised tomography colonography (CTC). 
Each screening modality has particular benefits and potential harms. Despite the 
absence of sufficient evidence for or against specific CRC screening (CRCS) 
modalities, CRCS has been implemented in many countries [132-134]. Rapidly 
evolving technologies and increasing expectations from healthcare users tend to 
exceed financial affordability and health policy responses in many countries. 
Guidance is required regarding choice, order of modalities and appropriate 
intervals, in order to minimise potential harms and maximise benefits among the 
eligible population groups. This paper systematically reviews the cost-
effectiveness evidence and provides a critical appraisal of methods used in the 
model-based economic evaluation of CRCS and subsequent surveillance. 
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3.2.3 Methods 
A search strategy was developed (see Appendix Table A3.1). Databases 
searched were National Health Service Economic Evaluation Database (NHS 
EED), EconLit, MEDLINE, EMBASE and HTA and limited to studies published 
January 1999 to November 2012. An initial search using the search term 
‘surveillance’ was extended to ‘screening’ because of the rarity of published cost-
effectiveness analysis of follow-up strategies in the topic area, and also due to 
terminologies being used interchangeably in the published literature. Key terms 
used in the search were colonoscopy, surveillance, screening, adenoma and 
colorectal cancer. Economic filters were used when searching for economic 
evidence on generalist databases such as MEDLINE. Simplified searches without 
economic search filters were performed when searching the economics specific 
databases [135].  
Full economic evaluations that considered costs and health outcomes of relevant 
types of intervention with outcomes expressed in cost per quality-adjusted life-
year (QALY) or cost per life-year gained were included. Studies published pre-
1999 [110, 136] were reviewed when they were used in the appraisal of newly 
introduced technologies. Sixty-eight studies were critically appraised by two 
reviewers using a set of criteria [137]. Search strategy (see Appendix Table A3.1), 
study selection criteria (see Appendix Table A3.2), included/excluded studies 
(Appendix Tables 3.3.1-3.3.2) are presented in Appendices and the included 
studies are summarised in Appendix Table A3.4.  
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3.2.4 Results 
Findings from selected studies are discussed in the following section.  
Economic models for surveillance programmes targeting people with a high risk 
of developing CRC were nested in the main screening model(s) in a number of 
studies. The countries of origin of the studies included in this paper are presented 
in Figure 3.1.  
 
Figure 3.1 Included studies – counties of origin 
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Modelling methods 
Two modelling methods have been used: cohort simulation and individual-level 
simulation. Some studies provided a limited description of the model [106, 107, 
130, 136, 138], others were marginal analyses of cost and benefits derived from 
published studies that were applied directly to the US population [112]. 
Computational complexity of the models ranged from a simple decision tree [82, 
103, 113, 117, 125, 126, 139, 140] to a Markov model [102, 104, 105, 110, 111, 
115, 116, 118, 119, 121, 124, 127-129, 141-159] to capture key aspects of the 
natural history of CRC. Most studies modelled the adenoma-carcinoma sequence 
over time. Threshold analysis was performed in some studies to investigate the 
optimal cut-off level for diagnostic tests or optimal reimbursement strategies for 
a new technology [160].  
Individual-level simulation models [79, 101, 114, 120, 160-167] have been based 
on three micro simulation models: Micro Simulation Screening Analysis 
(MISCAN); Simulated Model of CRC; Colorectal Cancer Simulated Population 
model for Incidence and Natural History. These were independently developed 
within the National Cancer Institute-funded Cancer Intervention and Surveillance 
modelling Network (CISNET) consortium. The natural history of CRC in these 
models was calibrated to autopsy studies and to Surveillance, Epidemiology, and 
End Results (SEER) Program data for the pre-screening era (1975-1979) [161]. 
CISNET models subsequently led to a number of secondary analyses [101, 115, 
120, 166, 167]. 
Initiation of CRC screening and subsequent follow-up was mostly around 50 to 
60 years of age, while the timing of cessation of screening or surveillance varied. 
In some surveillance models, people remained in the surveillance programme 
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until the end of the simulation [161, 166]. As a result, the surveillance costs would 
have been overestimated.  
Population considered 
People at average risk were the main focus in most studies, with follow-up 
surveillance nested in the screening model. For people with positive FOBT results, 
COL was commonly used as a confirmatory test [82, 96, 104, 167]. The 
importance of follow-up surveillance of individuals at high risk of developing CRC 
has been recognised in recent years. For example, people with newly diagnosed 
adenomas were considered in a follow-up strategy using COL compared with no 
follow-up [155], and people with asymptomatic polyps were followed-up using 
CTC compared with immediate referral for COL with polypectomy [103, 117].   
 
Screening modalities considered 
The main interventions chosen for modelling were stool tests, COL, SIG 
progressed to CTC either alone or combined with another modality. CTC was 
often compared with existing technologies that have emerged in the recent years. 
Evidence and recommendations on the use of BE remain inconsistent thus BE 
was considered as one of the current modalities in some studies [121, 126, 143, 
156] but excluded in others [118, 119].  
Stool-based tests, including guiaic FOBT (gFOBT), immunochemical FOBT 
(iFOBT) and stool DNA tests were used for mass screening of those at average 
risk of developing CRC compared with no screening [108, 152, 156, 168]. COL 
was the common test for the follow-up of detected adenomas/polyps and positive 
test results from the initial screening tests. Unlike COL, SIG provides visualised 
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examination of the left side of the bowel depending on the length of endoscopy 
and the depth of insertion with no sedation [169]. Narrow-band imaging (NBI) is 
one of the latest technologies with in-vivo histology function compared with 
conventional white light COL, in which removed adenomas from COL 
(polypectomy) would be analysed in the lab [144].  
 
Approximately 195 comparisons have been made across the 68 studies 
(simplifying considerations of the sequence of tests and excluding the interval of 
screening and follow-up strategies) as presented in Figure 3.2. This can be partly 
explained by differences in clinical practice between countries/settings 
dependent on the structure of health service delivery and reimbursement rules, 
as well as resource availability. Effectiveness and cost-effectiveness evidence 
relating to the combination of different tests or their sequence in CRC screening 
and follow-up was sparse. Stool-based tests were aggregated for simplicity. Each 
modality is coded using a different colour and shape outline. Numbers shared 
between circles or within a circle represent the number of comparisons across 
the studies. For example, NBI was compared with COL once; two comparisons 
were made of CTC followed by COL and CTC alone.  
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Figure 3.2 At a glance – 195 comparisons 
  
Barium enema (BE) (brown solid)  
Barium enema and colonoscopy (BECOL) (brown dotted) 
Capsule endoscopy (CapEndo) (green solid) 
Computerised-tomography colonography (CTC) (yellow solid) 
Computerised-tomography colonography followed by colonoscopy (CTCCOL) 
(grey solid) 
Colonoscopy (COL) (red solid),  
Narrow-band imaging (NBI) (purple dotted)  
No intervention (black solid) 
Sigmoidoscopy (SIG) (turquoise solid) 
SIG then COL (SIGCOL) (red dotted) 
Sigmoidoscopy combined with barium enema (SIG + BE) (olive green dashed) 
Stool tests (blue solid) 
Stool tests combined with BE (stool tests+BE) (brown solid) 
Stool tests combined with COL (stool tests+COL) (red dotted) 
Stool tests combined with SIG (stool tests+SIG) (turquoise) 
 ‘+’ combination of tests  
‘’ sequence of test 
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Threshold analyses at various costs and sensitivity of CTC in detecting polyps 
were presented in comparison with existing modalities among an average risk 
population [101, 114, 166]. Some studies found CTC, with or without a threshold 
strategy for the size of polyps, would be cost-effective, while others found COL 
or iFOBT to be cost-effective. This depended on where CTC was used in the 
screening pathway either primary screening or secondary follow-up test. Cost-
effectiveness of CTC was examined in recent years with an improved 
understanding of the test performance and indications among people with 
asymptomatic polyps or with a positive result from FOBT [103, 117, 170]. A 
definitive follow-up interval using CTC has not been empirically established, thus 
modelled intervals of CTC strategy varied from every 5 years to 10 years among 
the average risk population, or every 3 years among asymptomatic people with 
small polyps (6-9 mm) [128, 142, 151, 158].  
The potential harm of CTC was rarely considered, although exposure to radiation 
from CTC every 3 or 5 years was reported to be low [128]. CTC was considered 
as a primary screening test in an average population compared to FOBT [141], 
COL [128] and SIG [101, 149, 161]. No studies have considered the costs and 
consequences of extra colonic findings from CTC.  
CTC was not cost-effective as a follow-up test for individuals with positive results 
from stool tests when compared to COL [125, 158]. CTC was relatively cost-
effective or cost-saving among people with polyps 6-9 mm as presented in Table 
3.1 [103, 117]. The frequency and interval of the modelled strategies were 
restricted and simplified compared with day-to-day clinical practice and current 
guidance/recommendations. This could misrepresent the cost-effectiveness of 
CTC and other screening modalities [97].  
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Table 3.1. CTC as a follow-up test 
 Population Interventions Sensitivity (Se, %) 
Specificity (Sp, %) 
[ranges] 
Participation 
[Ranges for 
sensitivity 
analysis] 
Reported outcomes 
Pickhardt 
(2007) 
[105] 
People with 
small polyps 
(6-9 mm) 
detected at 
CTC 
screening 
CTC with or 
without polyp 
size reporting 
threshold 
(6mm) 
vs 
COL + 
polypectomy 
FSIG 
No screening 
(<=5mm polyps,6-9mm, 
>=10mm, CRC) 
CTC Se (48%, 70%, 
85%, 95%) Sp 86% 
COL Se(80%, 85%, 
90%, 95%) Sp 90% 
FSIG (45%, 45%, 60-
65%, 90%) 
Initial 65% [1-
100] 
Repeated 
80% [1-100] 
Compared with No screening (currency USD);  
$4361 per LYG (CTC with a 6-mm threshold), $7138 per 
LYG (CTC with no threshold), $7407 per LYG (FSIG), 
$9180 per LYG (COL).  
Compared with COL, CTC with a 6-mm threshold 
resulted in a 77.6% reduction in invasive endoscopic 
procedures and 1112 fewer reported COL-related 
complications from perforation or bleeding. 
CTC with non-reporting of diminutive lesions was found 
to be the most cost-effective and safest screening option 
evaluated.  
Pickhardt 
(2008a) 
[103] 
60 years old 
asymptomatic 
polyps; 
diminutive 
(≤5mm), 
small (6-
9mm), large 
(≥10mm) 
CTC then COL 
with 
polypectomy  
vs 
CTC only  
polyps (≤5mm, ≥6mm, 
≥10mm,) 
CTC Se (48%, 89%, 
94%) 
CTC Sp (80%, 8%, 96%) 
100% 
(assumption) 
(Currency USD) Estimated 10Y CRC risk for unresected 
diminutive (0.08%), small (0.7%) and large polyps 
(15.7%). ICER of removing all diminutive polyps was 
$465,407 perLYG, and small CTC-detected polyps 
$59,015 per LYG. Polypectomy for large CTC-detected 
polyps yielded a cost-saving of $151 per person 
screened. 
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 Population Interventions Sensitivity (Se, %) 
Specificity (Sp, %) 
[ranges] 
Participation 
[Ranges for 
sensitivity 
analysis] 
Reported outcomes 
Pickhardt 
(2008b) 
[117] 
60 years old 
asymptomatic 
individuals 
with small 
polyps (6- to 
9-mm) 
detected at 
CTC 
screening 
3-yearly CTC 
surveillance  
vs 
Immediate 
polypectomy 
CTC Se (polyps 6-9mm) 
89%, Sp 80% 
 
COL Se (6-9mm polyps) 
85%, Sp 100% 
Not stated (Currency USD) Without any intervention, the estimated 
5-year CRC death rate from 6- to 9-mm polyps in this 
concentrated cohort was 0.08%, which is a sevenfold 
decrease over the 0.56% CRC risk for the general 
unselected screening population. The death rate was 
further reduced to 0.03% with the CTC surveillance 
strategy and to 0.02% with immediate colonoscopy 
referral. However, for each additional cancer-related 
death prevented with immediate polypectomy versus 
CTC follow-up, 9,977 COL referrals would be needed, 
resulting in 10 additional perforations and an incremental 
cost effectiveness ratio of $372,853. 
Walleser 
(2007) 
[125] 
Individuals 
with a 
positive 
FOBT 
CTC  
vs  
COL 
(CRC-polyps ≥10 mm - 
polyps 6-9mm)  
CTC Se (89 [70-98]-63 
[59-85] - 51 [41-60]) Sp 
CTC lesions  ≥6mm 90 
[88-92] 
COL Se (96[80-100]-95 
[90-98]-99[95-100]) Sp 
COL lesions ≥6mm 99.6 
[99.2-100] 
Not stated Australian dollars per life-years gained 
CTC is less effective and more costly than COL; if CTC 
was more sensitive than COL, CTC was more effective, 
at higher cost. 
COL colonoscopy; CRC colorectal cancer; CTC computerised tomography colonography; FOBT fecal occult blood test; FSIG flexible sigmoidoscopy; 
ICER incremental cost effectiveness ratio; LY(G) Life Years (Gained); USD United States dollar
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Management of polyps/adenomas and CRC 
Follow-up was modelled for those with positive results from stool-based tests or 
polyps detected using endoscopy-based tests or image-based tests. For 
confirmed polyps, the interval and the degree of complexity of follow-up strategies 
varied greatly from simple COL at 3 -10 years after initial polypectomy to multiple 
strategies based on the current recommended guidelines [136, 159, 171]. Follow-
up was nested within a Markov model [126, 147, 152, 153] or a discrete event 
simulation [79, 172], or not modelled [151]. Crudely simplified follow-up strategies 
were considered with assumptions that departed from the real-world, for example, 
100% compliance or a common compliance rate at any screening round [103, 
136, 160, 162, 163]. Cost-effectiveness was generally recognised to depend on 
compliance with screening, however, one study suggested that high compliance 
rates were not necessary to achieve cost-effectiveness [113].   
Detected polyps were grouped into a single state or two or three depending on 
number and size of polyps found at the baseline COL [79, 105, 123, 145]. 
Modelled disease states of CRC were mainly local, regional or distant 
(disseminated, CRC or Dukes’ stages A to D). In some studies a single CRC 
disease state was used with an average lifetime treatment cost predicted or 
estimated, thus the results failed to predict benefits of early detection and 
prevention of CRC [106, 113, 129]. More recently the costs of CRC stage-specific 
treatment were modelled including combination and/or sequence of treatments 
[96, 119, 142, 171]. Costs of CRC treatment were not stated, or were crudely 
simplified as lifetime costs [129], or directly lifted from previous publications 
without adjusting to the current year [105, 139]. Given that the primary goal of 
screening is prevention and early detection of disease, it is crucial to capture not 
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only the initial years of screening [168] but also the longer term benefits accrued 
over a lifetime. Any differences in the CRC treatment costs as a result of 
prevention or early detection of CRC were not distinguished in the model.  
 
Input parameters 
Since direct evidence on the natural history of CRC is lacking, input parameters 
were taken from multiple sources ranging from epidemiological studies, hospital 
records, disease registries and expert opinion.  
Papers emphasised the improved test performance of their chosen modalities 
(and their effectiveness and cost-effectiveness) but often combined more recent 
information on test performance with existing, outdated information on resource 
use. For example, the cost-effectiveness of CRC screening with CTC was 
presented using a single CRC treatment cost taken from a previous study [173] 
and costs per test from 1998 [105]. COL related complications were modelled in 
terms of costs. Test performance of CTC varied in the studies from 33% to 100% 
depending on the size of polyp (see Table 3.1) [103, 105, 117]. In the absence of 
sensitivity and specificity data for new technologies, test performance similar to 
existing tests was assumed [128]. Quality of life relating to CRC was repeatedly 
taken from a single study [174] for over a decade [79, 102, 142, 171]. More 
recently, EQ-5D values of cancer-free and cancer states have been estimated 
from a national survey [96]. 
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Handling uncertainties and model validation 
Key assumptions were mainly examined using deterministic sensitivity analyses 
of the adenoma-carcinoma sequence, CRC prevalence rate, test performance, 
and compliance rate. In addition, threshold analyses, and scenario analyses were 
performed to address different types of uncertainty [101, 114, 166]. However, test 
performance of screening modalities was not subject to sensitivity analysis in 
some studies [143, 175]. Sensitivity analyses in most cases confirmed the base- 
case finding. Besides uncertainty from sampling variation in the general 
population, synthesising evidence from multiple sources in order to estimate cost-
effectiveness adds another layer of uncertainty. PSA was performed considering 
the uncertainty surrounding all parameters simultaneously [76, 79, 138, 148, 158] 
complementing the deterministic sensitivity analyses. The distributions used for 
PSA were reported in only two studies, although no justification was given for 
choosing these distributions [102, 141]. Uncertainties surrounding input 
parameters were addressed using appropriate types of sensitivity analyses in 
some studies, thus improving credibility and robustness of the reported results. 
For example, a number of scenario analyses were considered in which different 
adherence rates and lower subsequent adherence rates were applied across 
strategies [171]. Results were sensitive to costs but sometimes the cost data 
were not considered in the sensitivity analyses [105]. Other studies did not 
address the limitations related to their assumptions [106, 107, 121]. Methods for 
economic evaluation have been consolidated further over time and authors have 
accordingly explored uncertainty to a greater extent in recent publications. 
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Validation of models is desirable in order to minimise errors and improve study 
credibility and consistency with methodological guides [176]. Model results were 
not validated in early publications because no data set was available [110, 162, 
163]. An extensive ‘debudding exercise’ and the review of model structure by 
independent clinicians were reported as internal validation [171]. Validation of 
models was performed by comparing model simulation results with actual data 
sets [76, 105, 111, 116, 139, 154, 157, 175] or by calibration against published 
studies [114, 147, 153].  
Validation results showed overestimated efficacy for polypectomy [144], 
underestimated prevalence of adenoma compared to an existing study [151], or 
significantly different CRC incidence compared to a recent publication [117], 
slightly underestimated CRC mortality compared to existing studies [102] or the 
model’s prediction of CRC incidence reduction was consistent with the available 
data [118]. 
 
3.2.5 Discussion 
Evidence on the natural history of CRC is limited. The studies identified were 
predominantly model-based economic evaluations because no single trial could 
provide the large sample and long-term follow-up data required to compare 
screening strategies with differing screening intervals and 
sequences/combinations of tests. The assumed constant risks of individuals 
developing CRC would have under- or over-estimated CRC incidence and 
subsequent resource use for its treatment.  
In clinical practice, a sequence of the same or different tests is performed in CRC 
screening. Compared to current practice, the modalities modelled were limited 
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and the adenoma-carcinoma sequence was crudely simplified. As a 
consequence of rapidly evolving technology and the quite poor evidence base 
regarding natural history, costs and health outcomes, many evaluations have 
been of limited value in informing routine clinical practice. 
It is vital to know which test(s) should be considered first in a given population or 
in what combination or sequence, in order to maximise health benefit considering 
best available effectiveness and cost-effectiveness evidence in the prevention 
and early detection of CRC. For example, CTC appeared to be cost-ineffective 
as a primary screening modality compared with other tests among the average 
risk population, but potentially could be cost-effective when used as a follow-up 
test in a selected population in a pathway. A pathway for CRC including screening, 
follow-up surveillance and treatment for CRC would provide a bigger picture 
compared with studies that provide a snapshot view [177]. Given the 
computational complexity and additional data required for a pathway model, a 
balance must be struck between transparency and flexibility when choosing the 
modelling approach in each context.  
The studies often omitted to say (or simplified) how identified adenomas or CRC 
were to be managed or treated. CRC screening and follow-up tests aim to detect 
early CRC or prevent CRC, thus the consequent costs and health benefits should 
be accounted for in the model. The improved test performance of newer 
modalities was captured, but their downstream effects for screening/follow-up 
were dated. Current or existing guidance on the cost-effectiveness analysis of 
CRC treatments should be linked to the diagnostic tests when estimating cost-
effectiveness of CRC screening and follow-up strategies.  This is because the 
cost-effectiveness of a diagnostic strategy depends in part on the consequences 
for subsequent treatment. Furthermore, for the cost-effectiveness of a new 
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treatment, evidence tends to be generated through randomised clinical trials. 
However, input parameters for quality of life have suffered from selection bias 
because searches for data have not been conducted systematically and values 
generally have come from observational studies.  Efforts should be made to have 
up-to-date input parameters for down-stream effects in order to estimate the cost-
effectiveness of new modalities with less bias and uncertainty. 
Test performance and compliance rates will vary between screening rounds and 
subsequent follow-up testing. Such variations were crudely simplified by 
assuming a fixed test performance and a constant compliance rate, and were 
explored using deterministic sensitivity analysis in most studies. Further studies 
varying test performance and compliance rates at each screening round 
dependent on different tests are recommended. 
Extra colonic findings from CTC will influence average screening costs and the 
subsequent health outcomes, and therefore should be considered in order to 
estimate the relevant costs and health outcomes of CTC strategies.  
The time period during which the cancer is asymptomatic but detectable by the 
screening test or the time by which the CRC was diagnosed through screening 
were insufficiently modelled and explored in sensitivity analyses. Assumptions 
are necessary when constructing a model and uncertainties are introduced at 
various stages, for example, multiple sources of key parameters to populate the 
model (parameter uncertainty), and the choice of health states (structural 
uncertainty). Sensitivity analyses of carefully chosen aspects of uncertainties can 
increase confidence in or question results. Due to the limited evidence on the 
natural history of the adenoma-carcinoma sequence, key assumptions are 
required, however, the subsequent structural uncertainty was not fully explored 
in most studies. Alternative choices of health states or care pathways should be 
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explored using different scenario analyses.  Parameter uncertainty was not fully 
explored, although uncertainties around mean health and mean cost were 
explored to a degree. Cost data were rarely explored in PSA and when they were, 
the distributions were poorly justified. 
Cost-effectiveness of follow-up strategies and the inter-relation between CRC 
screening and follow-up programmes need further study. In addition, other factors, 
such as healthcare financing and delivery of health service, should also be 
considered because a modality can be cost-effective in a specific setting, 
however, this does not guarantee cost-effectiveness in a different setting. 
CRC screening and follow-up tests can be invasive with unintended 
consequences, such as perforation and bleeding, and also involve pre-procedural 
preparation and post-procedure rest. These impacts on quality of life have been 
under-studied and under-reported in most studies. Quality of life data in relation 
to CRC and colorectal adenoma are very limited, and for over a decade were 
largely based on a single study [174]. It is imperative to establish a better 
understanding of the impact on quality of life of CRC screening and follow-up in 
people with adenomas and CRC.  
 
3.2.6 Conclusion 
Despite many cost-effectiveness analyses having been published, important 
aspects remain under-researched, including the consideration of downstream 
effects (such as management of adenoma and CRC) linked to appropriate 
screening or follow-up tests. It is important to assess the cost-effectiveness of 
different combinations or sequences of follow-up strategies for those with positive 
results and identified adenomas from mass screening. Information generated will 
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serve as a key link between a mass CRC screening programme and the most 
appropriate follow-up tests and relevant treatments, this will also aid decision 
makers to introduce appropriate guidance/policy and will promote clinically 
effective and cost-effective follow-up strategies to appropriate individuals. 
Therefore, cost-effectiveness analysis of follow-up tests for people with confirmed 
adenomas is warranted.   
 
3.3 Updates of Research Paper II 
A detailed assessment of the economic evidence related to COL surveillance was 
provided in the Research Paper II [100]. A new economic model may not be 
always required if there is existing economic evaluation that could be adopted for 
the relevant setting of interest. This review has identified important gaps in the 
existing evidence at the time of publication. 
A search update of Medline and Embase was carried out on 31 October 2015 
and NHS EED to 31 March 2015 (ceased March 2015). A report relevant to this 
topic [99] was not captured in the original search because the report was indexed 
as a book in the database at the time of original search [100]. Therefore, the 
search was broadened to include the National Institute for Health and Care 
Excellence (NICE) website (www.nice.org.uk) to minimise the chance of missing 
relevant studies in the update. Table 3.2 presents the search update. 
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Table 3.2 Search update 
Initial hits N=1,453 
Duplicates removed N=46 
Included for full text review  after screening title/abstract N=143 
Included for full-text review N=52 
Included after full-text review N=18 
Included for review N=10 
 
 
A total of 1,453 additional publications were identified from the search. After 
sifting through the studies according to the selection criteria, 10 studies were 
selected to be included in the review update (see Appendix Table A3.5) [178-
187]. 
 
Main findings from the 10 included studies are: 
1) In addition to the existing 195 comparisons, thirty-two comparisons were 
further identified from the review update and the published Figure 2 was updated 
accordingly (see Figure 3.3). Stool-based tests and COL remained the most 
commonly chosen intervention for comparison. On the other hand, the sequential 
tests of FOBT then CTC followed by COL is compared to the stool test combined 
with COL [179].  
2) Polyp/adenoma management is increasingly considered part of the CRC 
screening model in some studies [179, 180, 182, 183, 185-188], however, no 
clear cost-effective strategies were reported in the follow-up COL surveillance 
among people with confirmed adenomas in CRCS. 
These findings are consistent with those from published studies, therefore the 
key findings from the original review remains relevant. 
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Figure 3.3 Updated Figure 2 At a Glance – 227 comparisons 
 
Barium enema (BE) (brown solid)  
Barium enema and colonoscopy (BECOL) (brown dotted) 
Capsule endoscopy (CapEndo) (green solid) 
Computerised-tomography colonography (CTC) (grey solid) 
Computerised-tomography colonography followed by colonoscopy (CTCCOL) 
Colonoscopy (COL) (red solid); Narrow-band imaging (NBI) (purple solid),  
No intervention (black solid); Sigmoidoscopy (SIG) (turquoise solid) 
Sigmoidoscopy combined with barium enema (SIG + BE) (olive green dashed) 
Stool tests (blue solid); Stool tests combined with BE (stool tests+BE) (brown solid) 
Stool tests combined with COL (stool tests+COL) (red dotted) 
Stool tests combined with SIG (stool tests+SIG) (turquoise dotted) 
Faecal occult blood test (FOBT) then CTC followed by COL (FOBTCTCCOL) 
(Orange solid) 
 ‘+’ combination of tests; ‘’ sequence of test 
Added interventions from updated search (+underscored number in Italic) 
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4 SYTEMATIC REVIEW OF HEALTH STATE UTILITY 
VALUES FOR ECONOMIC EVALUATION OF 
COLORECTAL CANCER  
 
 
4.1 Preamble to Research Paper III  
This chapter provides a detailed assessment of HSUVs for economic evaluation 
of CRC. In the next Research Paper III, the systematic review of evidence on the 
HSUVs will be addressed in order to identify potentially relevant HSUVs that are 
methodologically robust with health states of interest, which could be used in the 
cost-effectiveness analysis of COL surveillance in the prevention and early 
detection of CRC. This review assesses the advantages and disadvantages with 
respect to valuation methods used and CRC clinical pathways. An approach 
taken in a published systematic review of HSUVs of breast cancer [189] was 
adopted in the quality appraisal of CRC HSUVs.  
Of 57 studies included in the review, each study contributed between 1 and 16 
HSUVs. There was a limited number of HSUVs that were methodologically robust 
with the range of health states of interest that can inform the planned CUA 
(Chapter 5). A total of 368 HSUVs were identified from this review; however, the 
states which the HSUVs refer to were predominantly metastatic CRC stages. 
Reported HSUVs were often complex making pooling of values problematic. A 
further search was undertaken to identify HSUVs for an economic model in a 
Korean context using Korean databases (Appendix 5.6.1). Many studies 
collected HRQoL of a sample from CRC patients, the metastatic CRC stage in 
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particular. In the absence of directly relevant HSUVs for CRC among Koreans in 
a Korean setting, a set of HSUVs [190] was chosen because it was 
methodologically robust with health states of interest for the economic model from 
a group of people with similar mean age to that of the CRC cohort. Cross-
sectional data were collected among people with confirmed polyps or cancer 
(n=554; mean age ±SD 63.3±11.3) using the Chinese SF-6D in Hong Kong. The 
health preference scores were calculated by converting health state into a single 
index weighted summation from the SF-6D preference weight coefficients, based 
on published scoring algorithm for the Hong Kong population. Authors 
acknowledged the limitations of the study including the possible sampling bias 
resulting from convenience sampling from a specialist clinic leading to a limited 
generalisability of findings, and a high proportion of unemployed, low household 
income, or low level of education in the sample. To facilitate a consistent 
approach to appraisals across different areas, some institutes or organisations 
define a set of criteria for the economic evaluation which specifies that HSUVs 
should be derived from standardised and validated generic instruments which 
use a choice based method either time trade-off (TTO) or standard gamble (SG), 
and takes preference from the general public [83, 191]. However, CUAs utilising 
Korean data was 3 out of 16 CUAs with no study related to CRC [10]. Therefore, 
despite acknowledged limited generalisabilities of HSUVs [190] it was considered 
most pertinent with relevant health states in order to inform the CUA (Chapter 5) 
compared to other HSUVs.  
There are challenges in obtaining robust values for health states in COL 
surveillance. Findings may have limited generalisability if a sample size is not 
large enough. Unlike other pre-cancerous conditions, adenomas are 
asymptomatic. The impact on the utility values of asymptomatic adenomas or 
 
 
112 
 
future risk of CRC in people with asymptomatic adenomas remains uncertain. 
Additionally, it is unknown if the existing risk status related to adenomas would 
have an impact on the (dis)utility and whether the (dis)utility remains constant or 
diminishes over time. Future research related to the (dis)utility values concerning 
COL surveillance is warranted. 
 
Further searches of databases after 31 October 2015 have not been conducted 
since the publication of Research Paper III. Findings from this systematic review 
informed the modelling of different health states associated with CRCS and CRC 
and HSUVs for the economic model (Chapter 5).  
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4.2 Research Paper III Systematic review of HSUVs for 
economic evaluation of CRC 
 
4.2.1 Abstract 
Cost-utility analyses undertaken to inform decision making regarding colorectal 
cancer (CRC) require a set of health state utility values (HSUVs) so that the time 
CRC patients spend in different health states can be aggregated into quality-
adjusted life-years (QALY). This study reviews CRC-related HSUVs that could be 
used in economic evaluation and assesses their advantages and disadvantages 
with respect to valuation methods used and CRC clinical pathways. Fifty-seven 
potentially relevant studies were identified which collectively report 321 CRC-
related HSUVs. HSUVs (even for similar health states) vary markedly and this 
adds to the uncertainty regarding estimates of cost-effectiveness. There are 
relatively few methodologically robust HSUVs that can be directly used in 
economic evaluations concerned with CRC. There is considerable scope to 
develop new HSUVs which improve on those currently available either by 
expanded collections of generic measures or by making greater use of condition-
specific data, for example, using mapping algorithms.  
 
KEYWORDS 
Health state utility value; colorectal cancer; quality-adjusted life year (QALY); 
economic evaluation 
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4.2.2 Introduction 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide 
[192]. CRC was traditionally more common in the western world but some Asian 
countries have shown an increase in CRC incidence in recent years [193]. 
Economic evaluation to inform decision making regarding CRC requires a set of 
health state utility values (HSUVs) so that the time CRC patients spend in 
different health states can be aggregated into quality-adjusted life-years 
(QALYs).  
There are four ways by which the required HSUVs can be empirically generated: 
(1) There are generic preference-based measures (PBM), such as the EQ-5D, 
SF-6D, 15D and the HUI3, where generic health states are valued using a tariff 
based on the preferences of the general public elicited using methods such as 
the time trade-off (TTO) and the standard gamble (SG).  
(2) An alternative approach is to identify a number of relevant cancer-specific 
health states (as opposed to using generic health state descriptions) and to value 
these health states directly, again using methods such as the TTO and the SG.  
In this case the valuations are potentially made by cancer patients themselves, 
health care professionals or the general public. 
(3) A variation on this second approach is to develop a preference-based 
algorithm with which a full range of cancer-specific health states can be valued. 
Two such measures, the EORTC-8D and the QLU-C10D, are based on items 
from the Quality of Life Questionnaire C30 (QLQ-C30). 
(4) Finally, a mapping algorithm can be used to transform cancer-specific data 
such as the EORTC QLQ-C30 and the Functional Assessment of Cancer 
Therapy-General (FACT-G) into generic PBMs. 
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This paper reviews CRC-related HSUVs that could be used for economic 
evaluations and assesses their advantages and disadvantages with reference to 
the valuation methods used and CRC clinical pathways. 
 
4.2.3 Methods 
The literature was searched to identify CRC-related HSUVs for use in economic 
evaluation. MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, 
Embase (up to 30 October 2015) and Health Economic Evaluations Database 
(HEED, up to December 2014) were searched using the keywords colorectal 
cancer, health-related quality of life, QALY and economic evaluation. The search 
was restricted to studies in English. The search was broadened to include the 
National Institute for Health and Care Excellence (NICE) website 
(www.nice.org.uk) to minimise the chance of missing relevant studies. Economic 
filters were used when searching for evidence on generalist databases, such as 
MEDLINE. A simplified search was undertaken without using economic filters, for 
evidence on economics databases such as HEED. A further search was run on 
non-economic databases, including MEDLINE, to capture studies that are 
relevant to mapping. Search strategies were reported in Appendix Tables A4.1- 
A4.2. Relevant conference abstracts were tracked for full journal publications. All 
search results were downloaded into EndNote and duplicates were removed. 
Titles and abstracts were screened between two independent reviewers and full 
papers that did not meet the inclusion criteria were excluded. The study selection 
criteria are reported in Appendix Table A4.3. Studies were included if they 
contained CRC-related HSUVs which had not been previously reported, be they 
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generic PBMs or directly valued CRC-related health state descriptions, or 
mapping to generic PBMs based on direct statistical association mapping.  
Full text was acquired for the remaining studies (including those which had 
insufficient details, such as no abstract). All included studies were read and any 
disagreements were resolved by discussion between the two reviewers. Of the 
285 papers identified as potentially relevant, 228 were excluded because they 
did not report CRC-related HSUVs but presented psychometric validation studies 
without internal validation properties, the values were previously reported in other 
included studies, they involved unspecified or not clearly specified CRC-related 
health states, or a primary mapping function was not reported.  
A total of 57 studies were included in the review (see Appendix Table A4.4). The 
numerical summary of the search and selection process for the review is reported 
in Figure 4.1.  
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Figure 4.1 Numerical summary of the searches for the review 
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Descriptive characteristics (year of publication, country of origin, intervention 
type, number and mean age of respondents) and methodological characteristics 
(what was the measure of value; how the health state was described and valued; 
who valued it; how the QALY was aggregated) were collected for the fifty seven 
studies. Findings from selected studies are discussed in the following section. 
 
4.2.4 Results 
Of the 57 studies, eleven were set in the US [174, 194-203],  eight in the UK [204-
211], seven in the Netherlands [212-218], four in Canada [219-222], five in Hong 
Kong [190, 223-226], two each in Norway, Korea, Australia and Japan [227-234] 
and other country settings included Spain, India, Malaysia, Singapore, Sweden, 
and Turkey [235-242]. Some studies did not report their settings or were 
multinational or multicentre studies [243-248]. Studies were mostly published in 
the last 15-20 years and focussed narrowly on different interventions at specific 
stages of CRC. For example, the adverse events (AEs) of chemotherapy and 
survival (partial response) in metastatic CRC (mCRC) were the main conditions 
of interest in several studies [203, 209, 220, 221, 232, 236-238, 244, 246, 247]. 
HSUVs associated with rectal cancer have been reported [197, 207, 212-214, 
216, 240, 242].  
The 57 studies included in this review reported a total of 368 CRC-related 
HSUVs. All reported HSUVs are summarised in the Appendix Table A4.5. 
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Generic preference-based measures 
Thirty-two studies collected health state information from CRC patients using 
generic PBMs and have applied health state tariffs based on the preferences of 
the general public. These studies generally collect data from patients recruited to 
trials, usually several hundred patients and at multiple time points. The most 
widely reported generic PBM is the EQ-5D  valued using the UK (TTO-derived) 
value set with some exceptions [217, 245, 246] followed by the SF-6D [196, 222, 
224, 225] and HUI3 [199, 200, 221]. 
 
Direct valuation of CRC health states 
Fourteen studies directly valued CRC health states. Preferences have been 
elicited either using the TTO method with patients or a surrogate group [194, 195, 
220, 232, 233, 236-238] or SG [174, 197, 202, 209, 219]. Generally, these studies 
involved fewer than 100 respondents. The participants were drawn from CRC 
patients, health care professionals and the community or general population 
(non-patient, non-health care professional). Only one study recruited a sample 
entirely from the general population [232] and one entirely from patients [174]. 
Mean utility values from health care professionals were lower than those from 
patients across health states [164, 201]. The remission health state was valued 
similarly by both groups, whereas the community group assigned lower values to 
adjuvant therapy-related AEs [194]. 
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Preference-based condition-specific measures 
Another approach has recently been developed which offers an alternative to 
using directly valued health states from the literature. The EORTC-8D is a cancer-
specific PBM derived from the EORTC QLQ-C30 [249]. It utilises ten items from 
the thirty items of the QLQ-C30. A total of 85 EORTC-8D health states were 
valued by 350 members of the UK general public and these responses were then 
modelled to let any of the EORTC-8D states be valued. The QLU-C10D utilises 
twelve QLQ-C30 items to produce a ten dimensional measure, however, to date 
this approach has not been used to value CRC health states [250]. 
 
Mapping  
The absence of data on generic PBMs from most cancer trials has generated 
considerable interest in mapping algorithms, from cancer-specific measures such 
as the Functional Assessment of Cancer Therapy-General (FACT-G) and the 
EORTC QLQ-C30 to measures such as the EQ-5D and the SF-6D [116, 251]. 
While several studies have reported mapping algorithms in the cancer area [190, 
198, 222, 223, 229, 230, 235],  only one of the mapping algorithms was 
developed using responses from CRC patients [252] and only one study reported 
HSUVs for different CRC-related health states based on an algorithm [226]. The 
mapping studies are summarised in Appendix Table A4.6.  
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HSUVs and the clinical pathway 
For the purposes of estimating QALYs it is usually necessary to have information 
on HSUVs at several points along the clinical pathway. Evaluations of screening 
or diagnosis require valuations at the time of the intervention and subsequently 
following treatment.  
CRCS-related HSUVs  
Only one study reported CRC-screening related HSUVs as presented in Table 
4.1 [215].  
 
Table 4.1 CRC screening-related HSUVs 
Valuation 
methods used 
HSUVs reported Reference 
EQ-5D Negative FS after positive FIT 0.81 
Positive FS after positive FIT 0.82 
Kapidzic (2012) [215] 
COL colonoscopy; CRCS colorectal cancer screening; FIT faecal immunochemical test  
FS flexible sigmoidoscopy; HSUV health state utility value  
 
Colostomy-related HSUVs  
Sixteen colostomy-related HSUVs were reported from 4 studies [174, 195, 201, 
219]. Disutility of 0.09 [174] and of 0.111 [201, 219] were reported among rectal 
cancer patients with colostomy compared with those who without colostomy, 
respectively. The utility of having a stoma among former CRC patients with a 
reversed colostomy was 0.20 lower compared with those currently have a stoma 
[201]. HSUVs related to having a colostomy (surgery) and no colostomy 
(radiotherapy) were measured using SG in the primary treatment for rectal 
cancer. People with a colostomy assigned a higher value than people without a 
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colostomy [219]. The summary of colostomy-related HSUVs is presented in Table 
4.2. 
Table 4.2 Colostomy-related HSUVs 
Valuation 
methods used 
HSUVs reported Reference 
SG With colostomy 0.915 
Without colostomy 0.804 
Boyd* (1990) 
[219] 
TTO [20 years with CRC; 20 years with a colostomy] 
 
Unscreened  [0.80; 0.80] 
Screened  [0.80; 0.75] 
Enrolled in a COL screening program [0.85; 0.79] 
CRC patients [0.83; 0.90] 
Dominitz 
(1997) [195] 
EQ-5D With stoma 0.836 
Without stoma 0.870 
Hamashima 
(2002) [228] 
SF-6D With stoma 0.69 
Without stoma 0.73 
Hornbrook 
(2011) [196] 
SG Stage II/III rectal cancer, permanent colostomy 
0.50  
Stage II/III RC treated with resection, 
chemotherapy, radiation therapy and with 
permanent ostomy 0.50 
Stage IV metastatic/ unresectable disease 
without colostomy 0.25  
State IV metastatic/ unresectable disease with 
colostomy 0.25 
Ness (1999) 
[174] 
TTO Currently with colostomy 0.84 
Reversed colostomy 0.64  
Community members 0.63  
Smith (2006) 
[201] 
EQ-5D PRT and TME PS 0.823  
TME PS 0.853 
van den 
Brink (2004) 
[216] 
* Reported HSUVs are re-expressed on a 0-1 scale; COL colonoscopy; CRC colorectal 
cancer; HSUV(s) health state utility values; PRT preoperative radiotherapy; PS 
permanent stoma; RC rectal cancer; SG standard gamble; TME total mesorectal 
excision; TTO time trade-off  
 
 
HSUVs and colorectal polyps  
Wong and colleagues [190] reported two HSUVs using SF-6D for those 
individuals with low- and high-risk colorectal polyps (0.871 and 0.832, 
respectively).  
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HSUVs and rectal cancer  
HSUVs for hypothetical health states related to therapy for locally recurrent rectal 
cancer were higher among rectal cancer patients than health care professionals 
when measured using SG [197].  
Two sets of rectal cancer-related HSUVs were reported at different time points 
and at different levels of surgery using EQ-5D and TTO values assigned by the 
UK general public [253, 254]. However, no standard deviation of mean values 
was reported. Overall, improved survival outweighed the disutility related to AEs 
of preoperative radiotherapy compared with surgery alone [207, 216]. A summary 
of rectal cancer-related HSUVs is presented in Table 4.3. 
 
Table 4.3 Rectal cancer-related HSUVs 
Valuation 
methods 
used 
HSUVs reported Reference 
SG [Healthcare professionals; patients] 
Disease recurrence [0.69; 0.72] 
Surgical resection[ 0.69; 0.83] 
Pain and complications [0.50; 0.78] 
Miller (2000) 
[197] 
EQ-5D PRT+TME 0.70-0.86 
Recurrent 0.67 (local) 0.70 (distant) 0.48 (local/ distant) 
 
TME 0.63-1.0 
Recurrent 0.80 (local) 0.64 (distant) 0.45 (local/ distant) 
Van den 
Brink 
(2004)**[216] 
EQ-5D Mean EQ-5D (SD) 
Baseline before TME 0.88 (0.15) 
6 weeks after TME 0.85(0.18) 
12 weeks after TME 0.87 (0.19) 
26 weeks after TME 0.88 (0.17) 
52 weeks after TME 0.86 (0.6) 
Hompes 
(2015) [207] 
** Ranges of reported HSUVs; HSUV(s) health state utility value(s)PRT preoperative 
radiotherapy; SD standard deviation; SG standard gamble; TME total mesorectal 
excision 
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HSUVs and AEs/ treatments of CRC  
Best and colleagues (2010) [194] elicited preferences for seven health states 
associated with stage III colon cancer and adjuvant chemotherapy using TTO 
among CRC patients and community members. The TTO values for mCRC 
obtained from CRC patients were higher than those obtained from the community 
members. Several CRC health states were measured among CRC patients in 
Finland and were valued using the UK TTO tariff [239]. 
Skin toxicity is a common AE related to epidermal growth factor receptor (EGFR) 
agents. Improved HSUVs related to an EGFR agent were demonstrated using 
HUI3 among mCRC patients when compared with best supportive care. Health-
related quality of life (HRQoL) was measured in mCRC patients and valued by 
the public [221]. Skin toxicity associated with mCRC treatments was reported to 
have little impact on HRQoL among mCRC patients [244, 246]. HSUVs obtained 
from patients with or without anti-EGFR treatment were applied to the duration of 
the AEs (days with grade 3 or higher AEs) and time without symptoms or toxicity 
(TWiST), and the differences were measured using a quality-adjusted time 
without symptoms of disease or toxicity of treatment (Q-TWiST) analysis [248]. 
Q-TWiST analysis was used to estimate utility values for three health states 
among CRC patients with liver metastasis undergoing hepatic resection [218].  
HRQoL measured directly from patients is not always possible in mCRC, and 
around 30 carers were used a number of times as a proxy because terminally ill 
mCRC patients would have difficulties in understanding SG or TTO techniques 
[209, 220, 236-238]. A summary of HSUVs associated with CRC treatments and 
AEs are presented in Table 4.4. 
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Table 4.4 HSUVs associated with CRC treatments and AEs 
Valuation 
methods  
Health states and reported HSUVs  Reference 
EQ-5D [1st line] Panitimumab+FOLFOX4 0.778; FOLFOX4 0.756  
[2nd line] Panitimumab+FOLFIRI 0.769; FOLFIRI 0.762  
Bennett (2011) 
[244] 
TTO [CRC patients; community members] 
Remission [0.83; 0.82] Adjuvant, no neuropathy [0.61; 0.60] 
Adjuvant, mild neuropathy [0.61; 0.51] 
Adjuvant, moderate neuropathy [0.53; 0.46] 
Adjuvant, severe neuropathy [0.48; 0.34] 
Metastatic, stable [0.40; 0.51], Metastatic, progressive [0.37; 
0.21] 
Best (2010) 
[194] 
TTO FOLFOX+‘new drug’→FOLFIRI→BSC until death [2-33 months] 
0.68-0.89  
FOLFOX→FOLFIRI→BSC until death [2-32 months] 0.70-0.94 
Dranitsaris 
(2011a)** [238] 
TTO FOLFOX±’new drug’ → FOLFIRI → BSC until death [2-29 
months] 0.67-0.83 
FOLFOX→FOLFIRI→BSC until death [2-32 months] 0.72-0.91 
Dranitsaris 
(2011b)** [237] 
TTO FOLFOX+‘new drug’→FOLFIRI→BSC until death [2-29 months] 
0.52-0.84  
FOLFOX→FOLFIRI→BSC until death [2-32 months] 0.53-0.84 
Dranitsaris 
(2012a)** [236] 
TTO FOLFOX+‘new drug’→FOLFIRI→BSC until death [2-28 months] 
0.44-0.72  
FOLFOX→FOLFIRI→BSC until death [2-32 months]  0.44-0.71 
Dranitsaris 
(2012b)** [220] 
EQ-5D Metastatic disease 0.820  
Palliative care 0.643  
Farkkila (2013) 
[239] 
HUI3 Cetuximab+BSC 0.71-0.77 
BSC 0.66-0.71 
Mittmann 
(2009)** [221] 
EQ-5D [Panitumumab plus BSC;  BSC alone] 
Overall [0.72 ; 0.68]  Wild-type KRAS [0.73 ; 0.68] 
Mutant KRAS [0.71 ; 0.68]  
Odom (2011) 
[246] 
SG Partial response 1.0; Stable disease 0.95 
Progressive disease 0.575; Terminal disease 0.1 
Petrou (1997)* 
[209] 
TTO XELOX without AEs 0.59 ;FOLFOX without AEs 0.53  
Febrile neutropenia 0.39; Nausea/vomiting 0.38  
Diarrhoea 0.42; Hand-foot syndrome 0.39; Fatigue 0.45  
Peripheral neuropathy 0.45; Stomatitis 0.42  
Shiroiwa (2009) 
[232] 
EQ-5D [Panitumumab + BSC; BSC]  
TOX [0.6008; 0.4409], TWiST [0.7678; 0.6630],  
REL [0.6318; 0.6407] 
Wang (2011) 
[248] 
EQ-5D Disease-free 0.78;  Non-curative  0.67; Recurrence 0.74  
Recurrence with chemotherapy 0.82 
Recurrence without chemotherapy 0.68 
Wiering (2011) 
[217] 
EQ-VAS Baseline 61.76 (SD 23.15)  
Cycle 2 68.59 (SD 22.26) [p=0.06]  
End of study 66.54 (SD 23.18) [p=0.29] 
Ward (2014) 
[203] 
*Reported HSUVs are re-expressed on a 0-1 scale; ** Ranges of reported HSUVs; AE(s) 
adverse event(s); BSC best supportive care; CRC colorectqal cancer; FOLFOX 
Oxaliplatin + infusional 5 fluorouracil (5-FU); FOLFIRI Irinotecan + infusional 5 
fluorouracil (5-FU); FOLFOX4 5-fluorouracil/ folic acid and oxaliplatin; HSUV health state 
utility value; KRAS Kirsten rat sarcoma viral oncogene; REL (relapse period until death 
or end of follow-up); SD standard deviation; SG Standard gamble; TOX days with≥ grade 
3 adverse events; TTO time trade-off; TWIST time without symptoms or toxicity; XELOX 
capecitabine plus oxaliplatin
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Ness and colleagues (1999a) [174] reported much lower HSUVs for mCRC than 
did other studies [199, 200]. People who previously underwent the removal of 
colorectal adenomas assigned a much lower value to mCRC of 0.25 [174] 
compared to CRC survivors, 0.81 [199] and 0.85 [200]. CRC patients assigned 
relatively higher values to mCRC (0.820) and palliative care (0.643) compared to 
those who had no history of previous or current CRC [239]. Stable and 
progressive disease states were given a much higher value using SG by people 
who had colorectal adenomas removed [192] compared with those to CRC using 
TTO [194].  
 
Table 4.5 HSUVs in CRC 
Valuation methods 
used 
Reported HSUVs  Reference 
SG Stage I 0.74  
Stage II 0.74 (0.59*) 
Stage III 0.67 (0.59*) 
Stage IV 0.25  
Ness (1999a) 
[174] 
HUI3 Stage I 0.84  
Stage II 0.86  
Stage III 0.85  
Stage IV 0.84  
Ramsey (2000) 
[199] 
HUI3 Stage I 0.83  
Stage II 0.86  
Stage III 0.87  
Stage IV 0.81  
Ramsey (2002) 
[200] 
EQ-5D Dukes stage A+B 0.786$ 
Dukes stage C+D 0.806$ 
Wilson (2006) 
[211] 
SF-6D Stage I 0.831 
Stage II 0.858 
Stage III 0.817 
Stage IV 0.732 
Wong (2013b) 
[190]  
*Rectal cancer; SG Standard gamble; $Re-expressed on a 0-1 scale; FACT-C 
Functional Assessment of Cancer Therapy-Cancer 
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Of five studies reporting HSUVs of different CRC stages, HSUVs were clustered 
ranging from 0.732 to 0.87 [199, 200, 211, 224] with an exception of one study 
0.25 to 0.74 [174] . A summary of selected HSUVs in different CRC stages is 
presented in Table 4.5. 
 
4.2.5 Discussion 
There is no shortage of HSUVs available for those wishing to estimate the cost-
effectiveness of diagnostic and treatment strategies with respect to CRC. Those 
assessing cost-effectiveness face a number of challenges: first, justifying their 
selection of values when there is no set of values that are clearly superior to all 
others, and second, negotiating trade-offs between the advantages and 
disadvantages of the available values.  
This choice can be simplified where there is an agreed hierarchy regarding the 
appropriateness of different approaches to generating HSUVs. In order to aid 
resource allocation and decision making within a tax-funded healthcare system 
economic evaluation needs population values for specific health states related to 
CRC. Thus, the preferences of the public are generally deemed appropriate when 
health services are largely paid for by taxpayers [255]. Some agencies have a 
preference for generic PBMs being used to report the experience of patients in 
the trial from which the effectiveness of the treatment is being estimated when 
deciding whether or not to recommend a new treatment, or in the absence of such 
data similar measures reported in the literature would be used [191].  
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Researchers usually confront a series of trade-offs and must make judgements 
about the importance of having all HSUVs used in an economic evaluation come 
from the same source, or at least obtaining all the HSUVs using the same 
methods. The number of HSUVs required will in part depend on where in the 
clinical pathway the intervention being assessed is located. The earlier in the 
pathway, the larger the number of potentially relevant health states and the less 
likely it is that all the required HSUVs can come from a single study. Even with 
clear preferences over the type of measure and the source of values, the decision 
over which values to use can be challenging since the ranking of methods or 
sources might change in particular circumstances. For example, trial data is not 
always to be preferred to observational data, if the latter provide much larger 
numbers of observations and are more representative of patients in routine 
clinical practice. Also a directly collected generic PBM might not always be 
preferred to the same measure obtained through mapping, for example, if the 
latter allowed the valuation of a wider range of CRC-related health states. It is 
uncertain if HSUVs related to mCRC valued by CRC survivors are more relevant 
than those by health care professionals when making decisions. Also, the issues 
of whether or not HSUVs for mCRC valued by early CRC patients are more 
reliable than those valued by patients with different types of metastatic cancer, 
has received little attention.  
HSUVs have been measured by a surrogate group such as oncology nurses, 
pharmacists or other health care professionals [209, 220, 236-238]. Despite 
limitations to the study design (such as small sample size or under-explored 
uncertainties) these HSUVs continue to be used in economic evaluation studies 
associated with CRC [209]. Subsequently, these uncertainties are inherited by 
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the estimation of cost-effectiveness and of QALYs. Well-designed clinical studies 
continue to generate new evidence that is highly focussed on treatment effects 
with strong internal validity. Economic evaluation would be strengthened if health 
state data could be taken from the clinical studies that provide the estimates of 
effectiveness of treatment [256]. Further research which utilises data from 
patient-reported outcomes and population surveys cancer registry data in 
assessing HRQoL and HSUVs is recommended [257]. 
Given the absence of generic PBM data from many trials, existing mapping 
algorithms could be more fully utilised as an additional means of deriving HSUVs 
for economic evaluation of CRC, and also exploratory studies to derive HSUVs 
from EORTC QLQ-C30 data using the EORTC-8D or QLU_C10D are warranted. 
Although there are a number of algorithms for mapping from cancer-specific 
scales to generic PBMs, this approach has not been frequently reported with 
respect to CRC. Cancer-specific scales, such as the QLQ-C30, capture a number 
of clinical and domain-specific effects that might not be captured when using 
generic PBMs [258]. Mapping also has the advantage of producing QALYs 
measured using a familiar metric. However, any mapping inevitably introduces 
additional uncertainty to the QALY calculation and the cost-effectiveness 
estimation. 
Important questions associated with HSUVs for the economic evaluation of CRC 
remain unanswered. What is the most accurate way of measuring and valuing 
HRQoL in CRC? Is it better to collect HRQoL data directly from a small number 
of CRC patients over a follow-up period? The studies reviewed gave limited 
consideration to the best way to measure and value CRC health states [216].  
 
 
132 
 
This review highlights gaps in the evidence and opportunities for informative 
research. The most appropriate way to measure and value CRC-related health 
states should be studied. Developing a set of criteria for selecting the most 
appropriate HSUVs that fits the analyst’s purpose is encouraged. It is not known 
whether the mCRC-related HRQoL of CRC survivors is more representative than 
those derived from a small surrogate group. Also, whether mCRC-related HSUVs 
valued by early CRC patients are more appropriate than those valued by patients 
with different types of metastatic cancer for economic evaluation has been under-
researched. HSUVs play an integral role in economic evaluation. Methods of 
exploring and addressing uncertainties associated with the HSUVs chosen for 
economic evaluation should be studied. 
 
4.2.6 Conclusion 
CRC-related HSUVs vary markedly between studies and across methods. 
Despite the number of HSUVs published, there is not a set of HSUVs that are 
methodologically robust with a full range of values for health states of interest 
appropriate for the use in economic evaluation of CRC. There is considerable 
scope for new HSUVs to be developed which improve on those currently 
available and consequently to produce better estimates of QALYs and cost-
effectiveness, in order to better inform resource allocation and healthcare 
decision making. In addition, the use of existing mapping algorithms to derive 
CRC-related HSUVs should be further explored. 
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5 COST-EFFECTIVE STRATEGIES FOR PEOPLE WITH 
CONFIRMED ADENOMAS IN THE PREVENTION AND 
EARLY DETECTION OF COLORECTAL CANCER IN 
COLORECTAL CANCER SCREENING, NATIONAL 
HEALTH INSURANCE IN KOREA 
 
 
5.1 Preamble to Research Paper IV 
Gaps in the CRCS and the need for cost-effective evidence for the early detection 
and prevention of CRC were presented in Chapters 2-4. The focus of this chapter 
is the identification of cost-effective strategies for COL surveillance for the 
prevention and early detection of CRC in Korea. This will be achieved by 
developing an economic model and estimating the cost-effectiveness of COL 
surveillance strategies by utilising findings from Chapters 2-4: 
1) Adenoma recurrence rates post-polypectomy, resources used in COL 
surveillance and CRCS and CRC treatment were estimated through the short-
term analysis of the CRCS in NHS, Korea, 2009-2012 (CRC cohort, Chapter 2). 
2) The review of relevant cost-effectiveness evidence of COL surveillance and 
CRCS provided evidence on the common approaches taken in economic 
modelling, test modalities comparison, the follow-up strategies and down-stream 
effects in the published literature [100]. A further search of databases was 
undertaken in order to capture cost-effectiveness evidence in a Korean context 
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that might be relevant. The search confirmed there was no cost-effectiveness 
evidence for people with adenomas in the prevention and early detection of CRC 
(Chapter 3), therefore the construction of a de novo model was necessary to 
address the research questions posed in this thesis. Findings from the review 
informed for the potential modelling approaches of the economic evaluation of 
COL surveillance in the CRCS, NHI in Chapter 5.  
3) Health outcomes relevant to CRCS and CRC for the cost-utility analysis were 
identified through a systematic review of relevant HSUVs of CRCS and CRC 
[259]. Results from the systematic review (Chapter 4) informed in the choice of 
methodologically sound HSUVs of CRC for the economic model in Chapter 5. 
4) Also identified were cost-effectiveness evidence of COL surveillance and 
CRCS and HSUVs for CRC and CRCS in the context of Korea that informed a de 
novo cost-utility analysis of COL surveillance in the CRCS, NHI Korea (Chapter 
5). 
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5.2 Research paper IV Cost-effective strategies for people with 
confirmed adenomas in the prevention and early detection 
of colorectal cancer in colorectal cancer screening, 
National Health Insurance, Korea 
 
5.2.1 Abstract 
The aim of cost-utility analysis is to identify the most cost-effective strategies and 
to estimate the cost-effectiveness of follow-up colonoscopy (COL) options for 
colorectal cancer screening to inform the follow-up COL policy within the current 
colorectal cancer screening programme (CRCS) in the National Health Insurance 
(NHI) in Korea. A state transition model simulated the life experience of a cohort 
of individuals with confirmed colorectal adenomas, utilising results from short-
term analysis of CRCS in Korea (2009-2012, CRC cohort). Different intensities of 
COL surveillance were compared to No COL surveillance. Gaps in the evidence 
were complemented with the most relevant published evidence. A 0LR3HR 
strategy (that is COL offered to those in the high risk group every 3 year) appears 
to be the most cost-effective strategy, given a cost-effectiveness threshold of 
Korean Won 30,000,000 per QALY gained. The base-case result was sensitive 
to the cost of COL if it was set at as high as the cost of COL in the United States, 
otherwise it remained constant with the base-case results through a series of 
sensitivity analyses.  A full pathway modelling of CRCS linking the existing CRCS 
and COL surveillance by utilising CRCS and NHI data would provide further 
insights of the costs and benefits of CRCS in the NHI. 
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5.2.2 Introduction 
Colorectal cancer (CRC) is the third most common cancer in South Korea 
(hereafter, Korea) [48]. Indirect evidence suggested that the transformation of 
colorectal adenomas into carcinoma takes 10-15 years. The interruption of the 
adenoma-carcinoma sequence and the removal of the precursor of CRC 
(polypectomy) reduces the incidence of CRC [51]. Screening for CRC is offered 
routinely to individuals who are 50 years or older as part of the National Cancer 
Screening Programme (NCSP) in the National Health Insurance (NHI), Korea. 
There is limited cost-effectiveness evidence on the CRCS and follow-up 
strategies and further search was undertaken utilising published search 
strategies in order to identify economic evidence in the prevention and early 
detection of CRC for individuals with confirmed adenomas [100]. Of the five 
eligible studies identified, one was partially applicable despite limitations [260] 
and four studies were excluded [11, 261-263] due to severe limitations identified 
through a critical appraisal (see Appendix Tables A5.1.1-A5.1.2) [98]. There is a 
paucity of cost-effectiveness evidence regarding the intensity of colonoscopic 
surveillance (COL surveillance) in CRCS in the NHI, Korea, therefore a de novo 
economic analysis is needed. The focus of this economic analysis is marked with 
the green dotted in the Figure 5.1 (Reproduced from Figure 1.7 in section 1.6 of 
Chapter 1). 
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Figure 5.1 Gaps in the current CRCS NHI [Reproduced from Figure 1.7, section 1.6 
of Chapter 1]  
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Evidence associated with the true incidence rate of adenomas is limited in Korea 
[64]. Existing studies focused on people having COL surveillance tend to 
overestimate the prevalence of adenomas because study participants were likely 
to be at a higher risk of developing CRC than the general population. Index COL, 
defined as the most recent COL performed by an experienced specialist 
colonoscopist, is performed in order to remove detected polyps/adenomas and 
to establish risk status [24, 67, 69, 70]. The size of adenomas, the degree of 
dysplasia and the presence of villous features are then used in determining the 
individual’s risk status [21, 67]. The number of adenomas removed during a COL 
is not currently reported in the CRCS (see Appendix Figure A5.1). Instead, the 
number of biopsies taken during a COL is reported, this is clustered into 5 groups 
in the reporting template of CRCS. Therefore, the number of biopsies taken 
during a COL is used as the proxy for the number of adenomas being removed 
during a COL. In the model, low risk (LR) was defined as 1-3 adenomas or 
adenoma <10 mm or low-grade dysplasia; and high risk (HR) was defined as 4 
or more adenomas, adenoma >10 mm or high-grade dysplasia (see Table 5.1). 
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Table 5.1 Reported COL findings from CRCS and risk stratification in the model 
[Reproduced from Table 2.7 section 2.2.5 of Chapter 2] 
Reported COL findings from CRCS (CRC cohort) *Approximated risk 
stratification for the 
economic model 
Reported size of adenomas  
<10 mm LR 
≥10 mm HR 
Reported numbers of adenomas  
Number of 
adenomas 
Reported number of 
biopsies taken for 
pathology/ histology 
Reported 
numbers of 
biopsies  
 
Not reported 1-3 Group 1 LR 
Not reported 4-6 Group 2 HR 
Not reported 7-9 Group 3 HR 
Not reported 10-12 Group 4 HR 
Not reported 13 or more Group 5 HR 
Reported degree of dysplasia in 
adenomas 
LGD LR 
HGD HR 
COL colonoscopy; CRC cohort short-term analysis of the CRCS in NHI, Korea, 
2009-2012; CRCS colorectal cancer screening; HGD high-grade dysplasia; HR 
high risk LGD low-grade dysplasia; LR low risk; * approximated risk stratification 
was carried out using the CRC cohort data for the economic model in Chapter 5 
 
There are discrepancies in the risk stratification of adenomas between the CRC 
cohort and the existing Korean clinical guidelines. For example, when considering 
the number of adenomas, based on the data in the CRC cohort, group 1 included 
those with 1-3 adenomas, therefore this group was assigned as LR (see Table 
5.1), in contrast, the Korean clinical guidelines defined LR as having 1-2 
adenomas (see Table 5.2). Therefore, LR in the CRC cohort inevitably includes 
individuals with 3 adenomas that would have been in a HR group in the existing 
clinical guidelines in Korea. This was inevitable because the number of biopsies 
taken during a COL was reported in terms of groups 1 to 5 (Table 5.1). This would 
potentially lead to differences in the estimation of the risk of adenoma recurrence 
post-polypectomy.  
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Table 5.2 Discrepancies in the risk stratification of adenomas and identified gaps 
in the recommendations and current practice [Reproduced Table 1.7, section 1.6 
of Chapter 1] 
LR HR  Initial interval 
(year) of a 
follow-up 
COL post-
polypectomy  
Subsequent 
interval of 
COL follow-
up COL 
finds 
adenomas 
References 
Without any 
HR findings at 
index COL 
 
3 or more adenomas 
or any adenoma 
larger than 10 mm or 
any tubulovillous  or 
villous adenoma or 
any adenoma with 
HGD or any serrated 
polyps larger than 10 
mm  
5LR3HR  
(5 years for 
LR; 3 years for 
HR) 
Not specified Yang 
(2012) [24] 
Hong 
(2012) [67] 
 
Not specified In patients with 
alarming symptoms or 
with a high risk of 
interval cancer 
5LR 
HR≤5 (less 
than 5 years) 
Not specified Lee (2012) 
[40] 
Any adenomas 
without HR  
3 or more adenoma or 
adenoma > 10 mm or 
HGD or any 
tubulovillous or villous 
adenoma 
1HR Not specified Jung (2012) 
[77]  
6 mm tubular 
adenoma or 
two 6 mm 
tubular 
adenomas 
12 mm tubular 
adenoma with HGD 
12 mm tubulovillous 
adenoma 
LR ≤1 (less 
than 1 year); 
3LR; 5LR 
HR≤1; 3HR; 
5HR 
Not specified Sohn 
(2014) [72] 
Not specified <1 cm adenoma 
>1 cm or multiple 
adenomas 
After 3 years 
After 1 year 
Not specified 
Not specified 
NCC (2015) 
[264] 
Not specified Not specified Not specified Not specified NHIS 
(2014) [31] 
1-2 adenomas 
<10 mm  
3 or more adenomas 
or  ≥10 mm or > 25% 
villous structure or 
HGD 
3HR Not specified Chung 
(2011) [69] 
COL colonoscopy; HGD high-grade dysplasia; HR high risk; LR low risk; NCC National 
Cancer Centre; NHIS National Health Insurance  Service
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In a survey it was found that more than 50% of practitioners did not follow 
recommended COL surveillance or chose different guideline recommendations, 
and practitioners were reported to advise individuals in HR or LR to return for a 
follow-up COL in 1 year, in 3 or 5 years regardless of risk status (see Table 5.2) 
[72].  
The focus of this economic model is to identify the most cost-effective COL 
surveillance strategy in the current CRCS for people with confirmed adenoma(s) 
(see Figure 5.1). Currently, there is no evidence on the cost-effectiveness of COL 
surveillance strategies based on the risk status [24]. Furthermore, the intensity of 
COL surveillance is largely dependent on the clinician’s opinion [40, 72]. 
Therefore, the intervention strategies considered in the economic model varied 
the intensity of COL surveillance. The comparator strategy considered in the 
model was no COL surveillance, and individuals with confirmed adenomas 
continued to be invited to annual CRCS.  
 
5.2.3 Methods 
Model overview 
CRCS is offered to those 50 years and older up to the age of 80 [64]. A time 
horizon of 50 years was chosen to capture all important costs and benefits 
between the different intensities of COL surveillance [83]. A yearly cycle in the 
model is generally recommended, however, a quarterly cycle was chosen for this 
model as this allows movements between states (transitions) in between the 
states in the COL surveillance model [83]. This was reasonable when an annual 
COL is one of the comparators considered in the model.  
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At the HIRA, in the decision making process there is no explicit cost-effectiveness 
threshold. However, on a number of recent occasions a threshold of KRW 
30,000,000 per QALY gained was said to be used which is higher than the 
previous threshold of KRW 20,000,000 per QALY gained in NHI (personal 
communication). Key features of the economic analysis were addressed following 
the guideline by the HIRA, other guidelines for economic evaluation are 
considered where there were gaps (see Table 5.3) [83, 265].  
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Table 5.3 Key features of the economic analysis 
Element Chosen approaches/ values  Reference 
Population  50 years and older without current CRC 
or previous history of CRC treatments 
AND  
 had a positive FOBT result as part of 
CRCS AND 
 had a COL and the removal of 
adenomas (polypectomy) as part of 
CRCS  
CRC cohort 
NHIS (2014) [31] 
Interventions  A COL 5 years post-polypectomy for LR 
and 3 years for HR [5LR3HR] 
 5LR1HR  
 5LR2HR  
 1LR1HR  
 3LR1HR 
 3LR3HR 
 0LR1HR 
 0LR2HR 
 0LR3HR 
Hong (2012) [67] 
Yang (2012) [24] 
Kim (2012) [71] 
Lee (2012) [40] 
Sohn (2014) [72] 
Jung (2012) [77] 
CRC cohort 
NCC (2015) [15] 
Sohn (2014) [72] 
Chung (2011) [69] 
Comparator No COL surveillance (0LR0HR) within CRCS CRC cohort 
Starting and ceasing 
COL surveillance  
COL surveillance offered to individuals 50-80 
years old 
NHIS (2014) [31] 
Sohn (2015) [64] 
Outcomes Cost per QALY gained HIRA (2011) [83] 
Time horizon 50 years  HIRA (2011) [83] 
Modelling approach Cohort modelling with state transition using 
Microsoft Excel® 
HIRA (2011) [83] 
Type of economic 
analysis 
Cost-utility analysis HIRA (2011) [83] 
Cycle length Quarterly (yearly cycle is recommended) HIRA (2011) [83] 
Measuring health 
effects  
QALY HIRA (2011) [83] 
Discount for costs and 
benefits 
5% in base-case analysis 
0%, 3.5% and 7% in sensitivity analyses 
HIRA (2011) [83] 
Perspective of analysis NHI; societal  HIRA (2011) [83] 
Perspective on costs NHI; societal NICE (2014) [265] 
Currency and price data KRW, year 2015 HIRA (2011) [83] 
Perspective on 
outcomes 
All direct health outcomes NICE (2014) [265] 
Synthesis of evidence 
on outcomes 
Based on the short-term analysis of CRCS 
and relevant published evidence  
HIRA (2011) [83] 
Valuating health effects Preference based measure  HIRA (2011) [83] 
Source of data for 
measurement of QoL 
Reported directly by people using service 
and/or carers where possible 
HIRA(2011)  [83] 
Source of preference 
data for valuation of 
changes in HRQoL 
Representative sample of the Korean 
population where possible 
HIRA (2011) [83] 
  
Evidence on resource 
use and costs 
Direct costs of COL surveillance, CRC 
diagnosis and treatment  
HIRA (2011) [83] 
CRC cohort 
WTP threshold  KRW 30,000,000 per QALY gained 
 
Personal 
communication 
COL colonoscopy; CRC colorectal cancer; CRC cohort short-term analysis of the CRCS in 
NHS, Korea, 2009-2012 (Chapter 2); CRCS colorectal cancer screening; FOBT faecal occult 
blood test; HIRA Health Insurance Review & Assessment; HR high risk; HRQoL health-related 
quality of life; KRW Korean Won; LR low risk; NICE National Institute for Health and Care 
Excellence; NHI National Health Insurance; QALY quality-adjusted life year; QoL quality of life; 
WTP willingness-to-pay 
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A Markov model was developed which incorporated recurrent adenomas and the 
requirements of lifelong COL surveillance post-polypectomy in a cohort using a 
commonly accessible software, Microsoft Excel®. There are three parts in the 
economic model: adenoma-carcinoma, COL surveillance and CRC treatments 
with the corresponding health-related quality of life (HRQoL) data in each health 
state. This was to differentiate the different diagnostics and successive early 
detection of asymptomatic CRC through COL surveillance in CRCS, compared 
to the presentation of symptomatic CRC without COL surveillance. In the model, 
it is assumed that individuals who are diagnosed with CRC receive identical 
treatments depending on the disease state regardless of the means of CRC 
detection [51, 265, 266]. The effectiveness of COL surveillance was modelled as 
an intervention to determine cost-effectiveness of COL surveillance for the early 
detection and prevention of CRC in the CRCS, NHI in Korea. 
In the model, COL surveillance was assumed to be offered to individuals aged 
between 50 and 80 years who had confirmed adenomas at the index COL in the 
current CRCS policy in the NHI [31, 64]. It was assumed that all adenomas were 
detected and removed at the index COL and COL surveillance. The long-term 
outcome of the COL surveillance model captured the benefits of the different 
intensities of COL strategies, in order to detect and remove adenomas before 
developing to carcinomas. All CRCs were assumed to arise from adenomas. 
Therefore, the early detection of adenoma and its subsequent removal, and the 
early detection of CRC would impact on the health benefits and costs of each 
strategy compared to no COL surveillance in the model. 
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Adenoma-carcinoma: natural history 
The basis of the economic model has two parts: adenoma recurrence for COL 
surveillance model and adenoma-carcinoma sequence. The proportion of LR and 
HR groups was determined at the initial starting point of the model, 87.5% and 
12.5% respectively, based on the findings from the CRC cohort (Chapter 2). 
Adenoma recurrence rates were derived from the short-term analysis of CRCS, 
2009-2012 (section 2.2 of Chapter 2). The rate at which adenomas develop into 
CRC remains uncertain [39, 96]. The calculation of time at which adenomas 
become CRC was not feasible utilising the short-term follow-up of the data (2009-
2012) because of the limited information available from the CRC cohort.  
Various approaches can be considered in modelling the adenoma-carcinoma 
sequence. These include modelling the growth of individual adenomas; the 
number, size, type and location of adenomas, a progression from non-advanced 
to advanced adenomas, and the progression of LR adenomas to HR adenomas. 
The potential approach of modelling for the planned CUA (Chapter 5) was to 
incorporate available evidence from the CRC cohort (Chapter 2) with the use of 
best possible evidence identified from the review of economic evidence (Chapter 
3) to compliment gaps in the evidence related to the adenoma-carcinoma. Very 
limited data were available on transition rates post-polypectomy; there was 
considerable uncertainty surrounding the modelling of surveillance.  
Saini (2010) [76] calculated the relative risk of adenoma recurrence by utilising 
the NPS study [51] and the annual probability of developing CRC from adenomas 
by utilising a registry-based study [267]. Tappenden (2007) [79] obtained 
estimates of adenoma-carcinoma sequence using a calibration method, and the 
approach and estimates from the study were adopted in the subsequent studies 
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[99, 102]. From the original options appraisal by Tappenden (2007) [79], Whyte 
(2012) [96] applied an improved calibration to estimate the natural history of 
adenoma-carcinoma model parameters derived from large screening data sets 
from England, Italy, Germany and Korea [39, 43, 267-270]. Adenomas and CRC 
prevalence may vary by country, but the extent of this variation and related 
uncertainties remained unknown. The value of using data from more than one 
country was that it allows the use of large data sets from several screening 
modalities. The definitions used in the risk stratification of adenomas differed 
between countries, with the English Bowel Cancer screening data 
low/intermediate/high risk adenomas according to BSG guidelines, and the Italian 
and German screening data reporting advanced adenomas. In order to include 
these data sources within the calibration process, an adjustment had to be made 
to estimate the proportion of advanced adenomas that would be classified as HR. 
This adjustment was crude as it was based on a small data set, so it introduced 
uncertainty into the modelling. Overall, the benefit of including large data sets on 
different screening modalities was considered to outweigh the uncertainty 
associated with using data sets from different countries. Therefore, the reported 
estimates of adenoma-carcinoma [96] were considered best evidence to inform 
the economic model alongside the estimates of adenoma recurrence post-
polypectomy from the CRC cohort. (Chapter 2). See the quality appraisal of the 
study [96] in the Appendix Table A5.2. This is one of the limitations of this 
economic analysis. 
It was assumed that an individual with Dukes’ B, C, or stage D CRC was more 
likely to present symptomatically than an individual with Dukes’ A CRC. Clinically 
plausible ranges describing the probability of symptomatic presentation with CRC 
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were taken from an existing study [96]. Crude estimates of CRC and non-CRC 
mortalities were derived from the CRC cohort and published statistics [2].  
 
COL surveillance model   
Two mutually exclusive diagnostic states post-polypectomy, LR and HR, were 
modelled in the Markov model. These states only differ in terms of the intensity 
of COL surveillance. Any movement between two diagnostic states is through 
either COL surveillance or symptomatic presentation of CRC in the model. 
Identified diagnostic health states, LR and HR, and the four CRC disease states 
were mutually exclusive in the model (see Figure 5.2). The removal of adenomas 
through COL surveillance was linked to the early detection of CRC and reduction 
in CRC related mortality compared with symptomatic CRC without COL 
surveillance. Tunnel states were used to model differences in the probability of 
recurrence post-polypectomy between the first and second year and onward, in 
order to add time-dependency to the memory-less Markov model based on the 
findings from the CRC cohort [271]. In the model, there was no death due to 
Dukes’ A CRC. Transitions from adenoma free to adenoma recurrence and 
adenoma free were modelled in the COL surveillance (blue dotted circle in Figure 
5.2) and relevant transition probabilities for transitions were summarised in Table 
5.4. In the HR group, individuals with no HR findings in the next COL surveillance 
will be ‘down-graded’ to an interim risk group, then exit COL surveillance after no 
LR or HR findings in two consecutive rounds of COL surveillance. When there is 
no LR finding from COL surveillance, individuals in the LR group exit COL 
surveillance and return to CRCS. In the case of HR findings from COL 
surveillance, individuals in the LR group will be moved to the HR group (see 
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Figure 5.2). In the model, there was no death due to CRC from Dukes’ A CRC. 
Relevant costs and benefits for those exiting COL surveillance were included in 
the costs and benefits of each strategy.  
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Figure 5.2 Outline of the economic model    
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Poor uptake in the CRCS presented in Chapter 2 was specific to the initial 
invitation to FOBT. The uptake of FOBT was not important in the CUA of COL 
surveillance because FOBT was a step before the COL surveillance and 
differential uptake of FOBT does not directly affect the cost-effectiveness of COL 
surveillance. It was assumed that there was no dropout from the COL surveillance 
because: 1) there was very limited evidence regarding compliance with the initial 
and subsequent follow-up COLs [100]; 2) there was a high level of interest and 
increase in compliance among Koreans when they were informed of an increased 
risk of developing CRC (personal communications); 3) practitioners were often 
reported to advise shorter COL surveillance intervals than recommended by the 
guidelines [72]; 4) compliance to FOBT and initial follow-up COL has been 
reported but the subsequent COL compliance has never been estimated or 
reported even in the most recent report utilising NHIS data from 2003 – 2013 [8].  
While it is obvious that there will be some dropout from COL surveillance, the 
exact figure and how this varies with each subsequent follow-up appointment is 
unknown. To account for this in the model will require further assumptions that 
will inevitably weaken the model outputs. Taking the increase level of interest in 
compliance and the shorter intervals noted above, any lack of compliance is 
expected to be very small. 
It may be expected that a lack of compliance will decrease the costs related to 
COL, but increase the costs related to later diagnosis of CRC. While these factors 
move costs in opposite directions, the overall impact on cost will probably be an 
increase, though its exact magnitude cannot be estimated accurately. 
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Overall, the lack of compliance will decrease the QALY gain associated with 
screening as more people will develop avoidable CRC (COL detected CRC. 
therefore, one can expect that any lack of compliance will make the screening 
programme less cost effective overall. If the compliance to FOBT and CRCS 
dramatically improves in the future, the reported estimates of this economic 
model will be no longer valid. 
The potential complications associated with a COL procedure were considered 
to be rare among clinicians and practitioners [264]. Only one case of bowel 
perforation was reported in 15,270 COL procedures performed in the Korean 
Polyp Registry (N=17,276) over the period of April 2007 – November 2009 [272]. 
Given the very small probability of bowel perforation caused by a COL procedure 
and the lack of separate reporting of COL-related adverse events in the CRCS, it 
is assumed that there are no adverse events associated with a COL in the COL 
surveillance model.  
CRC disease model 
The CRC disease stages are frequently classified using different methods 
including Tumour-Node-Metastasis (TNM) staging or Dukes’ stages (see 
Appendix Table A5.3) [91, 92]. The CRC stages were modelled using Dukes’ 
stages and the transitions between CRC disease states were taken from a 
published study [96]. The transitions between health states were only allowed 
though a stepwise progression (see Figure 5.2). The main limitation of using a 
stepwise progression is the lack of face validity. However, a stepwise progression 
allows the modeller to incorporate uncertainty into a Markov model with a number 
of defined health states.  
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Transition probabilities associated with adenoma recurrence post-polypectomy 
were derived from the CRC cohort analysis as the CRC cohort represents the 
Korean population (see Appendix Tables A5.4.1-5.4.3). Given the limited data 
available regarding transition probabilities for CRC disease states, these were 
taken from a cost effectiveness analysis of CRC screening in the UK context [96]. 
The annual transition probabilities are converted into 3-monthly probabilities in 
order to fit the chosen cycle length in the model [271]. A Dirichlet distribution in a 
Bayesian framework allows the calculation of transition probabilities by utilising 
both the prior beliefs (the prior) and observed data (likelihood) resulting in the 
probability distribution of an event (the posterior) for a PSA to address parameter 
uncertainty (see Appendix Tables A5.5.1 - A5.5.4) [273]. Summary of parameter 
inputs for transition probabilities are presented in Table 5.4. 
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Table 5.4 Summary of parameter inputs – transition probabilities  
Parameter name Base 
case 
Distribution 
for PSA [271] 
Reference 
Proportion of LR:HR  87.5:12.5 NA CRC cohort 
Transition probabilities (3-monthly)  
LR to HR 0.002 Beta CRC cohort 
HR to Dukes’ A CRC 0.0063 Beta Whyte (2012) [96] 
Dukes’ A CRC to Dukes’ B CRC 0.1633 Beta Whyte (2012) [96] 
Dukes’ B CRC to Dukes’ C  CRC 0.2538 Beta Whyte (2012) [96] 
Dukes’ B CRC to CRC death 0.0025 Beta Whyte (2012) [96] 
Dukes’ C CRC to stage D CRC 0.2662 Beta Whyte (2012) [96] 
Dukes’ C CRC to CRC death 0.0154 Beta  Whyte (2012) [96] 
Stage D CRC to CRC death 0.1151 Beta Whyte (2012) [96] 
Adenoma free post-polypectomy 
(LR)   to LR at year 1 
0.0024 Beta CRC cohort 
Adenoma free post-polypectomy 
(LR) to LR at year 2 
0.0084 Beta CRC cohort 
Adenoma free post-polypectomy 
(HR) to LR at year 1 
0.0012 Beta CRC cohort 
Adenoma free post-polypectomy 
(HR) to LR at year 2 
0.0037 Beta CRC cohort 
Probability of presenting 
Symptomatic Dukes’ A CRC 
0.0102 Beta Whyte (2012) [96] 
Probability of presenting 
symptomatic Dukes’ B CRC 
0.0484 Beta Whyte (2012) [96] 
Probability of presenting 
symptomatic Dukes’ C CRC 
0.1091 Beta Whyte (2012) [96] 
Probability of presenting 
Symptomatic Stage D cancer 
0.2859 Beta Whyte (2012) [96] 
AF adenoma-free; Age age-dependent; CRC colorectal cancer; CRC cohort short-
term analysis of the CRCS in NHS, Korea, 2009-2012 (Chapter 2); CRC death death 
due to CRC; HR high risk (4 or more adenomas/polyps or one adenoma ≥10 mm in 
diameter or high-grade dysplasia); LR low risk (1-3 adenomas <10 mm or low-grade 
dysplasia); NA not applicable; PSA probabilistic sensitivity analysis 
 
 
Health states and selected HSUVs  
As reported in section 3.4 Chapter 3, the search of economic evaluations of CRC 
showed that reported outcomes were limited to cost per CRC prevented and cost 
per life years gained in the Korean context [11, 274] except for one cost utility 
analysis using the quality-adjusted life years (QALY) as an outcome measure in 
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which the source of the HSUVs was not reported [261]. Despite the number of 
HSUVs published, there are few HSUVs that can be used in cost utility analyses 
of CRC that are methodologically robust with the range of health states of interest, 
therefore further search was undertaken in order to identify HSUVs for an 
economic model in a Korean context by utilising published search strategies and 
study selection criteria (Appendix Tables A5.6.1-A5.6.2) [259]. In the absence of 
directly relevant HSUVs for CRC in the Korean setting, a reported set of HSUVs 
from Hong Kong was chosen for the model because these reported values were 
methodologically robust with health states of interest for this economic model 
[190]. The quality of life in CRC patients with chemotherapy-induced peripheral 
neuropathy has been examined using the European Organisation for Research 
and Treatment of Cancer Quality of Life Group (EORTC QLQ) C30 and CRC 
specific (EORT QLQ-CR29) questionnaires in a Korean setting [275]. These 
reported EORTC QLQ-C30 values were mapped onto EQ-5D and considered in 
the sensitivity analysis. Details of the mapping algorithm are reported in Appendix 
Tables A5.6.3 to A5.6.4.  
An adenoma-free post-polypectomy health state was used to represent time in 
which people remained adenoma-free while continuing in COL surveillance, as 
represented in the Figure 5.2 including LR, HR, Dukes’ A, Dukes’ B, Dukes’ C 
and Stage D CRC health states. In the absence of directly relevant HSUVs for 
CRC among Koreans in a Korean setting, a set of HSUVs (Wong 2013b) was 
selected from the systematic review (Chapter 4) because it was methodologically 
robust with health states of interest for the economic model from a group of 
people with similar mean age to that of the CRC cohort. Reported HSUVs were 
multiplied with the time spent on each health state then were adjusted to the cycle 
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length of the model. Individuals with adenomas are usually asymptomatic, thus 
HSUVs for an adenoma-free health state and a recurrent adenoma health state 
were assumed to be same as the general public utility value of 0.856 at the age 
of 50 in Korea [276]. A COL is an invasive procedure and the preparations prior 
to and during a scheduled COL may potentially cause temporary discomfort and 
inconvenience. COL-related disutility of 0.0025 was assumed in the published 
surveillance models [76, 99]. Therefore, a COL-related disutility of 0.0025 was 
included in the model [277]. The utility of being in the HR (0.832) or LR (0.871) 
groups may be different from being adenoma-free or cancer-free, these utility 
decrements of LR and HR were considered in the sensitivity analysis [190].  
Table 5.5 Summary of parameter inputs – Utility   
Parameter name Base-case For SA / 
Distribution 
for PSA [271] 
Reference 
Cancer-free Age-dependent 
50-59 0.0856 (±0.202) 
60-69 0.812 (±0.241) 
70+ (±0.369) 
NA Lee (2009) [276] 
Undiagnosed 
asymptomatic CRC; 
Adenoma-free post-
polypectomy 
Age-dependent 
50-59 0.0856 (±0.202) 
60-69 0.812 (±0.241) 
70+ (±0.369) 
NA Assumption  
LR  0.871 One-way SA Wong (2013b) 
HR 0.832 One-way SA Wong (2013b) 
Dukes' A CRC 0.831 Beta Wong (2013b) [190] 
Dukes' B CRC 0.853 Beta Wong (2013b) [190] 
Dukes' C CRC 0.817 Beta Wong (2013b) [190] 
Stage D CRC 0.732 Beta Wong (2013b) [190] 
Disutility associated 
with COL 
0.0025  Assumption (Saini 
2010, NICE 2011) 
CRC colorectal cancer; HR high risk (4 or more adenomas/polyps or one adenoma ≥10 
mm in diameter or high-grade dysplasia); LR low risk (1-3 adenomas <10 mm or low-
grade dysplasia); NA not applicable; PSA probabilistic sensitivity analysis; SA 
sensitivity analysis 
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HSUVs for CRC were selected which were methodologically robust with four CRC 
disease states (Dukes A, B, C and Stage D CRC) of interest for the CUA as 
presented in the Figure 5.2 (Wong 2013b). A probability of non-CRC related 
death was included for all health states in the model. Details of utility values for 
the economic model related to Figure 5.2 are provided in Table 5.5.  
 
Resources and costs associated with COL surveillance and CRC  
The relevant range of costs was first identified, then each item was measured 
and valued with the time horizon of 50 years in order to have all cost 
consequences of the COL intervention taken into account in the analysis [97]. 
The data from the CRC cohort is the primary resource used for the economic 
model. As the CRC cohort included reimbursement data at a Korean population 
level it has high external validity, however, it provided fewer details on the stage-
specific CRC treatments.   
COL in the CRCS is reimbursed  at KRW 74,240 in 2014 [56]. Health service fees 
are set and revised annually by the MoHW, and the set rate was reported to be 
below the minimum costs of COL service delivery [7, 32]. Non-insured items, such 
as fees for the light sedations for a COL procedure, are set by private providers, 
which tend to include profits and higher management salaries [278]. For example, 
propofol and midazolam are short-acting sedations that are commonly used for a 
COL procedure. The cost of these sedations was said to be up to KRW 5,000 per 
ampule but the price charged to service users ranged from KRW 75,000 to 
250,000 per COL procedure in Korea [31, 279, 280]. Costs associated with CRC 
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diagnosis in the NHI are considered in the model (CRC cohort, see Appendix 
Tables A5.7.1-A5.7.2). 
Approximately 38% of total cancer treatment was paid for by cancer patients, 
while 61.8% was being paid for by NHI in Korea (see Appendix Table A5.8) [281].  
Reported CRC stages were recorded using partially adopted Surveillance, 
Epidemiology and End Results Programme (SEER) in the CRCS. Given the lack 
of clear reporting of the CRC stages due to the partial adoption of SEER (1, 2, 7 
and 9) in the CRCS, SEER 1 was assumed to be equivalent to Dukes’ A CRC. It 
was assumed that SEER 2 regional CRC was equivalent to the sum of Dukes’ B 
and C, SEER 7 distant CRC to stage D CRC in the model (see Appendix Table 
A5.9). The resource use for CRC treatment was possibly under-estimated 
because the SEER 9 CRC (reported as ‘unknown or unspecified’) was not 
included in the resource estimation.  
Primary chemotherapy agents are recommended by clinicians and reimbursed 
by NHI, and designated guidelines for post-operative adjuvant chemotherapy 
must be followed for the full reimbursement. As for secondary chemotherapy 
agents, the timing, interval and indications of chemotherapy must be followed for 
the NHIS reimbursement (see Appendix Tables A5.10-A5.11) [282, 283]. CRC 
chemotherapy is recommended for CRC stages II-III, however, a recent survey 
revealed that 67.5% of hospitals had delivered chemotherapy for those with CRC 
stage I which may result in the additional OOP for the service users [50].  
Radiotherapy is recommended as part of CRC treatment (see Appendix Table 
A5.12). The common adverse events of CRC treatments are vomiting and pain. 
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The resource associated with the use of anti-emetics and pain management was 
considered in the model [50]. 
Cancer treatment costs were said to be highest in the initial phase and in the 
terminal stage of disease [283]. Direct medical costs were included in the model 
as almost all health care service utilisation is subject to co-payment including 
CRC treatments. Unrelated future medical costs incurred from clinical trials and 
productivity costs incurred from morbidity and mortality were excluded in the 
analysis [83]. Average annual co-payment by cancer patients has been reported 
to be higher than that of the general population with non-cancer chronic 
conditions such as hypertension or diabetes (see Appendix Table A5.8) [284].  
The follow-up costs of CRC are defined as the costs of follow-up visits, outpatient 
clinic visits for CRC and non-CRC. CRC treatment costs were possibly over- or 
under-estimated due to the claims data being aggregated. CRC patients’ non-
CRC related claims were included in the CRC treatment period of 12 months. For 
example, CRC patient’s specialist clinic visits for hypertension were included in 
the follow-up cost. Approximately 60% of CRC patients had existing chronic 
conditions such as hypertension, diabetes, and hyperlipidaemia leading to 
additional health service usage, therefore it appeared to be reasonable to have 
OOPs towards direct medical costs included in the base-case analysis because 
the average age of CRC diagnosis is 60 years and older in Korea [283].  
The initiation and completion of active treatment of CRC took place within the first 
6 months of CRC diagnosis [50]. Therefore, CRC treatment costs were estimated 
for the first 6 months of active treatment following a CRC diagnosis, and the 7th-
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12th months from CRC diagnosis were defined as the follow-up period after active 
treatment.  
Estimated mean costs of diagnosis, treatment and follow-up costs of CRC in the 
NHI are presented in Table 5.6. The number of people in the cohort moving from 
one health state to another are calculated using the transition probabilities, and 
the number in each state is multiplied with the sum of relevant costs e.g. COL 
surveillance, diagnosis, treatment and follow-up costs of CRC using costs as 
presented in Table 5.6. It was assumed that all stages of CRCs were treated the 
same regardless of the methods of CRC being detected, however, symptomatic 
presentations of CRC are anticipated to have a high proportion of Dukes C and 
stage D CRC compared  to the COL surveillance detected CRC [51, 99]. 
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Table 5.6 Estimated mean cost of diagnosis, treatment and follow-up of CRC  
(Unit: KRW; KRW 1,000=GBP 0.56) 
Description Base-case SE Lower Upper Distribution 
for PSA 
[271] 
Colonoscopy  74240 93471.46 58947 185040 Gamma 
Pathology for adenoma 56053 60575.24 30,390 112,106 Gamma 
Pathology for cancer 165811 263982.21 59123 415235 Gamma 
DA  diagnosis 856125 259160.12 1700520 2050127 Gamma 
DA  treatment 2896545 2952037.81 599852 4582151 Gamma 
DA  follow-up 1248482 1299701.26 401544 2154841 Gamma 
DB diagnosis 985615 1046022.98 545460 1956545 Gamma 
DB treatment 3365951 3851891.77 788952 5985154 Gamma 
DB follow-up 1589554 1408229.8 459892 2359594 Gamma 
DC diagnosis 985615 1046022.98 545460 1956545 Gamma 
DC treatment 3365951 3851891.77 788952 5985154 Gamma 
DC follow-up 1589554 1408229.8 459892 2359594 Gamma 
DD diagnosis 1235945 1309634.54 698915 2465612 Gamma 
DD treatment 4856959 4223921.42 894545 6592615 Gamma 
DD follow-up 1845465 3318769.46 348595 4825615 Gamma 
CRC colorectal cancer; CRC cohort short-term analysis of the CRCS in NHS, Korea, 2009-2012 
(Chapter 2); DA Dukes’ A CRC; DB Dukes’ B CRC; DC Dukes’ C CRC; DD stage D CRC; GBP 
Great British pound; KRW Korean Won; PSA probabilistic sensitivity analysis; SE standard error; 
SA sensitivity analysis
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5.2.4 Results 
The natural history of adenoma-carcinoma (No COL surveillance strategy) was 
validated against the life expectancy amongst the Korean population (see 
Appendix Table A5.13 and Appendix Figure A5.1) [2]. It was not feasible to 
validate the COL surveillance outcomes estimated by the model against Korean 
trial data because the CRC cohort data is the first of their kind from a population 
level in Korea. It would have been ideal if the predicted outcomes from a natural 
history of adenoma-carcinoma (absence of COL surveillance) compared to 
observed data from pre-screening era in Korea, however, there is no data 
representing the absence of COL surveillance in Korea. Information from the 
short-term analysis of the CRC cohort, 2009-2012 (Chapter 2) including fuller 
information in light of NC pathway can be improved further by utilising longer-
term CRCS data in the NHI. Such findings from the longer-term CRCS data will 
provide basis for the validation of future CUA. 
 
Base-case results 
Table 5.7.1 presents the results of the deterministic base-case analysis. 
Strategies are presented by increasing cost in order to identify dominated 
strategies (more costly and less effective) using incremental analysis given the 
multiple comparators. The results presented in Table 5.7.1 suggest that the 
0LR3HR strategy is expected to be most cost-effective strategy, given a cost-
effectiveness threshold of KRW 30,000,000 per QALY gained with the 
incremental cost-effectiveness ratio of KRW 29,538 per QALY gained compared 
to No_COL. 
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Table 5.7.1 Deterministic base-case analysis results 
(Unit: KRW; KRW 1,000=GBP 0.56) 
 Strategy Cost QALY Inc 
Cost 
Inc 
QALY 
ICER  
No_COL  4489 13.486132       
0LR3HR 7395 13.584507 2906 0.09838 29,538 
0LR2HR 7580 13.584454 185 -0.00005 Dominated by 0LR3HR 
0LR1HR 7775 13.584427 195 -0.00003 Dominated by 0LR3HR 
5LR3HR 48710 13.475073 40935 -0.10935 Dominated by 0LR3HR 
5LR2HR 48827 13.474953 117 -0.00012 Dominated by 0LR3HR 
5LR1HR 48969 13.474950 142 0.00000 Dominated by 0LR3HR 
3LR3HR 54495 13.471932 5526 -0.00302 Dominated by 0LR3HR 
3LR1HR 54656 13.471866 160 -0.00007 Dominated by 0LR3HR 
1LR1HR 59253 13.471011 4598 -0.00085 Dominated by 0LR3HR 
COL colonoscopy; GBP Great British pound; HR high-risk; ICER incremental cost-
effectiveness ratio; Inc incremental; KRW Korean Won; LR low-risk; No_COL no COL 
surveillance; QALY quality-adjusted life years 
 
 
The breakdown of costs and QALYs indicates that the benefit of an intervention 
is driven by early detection of CRC as presented in Table 5.7.2.  The 0LR3HR 
strategy resulted in 14 fewer CRC-related deaths compared to the No_COL 
strategy. Compared with the No_COL strategy, the 0LR3HR strategy resulted in 
5 fewer cancers and 9 less symptomatic CRC per 1000 patients entering COL 
surveillance. As the intensity of COL surveillance increased, the cost of 
surveillance also increased, with an average lifetime per patient cost of KRW 
3489 for the 0LR3HR strategy (least intensive) compared to the 1LR1HR strategy 
KRW 59,174 (most intensive, Table 5.7.2). Notably, the 1LR1HR strategy, which 
resulted in fewer symptomatic CRC and CRC-related deaths than the 0LR3HR 
strategy, also resulted in fewer QALYs possibly due to disutility from COL. 
 
 
 
 
166 
 
Table 5.7.2 Breakdown of costs and QALYs 
(Unit: KRW; KRW 1,000=GBP 0.56) 
Strategy  Total number 
of 
symptomatic 
CRC 
Total 
CRC 
deaths  
Cost of COL 
surveillance 
per person, 
KRW 
Treatment cost 
of symptomatic 
CRC per 
person, KRW 
QALYs: 
symptomatic 
CRC per 
person 
No_COL  150.68 397.49 0 17511837 0.0284 
0LR3HR 141.57 373.43 3489 15216767 0.0267 
0LR2HR 141.55 373.35 3674 15214061 0.0267 
0LR1HR 141.57 373.26 3870 15210407 0.0267 
5LR3HR 16.52 7.83 48305 803199 0.0051 
5LR2HR 16.08 7.61 48425 781931 0.0050 
5LR1HR 16.08 7.61 48568 781837 0.0050 
3LR1HR 3.63 0.85 54430 158181 0.0012 
1LR1HR 0.17 0.03 59174 7143 0.0001 
3LR3HR 3.83 0.92 54264 167168 0.0013 
COL colonoscopy; CRC colorectal cancer; GBP Great British pound; HR high-risk; Inc 
incremental; KRW Korean Won; LR low-risk; No_COL no COL surveillance; QALY 
quality-adjusted life years 
 
 
Sensitivity analysis 
A series of sensitivity analyses was undertaken to explore the potential impact on 
the results by varying individual parameters as presented in Table 5.8. When the 
reimbursement rate of COL was varied using the costs from UK, Singapore and 
the US (KRW 16,500-5,680,000) [32, 285] the 0LR3HR strategy appears to be 
the most cost-effective strategy compared to the No_COL given a cost-
effectiveness threshold of KRW 30,000,000 per QALY gained. Full results of 
sensitivity analyses are in Appendix Table A5.14. Another driver of the 
uncertainty is the structure of model. When the CRC-free health state was further 
divided into LR (0.217), HR (0.208) and CRC-free states (age-dependent) the No 
COL strategy was dominant (see Table 5.8) [190, 284]. However, this might not 
be the case in a Korean context where reported mean EQ-5D value of 0.93 
among Koreans with cancer compared to 0.98 in those without cancer [284] 
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Table 5.8 Summary results of sensitivity analyses  
(Unit: KRW; KRW 1,000=GBP 0.56) 
Description/ parameters Base-
case 
Sensitivity 
Analysis 
CE strategy  ICER 
(compared to) 
Reference 
Discount rates for future costs and benefits 
 5% 0% 0LR3HR 4,290  
(No_COL) 
HIRA (2011) 
[83] 
 5% 3.5% 0LR3HR  18,935 
(No_COL) 
HIRA (2011) 
[83] 
 5% 7% 0LR3HR  49,346  
(No_COL) 
HIRA (2011) 
[83] 
Alternate transition probabilities (quarterly)- Adenoma recurrence post-polypectomy 
Probability of adenoma 
recurrence at year 1 pp_LR 
0.0024 0.0084 0LR3HR 28,419 
(No_COL) 
Assumption 
Probability of adenoma 
recurrence at year 1 pp_HR 
0.0012 0.0037 0LR3HR 29,585 
(No_COL) 
Assumption 
*Probability of adenoma 
recurrence (LR) at year 1 
pp_LR 
0.0024 0.026 5LR3HR 3,718,969 
(0LR3HR) 
Whyte 
(2012) [96] 
*Probability of adenoma 
recurrence (LR) at year 1 
pp_HR 
0.0012 0.0026 0LR3HR 29,999 
(No_COL) 
Whyte 
(2012) [96] 
Risk stratification - number of adenomas 
 4≤HR 7≤HR 0LR3HR 25,386 
(No_COL) 
Assumption 
Proportion of LR:HR in the model 
 87.5:12.5 0:100  0LR3HR 237,256 
(No_COL) 
Assumption 
 87.5:12.5 50:50 0LR3HR 29,538 
(No_COL) 
Assumption 
Alternative HSUVs 
Dukes' A CRC 
Dukes' B CRC 
Dukes' C CRC 
Stage D CRC 
0.2078 
0.2133 
0.2043 
0.1830 
0.1654 
0.1654 
0.1671 
0.1667 
0LR3HR 37,753 
(No_COL) 
Assumption 
Kim (2011) 
[286] 
Dukes' A CRC 
Dukes' B CRC 
Dukes' C CRC 
Stage D CRC 
0.2078 
0.2133 
0.2043 
0.1830 
0.1850 
0.1675 
0.1250 
0.0625 
0LR3HR 81,070 
(No_COL) 
Ness (1999) 
[174] 
Cancer-free, LR and HR 
HSUVs  
Age LR 0.217 
HR 0.208 
AF Age 
0LR3HR 1,142,623 
(No_COL) 
Wong 
(2013b) 
[190] 
COL reimbursement in KRW 
 74,240 5,680,000 0LR3HR 1,603,549 
(No_COL) 
Ahn (2015) 
[285]  
 74,240 165,000 0LR3HR 476,300 
(No_COL) 
Ahn (2015) 
[285] 
 
COL surveillance start and ceasing age (years) 
 50-80  50-75   0LR3HR 30,451 
(No_COL) 
Sohn (2015) 
[64] 
 50-80 *40-80 0LR3HR 17,396 
(No_COL) 
Assumption 
*Risk-based strategies 
compared to No_COL 
  0LR3HR 29,538 
(No_COL) 
 
*Non-risk-based strategies 
compared to No_COL 
  No_COL Dominant  
AF adenoma-free; Age age–dependent; CE cost-effective; COL colonoscopy; CRC colorectal cancer; GBP 
Great British pound; HR high-risk; HSUVs health state utility values; ICER incremental cost-effectiveness ratio; 
KRW Korean Won; LR low-risk; No_COL no colonoscopic surveillance; pp _LR post-polypectomy of LR 
adenomas; pp_HR post-polypectomy of HR adenomas; *additional analyses added  
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Results from a PSA indicates that the 0LR3R strategy is expected to be cost-
effective with the incremental cost-effectiveness ratio (ICER) of 33,936 per QALY 
gained compared to the No_COL strategy (see Table 5.9).  
 
 
 
Table 5.9 Probabilistic base-case results 
(Unit: KRW; KRW 1,000=GBP 0.56) 
 Strategy Total cost Total QALY Inc 
Cost 
Inc 
QALY 
ICER  
No_COL  4136 13.48496       
0LR3HR 7094 13.57211 2958 0.0872                            33,936  
0LR2HR 7277 13.57202 183 -0.0001 Dominated by 0LR3HR 
0LR1HR 7470 13.57194 193 -0.0001 Dominated by 0LR3HR 
3LR1HR 54554 13.47195 47084 -0.1000 Dominated by 0LR3HR 
5LR3HR 48505 13.47539 -6049 0.0034 Dominated by 0LR3HR 
5LR2HR 48668 13.47530 163 -0.0001 Dominated by 0LR3HR 
5LR1HR 48780 13.47529 111 0.0000 Dominated by 0LR3HR 
3LR3HR 54379 13.47201 5600 -0.0033 Dominated by 0LR3HR 
1LR1HR 59053 13.47100 4674 -0.0010 Dominated by 0LR3HR 
No_COL no colonoscopic surveillance ; GBP Great British pound; HR high-risk; ICER 
incremental cost-effectiveness ratio; Inc incremental; KRW Korean Won; LR low-risk; 
No_COL no COL surveillance; QALY quality-adjusted life years 
 
 
The cost-effectiveness plane is presented in Figure 5.3. 
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Figure 5.3 Cost-effectiveness plane compared to No_COL 
 
No_COL no colonoscopic surveillance; HR high risk; LR low risk; QALY quality-adjusted 
life year 
 
 
There is 98.1% probability that the 0LR3HR strategy is expected to be most 
cost-effective at the threshold of KRW 30,000,000 per QALY gained, and 1.8% 
probability for the No_COL strategy. The results remain constant with the 
varying value of the WTP threshold from KRW 12,000,000 to KRW 32,000,000 
(personal communication in confidence and the person wishes to remain 
anonymous) [287]. Cost-effectiveness acceptability curves (CEAC) are 
presented in Figure 5.4. 
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Figure 5.4. Cost-effectiveness acceptability curve 
 
 
5.2.5 Discussions and conclusion 
COL surveillance was reported to be cost-effective when offered to all groups in 
the National Health Service UK differentiated with intervals based on the risk 
status of individuals by offering COL surveillance to those in the LR group at 5 
year intervals, for those in the intermediate risk at 3 year intervals and those in 
the HR at 1 year intervals [99], while COL surveillance was said to be most cost-
effective among the HR group from the long-term payer perspective in the US 
settings [76]. As the intensity of COL surveillance increased, the incidence of 
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symptomatic CRC and CRC-related death decreased (Table 5.7.1-5.7.2) that 
was similar to the reported results from Saini (2010) [76]. The 0LR3HR strategy 
resulted in 14 fewer CRC-related deaths compared to the No_COL strategy. 
Compared with the No_COL strategy, the 0LR3HR strategy resulted in 5 fewer 
CRC-related deaths and 9 less symptomatic CRC per 1000 patients entering 
COL surveillance. As the intensity of COL surveillance increased, the cost of 
surveillance also increased, with an average lifetime per patient cost of KRW 
3489 for the 0LR3HR strategy (least intensive) compared to the 1LR1HR strategy 
KRW 59,174 (most intensive, Table 5.7.2). Notably, the 1LR1HR strategy, which 
resulted in fewer symptomatic CRC and CRC-related deaths than the 0LR3HR 
strategy, also resulted in fewer QALYs possibly due to disutility from COL.  
COL surveillance offered to those with known HR remained cost-effective in the 
CRCS, NHI Korea. It is not directly comparable between the model results of this 
CUA and other reported studies mainly because of different risk stratifications 
being used in each study, different starting age of intervention, costs of 
intervention, different clinical practice, WTP for a QALY gained. Nonetheless, the 
direction of travel of evidence indicates that COL surveillance to selected people 
with certain characters e.g. HR to be cost-effective. 
Adapting or adopting existing cost-effective guidance from other settings to the 
NHI could not be easily transferred to the Korean NHI setting. This is because of 
the obvious differences in epidemiology, differences in the structure and delivery 
of health service, willingness-to-pay of payers, as well as the preferences of 
individuals and the general public [288, 289]. 
Despite the widespread use of COL as a follow-up of CRCS, there is no 
structured management for those who require follow-up COL in the CRCS. 
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Results of cost-utility analysis indicate that the 0LR3HR strategy is likely to be the 
most cost-effective strategy for COL surveillance in the prevention and early 
detection of CRC in the current CRCS, NHI in Korea.  
The main strength of this economic analysis is that the model parameters were 
derived and generated where possible from the short-term analysis of the CRC 
cohort as presented in Chapter 2. Plausible assumptions were used, and a range 
of sensitivity analyses was undertaken in order to explore uncertainties in the 
model by using the most up-to-date evidence where possible. This economic 
analysis demonstrated the feasibility of providing robust cost-effective evidence 
by utilising CRCS data that is meaningful and reliable in the Korean context.  
However, the modelled stepwise and mutually exclusive health states represent 
a simplified version of the real world. A critical appraisal of this cost-effectiveness 
analysis is presented in Appendix Table A5.15. 
Several model parameters related to transition probabilities from adenoma health 
states to CRC and probabilities of transiting through the pre-clinical cancer states 
remain largely unknown [39] and such evidence cannot be empirically observed 
as the CRCS has been widely offered in mass and/or opportunistic screenings in 
many countries [75]. Probable ranges for unknown parameters were derived from 
the existing literature and a wide uniform distribution was assigned to each 
parameter in order to carry out Monte Carlo sampling and all unknown 
parameters were simultaneously sampled and propagated through the model 
over 50,000 iterations to generate multiple sets of parameters [96]. The 
definitions of HR or LR in the risk stratification of adenomas differ between 
reported studies, registries or guidelines. This may have an impact on the 
adenoma developed into carcinoma in the economic model. When HR was 
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assumed to be those with 7 or more adenomas the 0LR3HR remained the most 
cost effective consistent with the base-case result. Clear definitions of LR and HR 
in the adenoma risk stratification for COL surveillance and CRCS should be a 
priority for CRCS in Korea. 
There are limitations in this analysis. The assumptions used in the model 
structure was not fully explored in the sensitivity analysis. This is because of the 
limited evidence around the natural history of adenoma-carcinoma, thus the 
stepwise progression of the disease was a reasonable assumption in the cohort 
simulation. As with many countries, the true baseline of index COL among the 
Korean population is unknown as the population is exposed to COLs through 
CRCS and various opportunistic screenings in different health care institutions 
over decades. A complete and detailed baseline index COL would have been key 
to understanding the natural history of the adenoma-carcinoma sequence, 
furthermore individuals with different characteristics and behaviours associated 
with the CRC incidence would provide information for the risk stratification for 
COL surveillance.    
Currently, there is no formally structured COL surveillance in the CRCS NHI 
Korea, and COL surveillance. In the model, the ‘COL surveillance’ referred to as 
no formal structured COL surveillance in order to incorporate the COL 
surveillance that has been offered irregularly with intervals and frequencies being 
determined mainly by clinical judgement. Ideally, the absence of COL 
surveillance as one of modelled strategies would have provided greater insights 
into the potential costs and relevant outcomes of COL surveillance. Considering 
the opportunistic screening has been offered to Koreans before the formal KCCR 
being set up in the 80s there is no data for the absence of COL surveillance in 
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Korea. The estimated recurrence rates for adenoma post-polypectomy were 
limited due to the limited date information of subsequent COLs in the CRC cohort. 
It is particularly problematic when the distinction could not be made between 
recurrent and missed adenomas in the CRC cohort due to the lack of structured 
management of follow-up COLs and the current reporting of COL follow-up in the 
CRCS. However, the base-case results were not sensitive to the alternative 
recurrence rates of adenomas post-polypectomy (see Table 5.8). 
The different CRC staging used by practitioners and governmental agencies adds 
uncertainties to the CRC cohort and the economic model. There should be a 
consensus on what should be used when CRC disease stages are reported to 
NHI to improve the reliability of CRC and NHI data for future studies.  
The risk stratifications of LR and HR utilising the CRC cohort may lead to 
differences in the estimation of adenoma recurrence post-polypectomy compared 
to the Korean clinical guidelines. The alignment of current CRCS reporting and 
the risk stratification from clinical guidelines will improve the future analyses of 
uncertainties around adenoma recurrence post-polypectomy. The modelled CRC 
disease states are simplified, and this requires further consideration as the costs 
and benefits of CRC treatments may be under- or over-estimated. HSUVs derived 
directly from CRC and adenoma among Koreans could be used to strengthen 
future economic analyses of CRC. 
This economic analysis considers COL surveillance as part of CRCS. It does not 
consider the potential impact of opportunistic screening among Koreans simply 
because there is no reported evidence related to those who ‘cross-over’ between 
CRCS and opportunistic screening.  
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In addition, the CRC cohort includes the period between 2009 and 2012. Due to 
the limited information available from the short-term CRC cohort the growth of 
missed adenomas into carcinomas and the location of adenomas were not 
considered in the model. Due to the short-term nature of these data the location 
of adenomas and the movements between the CRC disease states are derived 
from an alternative existing study [96]. A CRC cohort with a longer-term follow-
up will provide further evidence of the adenoma-carcinoma sequence and the 
movements between the CRC disease states, this will be crucial to improving the 
robustness of the results of future economic evaluations.  
 
In conclusion, a risk-based 0LR3HR strategy is considered most cost-effective 
for people with confirmed adenomas in the prevention and early detection of CRC 
in the CRCS, NHI in Korea. A full pathway modelling of CRCS linking the existing 
CRCS and COL surveillance utilising CRCS data would provide further insights 
and completeness of the costs and benefits of CRCS in the NHI [177]. 
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6 DISCUSSIONS AND CONCLUSION 
6.1 Introduction 
The focus of this thesis is to identify the most cost-effective COL surveillance 
strategy among individuals with confirmed adenomas for the prevention and early 
detection of CRC as part of CRCS in the NHI, Korea.  
The specific objectives of this thesis are as follows: 
1) Identification of resources used in CRCS and CRC treatment and mapping of 
the current clinical practice and CRCS pathways in the prevention and early 
detection of CRC. A unique opportunity arose to form a research collaboration 
with Dr Heeyoung Lee at Seoul National University Bundang Hospital, Korea 
which led to the establishment of a CRC cohort by utilising NHI reimbursement 
data to provide information for economic evaluation and to map out current 
practices in CRCS. 
2) Review of the relevant cost-effectiveness evidence of COL surveillance in 
people with adenomas – achieved by conducting a literature review of published 
cost-effectiveness evidence in the prevention and early detection of CRC. The 
review was also extended to search and identify relevant evidence in a Korean 
context. 
3) Identification of HSUVs relevant to CRCS and CRC in order to populate 
economic model(s) – achieved by conducting a systematic review of HSUVs for 
economic evaluation of CRC. This study assesses their advantages and 
disadvantages with respect to valuation methods used and CRC clinical 
pathways.  
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4) Identification of cost-effective COL surveillance strategies for individuals with 
confirmed adenomas in the prevention and early detection of CRC in the CRCS, 
NHI – achieved by conducting a cost-utility analysis by utilising findings from 1) 
to 3). 
This PhD thesis consists of a series of research papers which are either published 
and/or submitted or ready to be submitted to peer-reviewed journals for 
publication. The presentation of the chapters and relevant papers reflect the 
logical order of the research questions. Each of these papers includes a 
discussion section specific to the findings presented in that paper.  
The following sections 6.2 and 6.3 present the overall findings and the limitations 
of this thesis. The next section (6.4) then describes the contributions made to 
current knowledge concerning the cost effectiveness of risk-based COL 
surveillance strategies in the CRCS, NHI in Korea. The implications for policy and 
areas for future research are presented in sections 6.5 and 6.6. 
 
6.2 Findings of the thesis 
6.2.1 Identification of common pathways in the CRCS and relevant costs 
by utilising the short-term analysis of CRC cohort, 2009-2012 
Any economic evaluation based solely on the published literature could be easily 
detached from current practice and reality, and as a result the findings could be 
misleading. The collaboration formed with a Korean researcher led to the 
development and analysis of a CRC cohort (2009-2012) to ensure that this thesis 
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reflected Korean practice. Therefore, the results from this thesis are meaningful 
to the decision makers in a Korean context. Four common pathways (NC, CRCS 
only, CRCS combined with HCSU and HCSU only) were identified in the CRCS, 
indicating varying clinical practice that is inconsistent with the CRCS 
reimbursement policy in the NHI. Resources used in the CRCS and the treatment 
of CRC were identified for the economic evaluation of CRC. This short-term 
analysis of CRCS is the first study to map out common pathways in the CRCS by 
utilising the NHI data at a population level in Korea. This analysis exemplifies the 
potential advantages of utilising NHI data in population health research which 
could provide invaluable information on the current practice and resources used 
in the CRCS and NCSPs, NHI.  
 
6.2.2 Review of cost-effectiveness of COL surveillance and CRCS 
The cost-effectiveness of CRCS has long been studied in many countries, 
however the cost-effectiveness of COL surveillance remains under-studied [100]. 
Results from this review indicate that the chosen comparators and intervention 
did not fully reflect current practice and uncertainties associated with parameter 
inputs and structure were not fully addressed. Modelled downstream effects of 
COL surveillance or CRCS were limited.  
A further review of Korean evidence, presented in Appendix Tables A5.1.1-
5.1.2, indicated that there is a paucity of cost-effectiveness evidence regarding 
the intensity of COL surveillance in the CRCS, NHI. 
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6.2.3 Systematic review of HSUVs for economic evaluation of CRC 
The systematic review of HSUVs for economic evaluation of CRC revealed 
striking variations in CRC-related HSUVs, even for similar health states [259]. 
Such variations directly increase the uncertainty regarding cost-effectiveness. 
This review also found that there were few methodologically robust HSUVs with 
the health states of interest that can be directly used in the economic evaluation 
of CRC. Thus, there is considerable scope for new HSUVs to be developed which 
improve on those currently available to produce better estimates of QALYs and 
cost-effectiveness in order to inform the decision making and resource allocation 
in the CRCS. In addition, the review highlighted gaps in the evidence and 
opportunities for informative research into the most appropriate method to 
measure and value CRC-related health states. 
A further review of evidence revealed the lack of HSUVs that were robust enough 
for the economic evaluation of CRC in the Korean context as presented in 
Appendix Tables A5.6.1-5.6.4.  
 
6.2.4 Identification of cost-effective strategies for COL surveillance in the 
CRCS, NHI  
A cost-utility analysis was undertaken in line with the HIRA’s current guideline for 
economic evaluation for the NHI submission [83]. Parameter inputs were derived 
from the CRC cohort analysis where possible. Gaps in the CRC cohort were 
complemented by the most up-to-date and most relevant published evidence [96]. 
Plausible assumptions were explored through a series of sensitivity analyses to 
address uncertainties around the cost-effectiveness estimates. Results from the 
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economic evaluation indicated that the risk-based 0LR3HR strategy would be the 
most cost-effective strategy for COL surveillance in the CRCS, NHI.  
 
6.3 Overall limitations   
6.3.1 Short-term analysis of CRCS using the NHI reimbursement data 
The short-term analysis of CRCS highlighted the potential of the comprehensive 
CRCS data for future use of informing the decision making process in the NHI. 
However, the continuity of data collection can be strengthened by linking 
reimbursement data with disease registry data.  
For the purpose of mapping CRCS pathways it was assumed that pathways were 
mutually exclusive in the short-term analysis of CRCS, 2009-2012. Four 
pathways were mapped out using the CRC cohort data: CRCS only, HCSU only, 
CRCS combined with HCSU and NC. The mapped pathways did not consider 
additional tests performed after CRC diagnosis or those individuals who dropped 
out of the CRCS but later returned to CRCS via separate pathways. Therefore, 
reported diagnostic costs of CRC might have been under-estimated in this 
analysis. Furthermore, additional resources used and costs associated with the 
NC group were outside the current CRCS and NHI, thus leading to a possible 
under-estimation of resources used in the NC pathway. 
The reporting of COL results did not include the number of adenomas 
detected/removed during the follow-up COL in the CRCS, therefore the number 
of biopsies taken during the follow-up COL was used as a proxy for the number 
of adenomas in the risk stratification for the cost-effectiveness analysis. The 
 
 
181 
 
short-term CRC cohort, 2009-2012, was not comprehensive enough to inform the 
economic model fully. 
A risk-based extrapolation of CRC-free survival post-polypectomy beyond the 
short-term period of CRC cohort (2009-2012) was not possible due to the limited 
information on the dates of follow-up COLs linked to their outcomes thus the risk-
based (LR or HR) extrapolation was not undertaken. 
 
6.3.2 Potential selection biases in the reviews 
Two empirical evidence reviews undertaken as part of this research have 
potential selection biases because the searches were restricted to publications in 
English or Korean [100, 259]. Studies or reports published in non-English or non-
Korean languages were omitted in the reviews of economic evaluations and of 
HSUVs in the Korean context. 
 
6.3.3 Cost-effectiveness analysis of COL surveillance, CRCS 
Little is known about the natural history of the adenoma-carcinoma sequence and 
the probability of those in the HR group developing cancer, therefore the 
probabilities for CRC disease progression were derived from existing evidence 
[96]. Adenoma recurrence rates post-polypectomy were derived from a short-
term CRC cohort analysis, thus there is uncertainty around the modelling of 
surveillance due to the short-term data, 2009-2012.  
The risk stratification of LR and HR groups utilising the CRC cohort data may lead 
to differences in the estimation of adenoma recurrence post-polypectomy 
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because of discrepancies between the reporting of COL results in the CRCS and 
the risk stratifications from Korean clinical guidelines. The location of adenomas 
associated with the different location of CRC were not considered in the model. 
This analysis combined data on the natural history of adenoma-carcinoma from 
Korea and the UK where the prevalence of adenoma and CRC may differ 
between the two countries. 
 
6.4 Overall contribution of thesis   
Despite the limitations discussed in the previous sections, the findings of this 
thesis highlight the gaps in research concerning cost-effectiveness evidence of 
COL surveillance for individuals with confirmed adenomas in the prevention and 
early detection of CRC in the CRCS, NHI in Korea and identified the most cost-
effective COL surveillance strategy based on the best available evidence. This 
thesis has made the following contributions to knowledge concerning the cost-
effectiveness of COL surveillance in the prevention and early detection of CRC 
in Korea: 
1) This thesis includes the first CRC cohort analysis, 2009-2012 by utilising the 
comprehensive NHI dataset. This review mapped out common pathways in the 
CRCS.  
2) This thesis includes the cost-effectiveness evidence review of CRCS and COL 
surveillance in the prevention and early detection of CRCS from various settings. 
A further search of Korean evidence identified gaps in the cost-effectiveness 
evidence on COL surveillance in CRCS Korea.  
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3) This thesis includes a systematic review of HSUVs of CRC for economic 
evaluation. This study reviews CRC-related HSUVs that could be used in 
economic evaluation and assesses their advantages and disadvantages with 
respect to valuation methods used and CRC clinical pathways.  
4) This thesis contains the first cost-utility analysis of COL surveillance by utilising 
findings from the short-term analysis of a CRC cohort in CRCS in the NHI, Korea. 
 
6.5 Implications for policy 
Policies to increase compliance to FOBT and follow-up tests are required in the 
current CRCS. Further studies related to incremental costs and benefits of CRCS 
and follow-up COL are warranted. Policies for the structured follow-up COL post-
polypectomy that is linked to the existing CRCS should be developed. 
The results of the economic evaluation will be useful in aiding decision making in 
both policy and clinical settings to promote efficient use of health care resources 
in the NHI.  
The use of cost-effectiveness evidence as one of the tools in resource allocation 
is currently limited to pharmaceutical products in the NHI, and the expansion of 
cost-effectiveness evidence can be of great help to promote transparent decision 
making in clinical practice. The focus of this research was the cost-effectiveness 
of strategies for COL surveillance of individuals with confirmed adenomas within 
the CRCS. The approaches taken with the CRC cohort (2009-2012), identified 
methodological and practical challenges which are also applicable to other 
NCSPs in the NHI which can inform the decision making process in the NHI. 
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Over a decade, a great deal of effort has been committed to the CRCS, however, 
there are no cost-effective COL surveillance strategies for individuals with 
confirmed adenomas in the current CRCS, but COLs performed as part of the 
follow-up process have been reimbursed without a ceiling (limit) in cost under the 
current CRCS reimbursement policy. This thesis indicates that the 0LR3HR 
strategy based on the risk status of individuals is likely to be the most cost-
effective follow-up strategy in the CRCS, NHI. Thus the existing reimbursement 
decision should be reviewed and amended accordingly. In addition, people who 
are currently diagnosed with and treated for CRC should to be excluded from the 
annual CRCS invitation.  
 
HIRA’s guidelines for economic evaluation do not indicate a specific cost-
effectiveness threshold but the implicit WTP is said to be KRW 30,000,000 per 
QALY gained (personal communication). A review of the economic evidence 
submitted for thirteen reimbursement decisions (2005-2009) reported an implicit 
WTP of about KRW 32,000,000 per QALY gained [290]. The lack of WTP 
thresholds clearly communicated to stakeholders, often creates myths and 
mistrust regarding which new costly technologies would or would not be funded 
in the NHI. Submitted economic evidence to HIRA for the reimbursement decision 
did not specify the source of HRQoL or HSUVs used in the cost-utility analysis, 
nor uncertainties associated with HSUVs being addressed in the decision [10] 
whereas  the importance of choosing the most appropriate HSUVs for economic 
evaluation was highlighted as inappropriate HSUVs would have direct impact on 
the final decision. Economic evaluation can be used to bring multiple 
stakeholders together rather than divide them – there are areas which can 
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improve and promote a better use of economic evidence in the decision making 
process in the NHI.  
The harmonisation of reporting and communication of CRCS findings between 
governmental bodies, professional bodies and health service providers is crucial 
to improving the existing data quality in the CRCS and the fuller utilisation of a 
comprehensive NHI dataset. With the rising demands from service users and a 
rapidly ageing population, improved transparency in decision making and a better 
communication with stakeholders about results from robust economic evaluation 
for reimbursement decisions should be of priority in order to maintain effective 
working relationship with all stakeholders in the NHI. Consensus around the 
reporting of CRCS results, a clearly agreed risk stratification of adenomas and 
CRC disease stages in the current CRCS are of paramount importance as they 
determine the most appropriate treatment for improving survival.  
 
Although the consensus guideline for CRCS and a regular follow-up of individuals 
with adenomas are recommended in the Asian Pacific Guideline [59, 60], only 
Japan and Korea offer CRCS at a national level due to resource constraints in 
other countries [134]. The approaches taken and the findings of this thesis 
demonstrate how to utilise data captured in the existing reporting infrastructure 
that could inform the decision making, mapping current clinical practice, and 
provide a basis for the economic analyses of other NCSPs in Korea. Methods 
used in the identification of relevant economic evidence, the HSUVs for economic 
evaluation of CRC and a de novo cost-utility analysis from this thesis could be 
considered in further comparative policy analyses in other Asian countries where 
similar trends of CRC are observed. Risk-based COL surveillance may be more 
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cost-effective than universal COL surveillance in the existing CRCS and this may 
be generalizable to other Asian countries considering the increasing incidence of 
CRC in Asia [291]. For example, cost-effectiveness analysis of risk-based COL 
surveillance strategies could promote evidence-informed decision making where 
a  COL is routinely offered to individuals 40 years and older in Japanese CRCS 
[134].  
 
Health service fees in the NHI are set by the MoHW, and these have been 
perceived insufficient to meet the minimum costs of service delivery by service 
providers [7, 261]. For example, non-insured items such as fees for the light 
sedations for a COL procedure are 10-25 times higher than their cost [8, 279, 
280]. The state-set fee for COL led to wide variations in the price of sedation for 
COL by private health service providers – there should be an open process of 
engagement and communication between the state and the health service 
providers. Economic evaluation has been recently introduced in reimbursement 
decision making in Korea but the much-needed transition from state-set health 
service fees to transparent communication of decision making is yet to take place 
in the CRCS and NHI.  
 
The findings provide invaluable intelligence on the current practice as to CRCS 
pathways and relevant costs in the CRCS at a population level. With the rapidly 
increasing health care expenditure, the government attempts to move towards 
evidence-informed decision-making for health care resource allocation, thus the 
use of economic evaluation of existing CRCS and NCSPs would provide a better 
alternative to state-regulated cost control for the NHI in the long term. Together 
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with the evidence-informed decision making, a genuine consultation with all 
stakeholders should be embedded in the decision making process such as the 
decision rules and the process of evidence to recommendations, as opposed to 
the notification of reimbursement decisions alone [10]. 
 
There is a road ahead for the CRCS in the NHI as the current decision making 
process could be improved by reinforcing and adding the following steps: 
1) A risk-based 0LR3HR strategy is expected to be the most cost-effective in COL 
surveillance, given a cost-effectiveness threshold of KRW 30,000,000 per QALY 
gained compared to No COL surveillance strategy in the current CRCS, NHI. 
Therefore, risk-based 0LR3HR COL surveillance should be implemented in the 
CRCS. 
2) A stakeholder consultation that is meaningful and genuine is lacking in the 
current process of evidence review leading to the reimbursement decision 
making [83].  
3) Clear criteria should be set for the frequency and reimbursement for the COL 
surveillance that is seamless from CRCS, COL surveillance to HCSU in the NHI. 
As such the number of unnecessary COLs would be curbed. There should be a 
mechanism to avoid duplication of payment for repeated COL procedures in the 
CRCS, NHI. 
4) The reporting of COL and CRCS should include much needed information for 
contributing to the risk stratification of COL surveillance and the CRC disease. 
The number and size of adenomas detected/removed from COL should be added 
to the existing reporting of CRCS. Risk stratification and CRC staging information 
should be based on consensus, complete and comprehensive reporting in CRCS.  
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5) A separate follow-up programme for the individuals with CRC needs to be 
considered rather than including them with the general population in the annual 
invitation of CRCS.  
 
6.6 Areas for further research  
The CRC cohort and the cost-effectiveness analysis in this thesis demonstrate 
the feasibility of utilising existing NHI data for future research. Information from 
the short-term analysis of the CRC cohort, 2009-2012 can be improved further 
by utilising longer-term CRCS data in the NHI. A CRC cohort with data for a 
longer-term period would enable the estimation of CRC-free survival post-
polypectomy in the LR and HR groups.  
The natural history of adenoma-carcinoma is under-studied and consideration 
should be given to utilising longer-term CRCS data from NHI as a suitable 
alternative to provide evidence related to the adenoma-carcinoma sequence and 
better estimates of resources and costs used in the CRCS.  
Methodologically robust HSUVs with health states of CRC and CRCS for cost-
utility analysis in a Korean setting should be given priority. There is considerable 
scope to develop new HSUVs which improve on these currently available and 
consequently to derive better estimates of QALYs and cost-effectiveness to 
inform decision-making. The use of existing mapping algorithms to derive HSUVs 
for the economic evaluation of CRC should be further researched. 
A full pathway modelling of CRCS utilising the CRCS data will provide further 
insights on the wider costs and benefits of CRCS linked to the COL surveillance 
in the NHI in the future. 
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6.7 Conclusion   
The aim of the thesis was to identify the cost-effective COL surveillance strategy 
for people with confirmed adenomas in the CRCS, NHI in Korea. In spite of 
previously published economic evaluation of the CRCS, the importance of a 
transparent development process of economic analysis for COL surveillance in 
the context of Korea became apparent. A rare opportunity arose to form a 
collaboration with a Korean researcher and obtain access to the CRCS data 
(2009-2012) in the NHI. Therefore, a CRC cohort was constructed to inform the 
economic model in addition to the identified objectives of the research. A de novo 
cost-utility analysis of COL surveillance was conducted by utilising findings from 
a CRC cohort analysis and two reviews performed, which were the first of their 
kind in the economic evaluation in a Korean context. Results from a de novo 
economic analysis indicate that a risk-based 0LR3HR strategy is considered 
most cost-effective for individuals with adenomas in the COL surveillance in the 
CRCS NHI.  
This thesis demonstrated the process of evidence review and development of 
cost-effective strategies for the COL surveillance in the context of CRCS, Korea. 
Transparent and systematic approaches taken in this thesis and its subsequent 
results provide a basis for further evaluation of existing NCSPs in NHI and other 
neighbouring countries.  
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Figure A2.3 CRCS mapping pathways I 
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'number of polyps detected reported'
1 CRCS - FOBT 
invitation
2 FOBT C or NC
5.2  COL
4-6 Bx
4.2-5.2
5.1 COL
1-3 Bx
4.2-5.1
5.3 COL
7-9 Bx
4.2-5.3
5.4 COL
10-12 Bx
4.2-5.4
5.5 COL
13+ Bx
4.2-5.5
4.1 xCOL
1.0-2.2-4.1
1.0-2.3-4.1
1.0-2.4(=4.1)
1.0-2.1-4.1
4.2 COL
1.0-2.6-4.2
1.0-2.6-3.1-4.2
5.7 xCOL
4-6 Bx
4.1-5.7
3.2-5.7
5.6 xCOL
1-3 Bx
4.1-5.6
3.2-5.6
5.8 xCOL
7-9 Bx
4.1-5.8
3.2-5.8
5.9 xCOL
10-12 Bx
4.1-5.9
3.2-5.9
5.10 xCOL
13+ Bx
4.1-5.10
3.2-5.10
7.1 CRC deaths
4.1-5.6-6.1
4.1-5.7-6.1
4.1-5.8-6.1
4.1-5.9-6.1
4.1-5.10-6.1
3.0-7.1
4.0-7.1
6.4-7.1
6.5-7.1
7.2 non-CRC 
deaths
6.1-7.2
6.2-7.2
6.3-7.2
6.4-7.2
6.5-7.2
6.6-7.2
6.0 Returnt to 1 (CRCScreen post-CRC diagnosis in 2009) 2010-2012 
6.1-1;  6.4-1; 6.2-1;  6.5-1; 6.3-1;  6.6-1
3.0 NC-R Return to 
1 
[-ve FOBT OR 
+ve FOBT but NCf]
1.0-2.0-1
1.0-2.2-1
1.0-2.3-1
1.0-2.4-1
4.0 NC-R Return to 
3.0-1 C 
C FOBT+ve Cf DCBE-
ve Return to 1
3.6-1 C 
C FOBT-ve, Return 
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Table A2.1 CRCS mapping pathways II 
  Pathway Pathway Definition Group 
1 1.0-2.0-1 NC FOBT then and no CRC H 
2 1.0-2.1-1 NC FOBT then xSIG and no CRC F 
3 1.0-2.2-1 NC FOBT then xFOBT and no CRC F 
4 1.0-2.3-1 NC FOBT then xDCBE and no CRC F 
5 1.0-2.4-1 NC FOBT then xCOL and no CRC F 
6 1.0-2.0-1-6.1 (alive) NC FOBT then CRC LOC diagnosis G 
7 1.0-2.0-1-6.2 (alive) NC FOBT then CRC REG diagnosis G 
8 1.0-2.0-1-6.3 (alive) NC FOBT then CRC DIS diagnosis G 
9 1.0-2.2-1-6.1 (alive) NC FOBT, xTESTs then CRC LOC diagnosis E 
10 1.0-2.2-1-6.2 (alive) NC FOBT, xTESTs then CRC REG diagnosis E 
11 1.0-2.2-1-6.3 (alive) NC FOBT, xTESTs then CRC DIS diagnosis E 
12 1.0-2.6-1 C FOBT return to CRC cohort 1 D 
13 1.0-2.6-4.2-1 C FOBT, COL then no CRC D 
14 1.0-2.6-6.4 C FOBT, CRC LOC after 90days (90d) B 
15 1,0-2.6-6.5 C FOBT, CRC REG after 90d B 
16 1.0-2.6-6.6 C FOBT, CRC DIS  after 90d B 
17 1.0-2.6-4.2-5.1 C FOBT, COL then COL Bx 1-3 and nCRC D 
18 1.0-2.6-4.2-5.1-6.4 C FOBT, COL then COL Bx 1-3, CRC LOC in 90d A 
19 1.0-2.6-4.2-5.1-6.4 C FOBT, COL then COL Bx 1-3, CRC LOC after 90d C 
20 1.0-2.6-4.2-5.1-6.5 C FOBT, COL then COL Bx 1-3, CRC REG  in 90d A 
21 1.0-2.6-4.2-5.1-6.5 C FOBT, COL then COL Bx 1-3, CRC REG after 90d C 
22 1.0-2.6-4.2-5.1-6.6 C FOBT, COL then COL Bx 1-3, CRC DIS  in 90d A 
23 1.0-2.6-4.2-5.1-6.6 C FOBT, COL then COL Bx 1-3, CRC DIS  after 90d C 
24 1.0-2.6-4.2-5.2 C FOBT, COL then COL Bx 4-6 and nCRC D 
25 1.0-2.6-4.2-5.2-6.4 C FOBT, COL then COL Bx 4-6, then CRC LOC in 90d A 
26 1.0-2.6-4.2-5.2-6.4 C FOBT, COL then COL Bx 4-6, then CRC LOC after 
90d 
C 
27 1.0-2.6-4.2-5.2-6.5 C FOBT, COL then COL Bx 4-6, then CRC REG  in 90d A 
28 1.0-2.6-4.2-5.2-6.5 C FOBT, COL then COL Bx 4-6, then CRC REG after 
90d 
C 
29 1.0-2.6-4.2-5.2-6.6 C FOBT, COL then COL Bx 4-6, then CRC DIS  in 90d A 
30 1.0-2.6-4.2-5.2-6.6 C FOBT, COL then COL Bx 4-6, then CRC DIS  after 
90d 
C 
31 1.0-2.6-4.2-5.3 C FOBT, COL then COL Bx 7-9 and nCRC D 
32 1.0-2.6-4.2-5.3-6.4 C FOBT, COL then COL Bx 7-9, then CRC LOC in 90d A 
33 1.0-2.6-4.2-5.3-6.4 C FOBT, COL then COL Bx 7-9, then CRC LOC  after 
90d 
C 
34 1.0-2.6-4.2-5.3-6.5 C FOBT, COL then COL Bx 7-9, then CRC REG in 90d A 
35 1.0-2.6-4.2-5.3-6.5 C FOBT, COL then COL Bx 7-9, then CRC REG after 
90d 
C 
36 1.0-2.6-4.2-5.3-6.6 C FOBT, COL then COL Bx 7-9, then CRC DIS  in 90d A 
37 1.0-2.6-4.2-5.3-6.6 C FOBT, COL then COL Bx 7-9, then CRC DIS after 90d C 
38 1.0-2.6-4.2-5.4 C FOBT, COL then COL Bx 10-12 and nCRC D 
39 1.0-2.6-4.2-5.4-6.4 C FOBT, COL then COL Bx 10-12, CRC LOC in 90d A 
40 1.0-2.6-4.2-5.4-6.4 C FOBT, COL then COL Bx 10-12, CRC LOC after 90d C 
41 1.0-2.6-4.2-5.4-6.5 C FOBT, COL then COL Bx 10-12, CRC REG in 90d A 
42 1.0-2.6-4.2-5.4-6.5 C FOBT, COL then COL Bx 10-12, CRC REG after 90d C 
43 1.0-2.6-4.2-5.4-6.6 C FOBT, COL then COL Bx 10-12, CRC DIS in 90d A 
44 1.0-2.6-4.2-5.4-6.6 C FOBT, COL then COL Bx 10-12, CRC DIS after 90d C 
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  Pathway Pathway Definition Group 
45 1.0-2.6-4.2-5.5 C FOBT, COL then COL Bx 13+, nCRC D 
46 1.0-2.6-4.2-5.5-6.4 C FOBT, COL then COL Bx 13+, CRC LOC in 90 days A 
47 1.0-2.6-4.2-5.5-6.4 C FOBT, COL then COL Bx 13+, CRC LOC after 90d C 
48 1.0-2.6-4.2-5.5-6.5 C FOBT, COL then COL Bx 13+, CRC REG in 90 days A 
49 1.0-2.6-4.2-5.5-6.5 C FOBT, COL then COL Bx 13+, CRC Reg after 90d C 
50 1.0-2.6-4.2-5.5-6.6 C FOBT, COL then COL Bx 13+, CRC DIS in 90d A 
51 1.0-2.6-4.2-5.5-6.6 C FOBT, COL then COL Bx 13+, CRC DIS after 90d C 
52 1.0-2.6-4.2-5.1 C FOBT-ve then xCOL Bx 1-3 M 
53 1.0-2.6-4.2-5.1-6.4 C FOBT-ve then xCOL Bx 1-3, CRC LOC L 
54 1.0-2.6-4.2-5.1-6.5 C FOBT-ve then xCOL Bx 1-3, CRC REG L 
55 1.0-2.6-4.2-5.1-6.6 C FOBT-ve then xCOL Bx 1-3, CRC DIS L 
56 1.0-2.6-4.2-5.2 C FOBT-ve, then xCOL Bx 4-6 M 
57 1.0-2.6-4.2-5.2-6.4 C FOBT-ve then xCOL Bx 4-6, then CRC LOC L 
58 1.0-2.6-4.2-5.2-6.5 C FOBT-ve then xCOL Bx 4-6, then CRC REG L 
59 1.0-2.6-4.2-5.2-6.6 C FOBT-ve thenx COL Bx 4-6, then CRC DIS L 
60 1.0-2.6-4.2-5.3 C FOBT-ve then xCOL Bx 7-9 M 
61 1.0-2.6-4.2-5.3-6.4 C FOBT-ve then xCOL Bx 7-9, then CRC LOC L 
62 1.0-2.6-4.2-5.3-6.5 C FOBT-ve then xCOL Bx 7-9, then CRC REG L 
63 1.0-2.6-4.2-5.3-6.6 C FOBT-ve then xCOL Bx 7-9, then CRC DIS L 
64 1.0-2.6-4.2-5.4 C FOBT-ve then xCOL Bx 10-12 M 
65 1.0-2.6-4.2-5.4-6.4 C FOBT-ve then xCOL Bx 10-12, CRC LOC L 
66 1.0-2.6-4.2-5.4-6.5 C FOBT-ve then xCOL Bx 10-12, CRC REG L 
67 1.0-2.6-4.2-5.4-6.6 C FOBT-ve then xCOL Bx 10-12, CRC DIS L 
68 1.0-2.6-4.2-5.5 C FOBT-ve then xCOL Bx 13 and more M 
69 1.0-2.6-4.2-5.5-6.4 C FOBT-ve then xCOL Bx 13 and more, CRC LOC L 
70 1.0-2.6-4.2-5.5-6.5 C FOBT-ve then xCOL Bx 13 and more, CRC REG L 
71 1.0-2.6-4.2-5.5-6.6 C FOBT-ve then xCOL Bx 13 and more, CRC DIS L 
72 1.0-2.6-3.2-4.3-5.6 C FOBT but NCf, xCOL Bx 1-3 K 
73 1.0-2.6-3.2-4.3-5.6-6.1 C FOBT NCf, xCOL Bx 1-3, CRC LOC I 
74 1.0-2.6-3.2-4.3-5.6-6.1 C FOBT NCf, xCOL Bx 1-3, CRC REG I 
75 1.0-2.6-3.2-4.3-5.6-6.3 C FOBT NCf, xCOL COL Bx 1-3, CRC DIS I 
76 1.0-2.6-3.2-4.3-5.7 C FOBT NCf, xCOL COL Bx 4-6 K 
77 1.0-2.6-3.2-4.3-5.7-6.1 C FOBT NCf, xCOL COL Bx 4-6, CRC LOC I 
78 1.0-2.6-3.2-4.3-5.7-6.2 C FOBT NCf, xCOL COL Bx 4-6, CRC REG I 
79 1.0-2.6-3.2-4.3-5.7-6.3 C FOBT NCf, xCOL COL Bx 4-6, CRC DIS I 
80 1.0-2.6-3.2-4.3-5.8 C FOBT NCf xCOL Bx 7-9 K 
81 1.0-2.6-3.2-4.3-5.8-6.1 C FOBT NCf, xCOL Bx 7-9, CRC LOC I 
82 1.0-2.6-3.2-4.3-5.8-6.2 C FOBT NCf, xCOL Bx 7-9, CRC REG I 
83 1.0-2.6-3.2-4.3-5.8-6.3 C FOBT NCf, xCOL Bx 7-9, CRC DIS I 
84 1.0-2.6-3.2-4.3-5.9 C FOBT NCf xCOL Bx 10-12 K 
85 1.0-2.6-3.2-4.3-5.9-6.1 C FOBT NCf, xCOL Bx 10-12, CRC LOC I 
86 1.0-2.6-3.2-4.3-5.9-6.2 C FOBT NCf, xCOL Bx 10-12, CRC REG I 
87 1.0-2.6-3.2-4.3-5.9-6.3 C FOBT NCf, xCOL Bx 10-12, CRC DIS I 
88 1.0-2.6-3.2-4.3-5.10 C FOBT but NCf xCOL Bx 13 and more K 
89 1.0-2.6-3.2-4.3-5.10-6.1 C FOBT NCf, xCOL Bx 13, CRC LOC I 
90 1.0-2.6-3.2-4.3-5.10-6.2 C FOBT NCf, xCOL Bx 13, CRC REG I 
91 1.0-2.6-3.2-4.3-5.10-6.3 C FOBT NCf, xCOL Bx 13, CRC DIS I 
92 1.0-2.6-3.1-4.2-5.6 C FOBT, C DCBE then xCOL Bx 1-3 K 
93 1.0-2.6-3.1-4.2-5.6-6.4 C FOBT, Cf DCBE then xCOL Bx 1-3, CRC LOC   J 
94 1.0-2.6-3.1-4.2-5.6-6.5 C FOBT, Cf DCBE then xCOL Bx 1-3, CRC REG  J 
95 1.0-2.6-3.1-4.2-5.6-6.6 C FOBT, Cf DCBE then xCOL Bx 1-3, CRC DIS J 
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96 1.0-2.6-3.1-4.2-5.7 C FOBT, Cf DCBE then xCOL Bx 4-6 K 
97 1.0-2.6-3.1-4.2-5.7-6.4 C FOBT, Cf DCBE then xCOL Bx 4-6, CRC LOC in 90d J 
98 1.0-2.6-3.1-4.2-5.7-6.5 C FOBT, Cf DCBE then xCOL Bx 4-6, CRC REG in 90d J 
99 1.0-2.6-3.1-4.2-5.7-6.6 C FOBT, Cf DCBE then xCOL Bx 4-6, CRC DIS in 90d J 
100 1.0-2.6-3.1-4.2-5.8 C FOBT, Cf DCBE then xCOL Bx 7-9 K 
101 1.0-2.6-3.1-4.2-5.8-6.4 C FOBT, Cf DCBE then xCOL Bx 7-9, CRC LOC in 90d J 
102 1.0-2.6-3.1-4.2-5.8-6.5 C FOBT, Cf DCBE then xCOL Bx 7-9, CRC REG in 90d J 
103 1.0-2.6-3.1-4.2-5.8-6.6 C FOBT, Cf DCBE then xCOL Bx 7-9, CRC DIS in 90d J 
104 1.0-2.6-3.1-4.2-5.9 C FOBT+ve, Cf DCBE+ve then xCOL K 
105 1.0-2.6-3.1-4.2-5.9-6.4 C FOBT, Cf DCBE then xCOL Bx 10-12, CRC LOC in 
90d 
J 
106 1.0-2.6-3.1-4.2-5.9-6.5 C FOBT, Cf DCBE then xCOL Bx 10-12, CRC REG in 
90d 
J 
107 1.0-2.6-3.1-4.2-5.9-6.6 C FOBT, Cf DCBE then xCOL Bx 10-12, CRC DIS in 
90d 
J 
108 1.0-2.6-3.1-4.2-5.10 C FOBT+ve, Cf DCBE+ve then xCOL K 
109 1.0-2.6-3.1-4.2-5.10-6.4 C FOBT, Cf DCBE then xCOL Bx 13+CRC LOC in 90d J 
110 1.0-2.6-3.1-4.2-5.10-6.5 C FOBT, Cf DCBE then xCOL Bx 13+ CRC REG in 90d J 
111 1.0-2.6-3.1-4.2-5.10-6.6 C FOBT, Cf DCBE then xCOL Bx 13+ CRC DIS in 90d J 
90d 90 daysBx; biopsies; C compliant CRCS invitation; Cf compliant follow-up; COL colonoscopy; 
CRC colorectal cancer; CRCS colorectal cancer screening; DCBE double-contrast barium enema; 
DIS distant; Dx diagnosis; LOC Localised; NC non-compliant FOBT; NCf non-compliant follow-up; 
NHI National Health Insurance; REG regional; rHCU Healthcare utilisation CRCS (xTests) then CRC 
Tx; symCRC symptomatic CRC (no CRCS done); tCRC CRCS FOBT negative then 90 days later 
CRC Tx; Tx treatment; xFOBT FOBT outside CRCS within NHI; xSIG sigmoidoscopy outside CRCS 
within NHI; xDCBE DCBE outside CRCS within NHI; xCOL COL outside CRCS within NHI; zHCU 
Healthcare utilisation CRCS only (xTests outside CRCS within NHI); +ve positive; -ve negative 
Group A-D CRCS only; E-F HCSU only; G-H NC; I-K CRCS positive then HCSU; L-M CRCS 
negative results then HCSU 
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Table A2.2 Summary of recommended chemotherapy agents for CRC  
Primary chemotherapy agents Indications Reference  
Fluorouracil + leucovorin Clinician’s judgement HIRA (2015) 
Fluorouracil + cisplatin Clinician’s judgement HIRA (2015) 
Fluorouracil + leucovorin + cicplatin Clinician’s judgement HIRA (2015) 
Fluorouracil + leucovorin + carboplatin Clinician’s judgement HIRA (2015) 
Tegafur + uracil + leurovorin (oral) Clinician’s judgement HIRA (2015) 
leurovorin (oral) Clinician’s judgement HIRA (2015) 
Tegarfut + uracil + leucovorin (oral) + 
cisplatin 
Clinician’s judgement  HIRA (2015) 
leucovorin (oral) + cisplatin Clinician’s judgement HIRA (2015) 
Mitomycin C Clinician’s judgement HIRA (2015) 
Mitomycin C  + leucovorin (oral) Clinician’s judgement HIRA (2015) 
Mitomycin C + tegarfur + uracil + 
leucovorin (oral) 
Clinician’s judgement HIRA (2015) 
Cisplatin Clinician’s judgement HIRA (2015) 
Etoposide (intravenous or oral)  Clinician’s judgement HIRA (2015) 
Secondary chemotherapy agents   HIRA (2015) 
Neoadjuvant   HIRA (2015) 
Capecitabine + radiotherapy CRC Stages II & III HIRA (2015) 
Oxaliplatin + leucovorin + infusional 
flourouracil (FOLFOX) 
CRC stage II (post-
operative) 
CRC stage III 
HIRA (2015) 
Capecitabine  CRC stage II (post-
operative) 
CRC stage III 
HIRA (2015) 
Oxaliplatin + capecitabine  CRC stage III  HIRA (2015) 
Palliative  
Irinotecan + leucovorin fluorouracil 
(infusion)(FOLFIRI) + bevacizumab 
Metastasis HIRA (2015) 
Irinotecan + leucovirin + fluoroucil 
(infusion) (FOLFIRI) + cetuximab 
EGFR positive, KRAS 
wild-type metastatic 
CRC 
HIRA (2015) 
Irinotecan + leucovorin + fluorouracil 
(infusion) (FOLFIRI) + bevacizumab 
Metastasis HIRA (2015) 
Oxaliplatin + leucovorin + fluoroucil 
(infusion) (FOLFOX) + bevacizumab 
Metastasis HIRA (2015) 
CRC colorectal cancer; EGFR epidermal growth factor receptor; KRAS mutations in the 
Kirsten Ras gene 
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APPENDICES TO CHAPTER 3 
Table A3.1 Search strategy - MEDLINE 
Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) 1946 to Present 
# Searches Results 
1 ((colorectal or colon$ or rectum or rectal) adj2 (cancer$ or 
tumour$ or tumor$ or neoplasm$ or carcinoma$ or adenoma$ 
or polyp$)).ti,ab. 
115391 
2 Colonoscopy/ 16294 
3 colonoscop$.ti,ab. 16760 
4 sigmoidoscop$.ti,ab. 3592 
5 exp Mass Screening/ 93902 
6 exp Population Surveillance/ 46155 
7 Diagnostic tests, routine/ 6251 
8 screen$.ti,ab. 415503 
9 2 or 3 or 4 26014 
10 5 or 6 or 7 or 8 495330 
11 1 and 9 and 10 4432 
12 limit 11 to yr="1999 -Current" 3671 
13 Economics/ or exp "Costs and Cost Analysis"/ or Economics, 
Dental/ or exp Economics, Hospital/ or exp Economics, 
Medical/ or Economics, Nursing/ or Economics, 
Pharmaceutical/ or Budgets/ or exp Models, Economic/ or 
Markov Chains/ or Monte Carlo Method/ or Decision Trees/ 
256934 
14 (Economic* or cost or costs or costly or costing or costed or 
price or prices or pricing or pharmacoeconomic$ or pharmaco 
economic$ or budget*).ti,ab. 
420310 
15 ((monte adj carlo) or markov or (decision adj2 (tree$ or 
analys$))).ti,ab. 
40324 
16 Quality-Adjusted Life Years/ 6140 
17 (quality adjusted life or qaly*).ti,ab. 6297 
18 (disability adjusted life or daly).ti,ab. 1231 
19 (value adj2 (money or monetary)).ti,ab. 1173 
20 13 or 14 or 15 or 16 or 17 or 18 or 19 580430 
21 12 and 20 610 
 
  
 
 
216 
 
Table A3.2 Further details – Study selection criteria 
Inclusion criteria Full economic evaluations that considered costs and health 
outcomes of relevant types of interventions with outcomes 
expressed in cost per quality-adjusted life-year (QALY) or cost 
per life-year gained. The population considered was adults 
with confirmed colorectal adenoma/polyp who are 
otherwise healthy with no personal or familial history of 
CRC. Follow-up strategies and screening strategies based 
on the best available evidence on the screening modalities 
were considered, including current practice and no 
intervention. 
Exclusion criteria Burden of disease studies or non-comparative costing studies 
were excluded.  Any studies which did not assess costs and 
related health outcomes in line with the research 
questions were excluded. Clinical investigation or 
therapeutic interventions for suspected CRC or conditions 
other than colorectal adenoma/polyp were not considered. 
Screening Title and abstracts were screened and papers that did not 
meet the inclusion criteria were excluded. Full text was 
acquired for the remaining studies. When studies 
presented insufficient detail (for example, no abstract 
available) full-text was reviewed. All abstracts were 
screened, and any disagreements were resolved by 
discussion between two reviewers. 
Data extraction Data were extracted on author(s), year of publication, 
modelling approach, screening modalities, population 
groups, perspective of analysis and analytic horizon, 
effectiveness data sources, outcome measures, cost 
elements, cost data sources, year of costing reported, 
adjustment for inflation, discount rate, baseline results, 
variables used in the results and sensitivity analyses, 
reported limitations, reported model validation and 
reported conclusion. In addition, modelled strategies for 
follow-up of positive results from first-line screening and 
follow-up of adenoma/polyp and CRC treatments were 
reviewed. 
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Appendix Table A3.3 Included/excluded studies 
Table A3.3.1 Included studies 
1 Chauvin, P., J.M. Josselin, and D. Heresbach, Incremental net benefit and 
acceptability of alternative health policies: A case study of mass screening for 
colorectal cancer. European Journal of Health Economics, 2012. 13(3): p. 237-250. 
2 Dan, Y.Y., et al., Screening based on risk for colorectal cancer is the most cost-
effective approach. Clinical Gastroenterology & Hepatology, 2012. 10(3): p. 266-
71.e1-6. 
3 Di Bidino, R., et al., Impact of technology overlapping: a case study on colorectal 
cancer screening. Technology & Health Care, 2010. 18(4-5): p. 303-15. 
4 Eddy, D.M., Screening for colorectal cancer. American Journal of Physicians, 1990. 
113: p. 373-384. 
5 Flanagan, W.M., et al., Potential impact of population-based colorectal cancer 
screening in Canada. Chronic Diseases in Canada, 2003. 24(4): p. 81-8. 
6 Frazier, A.L., et al., Cost-effectiveness of screening for colorectal cancer in the 
general population. JAMA, 2000. 284(15): p. 1954-61. 
7 Hassan, C., et al., Value-of-information analysis to guide future research in 
colorectal cancer screening. Radiology, 2009b. 253(3): p. 745-752. 
8 Hassan, C., et al., Cost-effectiveness of early one-year colonoscopy surveillance 
after polypectomy. Diseases of the Colon & Rectum, 2009a. 52(5): p. 964-71; 
discussion 971. 
9 Hassan, C., P.J. Pickhardt, and D.K. Rex, A resect and discard strategy would 
improve cost-effectiveness of colorectal cancer screening. Clinical 
Gastroenterology & Hepatology, 2010. 8(10): p. 865-9, 869.e1-3. 
10 Hassan, C., et al., Colon cancer prevention in Italy: cost-effectiveness analysis with 
CT colonography and endoscopy. Digestive & Liver Disease, 2007. 39(3): p. 242-
50. 
11 Hassan, C., et al., Cost-effectiveness of capsule endoscopy in screening for 
colorectal cancer. Endoscopy, 2008. 40(5): p. 414-21. 
12 Heitman, S.J., et al., Colorectal cancer screening for average-risk North Americans: 
an economic evaluation. PLoS Medicine / Public Library of Science, 2010. 7(11): 
p. e1000370. 
13 Heitman, S.J., et al., Cost-effectiveness of computerized tomographic 
colonography versus colonoscopy for colorectal cancer screening. CMAJ 
Canadian Medical Association Journal, 2005. 173(8): p. 877-81. 
14 Helm, J.F., et al., Effectiveness and economic impact of screening for colorectal 
cancer by mass fecal occult blood testing. American Journal of Gastroenterology, 
2000. 95(11): p. 3250-8. 
15 Heresbach, D., et al., Cost-effectiveness of colorectal cancer screening with 
computed tomography colonography or fecal blood tests. European Journal of 
Gastroenterology & Hepatology, 2010b. 22(11): p. 1372-9. 
16 Heresbach, D., et al., Cost-effectiveness of colorectal cancer screening with 
computed tomography colonography according to a polyp size threshold for 
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Table A3.4 Summary of included studies 
Author  Perspective Population  Intervention(s) Comparators Reported results  
Chauvin 
(2012) 
3rd party 
payer  
50 - 80yrs 
average risk 
people, 
France 
CTCq5Y (every 5 year) 
CTCq10Y 
Immunological 
FOBTq2Y 
Close expected net benefits between iFOBT and CTCq5 induced 
uncertainty in the choice of the optimal strategy. PSA then 
suggested that below a WTP per LYG of 8,587€/LYG, CTCq10Y 
was optimal, while CTCq5Y would be preferred beyond a WTP of 
8,587€/LYG. 
Dan (2012) Societal  50-75 yrs 
individuals, 
Singapore 
SIG once 
iFOBTq1Y 
BEq5Y 
COL once 
SIGq5Y 
SIGq5Y + iFOBTq1Y 
Stool DNAq5Y 
COLq10Y 
CTCq5Y 
iFOBT + COLq10Y 
No screening Performing single SIG at 60yrs was the cheapest screening 
strategy; Screening subjects 50 to 60 yrs old by iFOBT and 
subjects 60 to 72 yrs old with COL q10Y was the most CE 
strategy (USD $25,000/QALY).  
Hassan 
(2010) 
Societal Average risk 
50yrs 
Population in 
the US 
NBI with resect and 
discard policy using q10Y 
COLq10Y  
no screening  
With universal referral of resected polyps to pathology, COL 
screening costs an estimated $3222/person, with a gain of 51 
days/person 
Heitman 
(2010) 
Publicly 
funded 
health care 
system  
50-75yrs age-
two stratified 
groups (50-
64yrs, 65-
75yrs) 
Average risk 
population, 
Canada 
FOBTq1Y (low- high-) 
FITq1Y(3 strategies-low, 
mid, high test 
performance) 
Fecal DNAq3Y 
FSIGq5Y 
CTCq5Y 
COLq10Y 
No screening 
compared to 
each modality 
FIT1q1Y, assuming mid-range testing characteristics, was more 
effective and less costly compared to all strategies (including no 
screening) except FIT-high. Among the lifetimes of 100,000 
average-risk patients, the number of CRC could be reduced from 
4,857 to 1,782 and the number of CRC deaths from 1,393 to 457, 
while saving Canadian $68 per person.  
 
 
225 
 
Table A3.4 Summary of included studies 
Author  Perspective Population  Intervention(s) Comparators Reported results  
Heitman 
(2005) 
To inform 
Canadian 
Health policy 
decision 
makers 
50 years, 
Canada 
CTC then COL for 
adenomas 6mm or larger 
COL CTC for CRC screening would cost $2.27mil extra per 100 000 
patients screened; 3.78 perforation-related deaths would be 
avoided, but 4.11 extra deaths would occur from missed 
adenomas. Because CTC screening would cost more and result 
in more deaths overall compared with COL, the latter remained 
the dominant strategy. Our results were sensitive to CTC test 
performance characteristics, the malignant risk of missed 
adenomas, the risk of perforation and related death, the 
procedural costs and differences in screening adherence. 
Heresbach 
(2010b) 
3rd party 
payer, only 
direct costs 
Average risk 
50-74 years, 
follow up 
model 
considered 
people with 
adenoma, 
France 
gFOBTq2Y iFOBTq2Y 
CTCq10Y 
Using CTC requires substantially less COL than iFOBT and is CE 
for low values of WTP(less than 20000/LYG). However, iFOBT is 
the preferred screening strategy for a WTP greater than 
6207euro/LYG. 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
Ho (2008) Publicly 
funded 
health care 
system 
Average-risk 
Canadians 
aged 50-74yrs 
CTCq10Y COLq10  
FOBTq1Y 
No screening 
When compared to no screening using a cost-effectiveness 
framework, COL, FOBT and CTC were associated with 
incremental gains in quality-adjusted life expectancy (0.04, 0.02, 
and 0.03 additional QALY, respectively). In the base-case, the no 
screening strategy was the least expensive, followed by FOBT 
and then COL. CTC was associated with worse clinical outcomes 
and higher costs than COL. Compared to no screening COL was 
associated with a cost per QALY gained of $7,937. In PSA, 
compared to no screening, COL is associated with a cost per 
QALY of less than $10,000 nearly 99% of the time, while COL is 
cost saving by comparison to CTC 91% of the time.  
Khandker 
(2000) 
Payer's 
perspective 
50yrs and 
older without 
predisposing 
factors 
(screening 50-
85yrs), US 
1 )annual FOBT  
2) FSIGq3Y 
3) FSIGq5Y  
4) annual FOBT and 
FSIGq5Y  
5) DCBEq5Y  
6) COLq5Y  
7) COLq10Y 
No screening  Lifetime costs of CRC $643 per person with no screening, 
compared to $2058 (annual FOBT), $2079 (FSIGq3Y), $1713 
(FSIG q5Y), $2854 (FOBT annual and FSIGq3Y), $2639 (annual 
FOBT and FSIGq5Y), $2577 (DCBEq5Y), $3906 (COLq5), $2602 
(COLq10). SIGq5Y and annual FOBT were the most cost-
effective strategies; FOBT was less cost-effective when the 
compliance is low.  
Lee (2010) NHS Average risk 
60-69yrs CRC 
screening, UK 
CTC FOBT 
FSIG 
COL 
CRCq10Y was cost-effective compared to biennial FOBT.  
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Author  Perspective Population  Intervention(s) Comparators Reported results  
Lejeune 
(2004) 
French 
health-care 
insurance 
system 
Individuals  
until 85, 
France 
FOBT (Hemoccult-II 
test)q2Y 50-74yrs 
No screening Modelling biennial screening vs the absence of screening over a 
20-year period resulted in a 17.7% mortality reduction and a 
discounted incremental cost-effectiveness ratio of €3,357 per life-
years gained among individuals 50-74 years of age. Sensitivity 
analyses performed on epidemiological and economic data 
showed the strong impact on the results of colonoscopy cost, of 
compliance to screening and of specificity of the screening test. 
 
Lejeune 
(2010) 
Possibly 
French 
health-care 
insurance 
system 
Individuals 
aged 50 to 74 
(screening 
offered) and 
followed until 
85yrs or 
death, France 
gFOBTq2Y iFOBT   
No screening 
Compared to no screening, gFOBT and iFOBT were associated 
with a decrease in colorectal cancer mortality of 17.4% and 
25.2%, respectively. With regard to cost-effectiveness, expressed 
as cost per life-years gained, iFOBT was the most effective and 
most costly alternative. Compared to no screening, gFOBT and 
iFOBT presented similar discounted incremental cost-
effectiveness ratios: €2739 and €2819 respectively per LYG. 
When compared to gFOBT, iFOBT presented an ICER of 2988 
per LYG. 
 
Loeve (1999)  Not 
specified 
50yrs olds, 
US 
Planned intervention(s) 
for economic evaluation: 
FSIGq3Y (till 74yrs) 
unhydrated FOBTq2Y (till 
80yrs) 
No screening All kinds of assumptions on the natural history of CRC and 
screening and surveillance strategies can easily be incorporated 
in the model. MISCAN-COLON gives detailed output of 
incidence, prevalence and mortality, and the results and effects 
of screening. It can be used to test hypotheses about the natural 
history of colorectal cancer, such as the duration of progressive 
adenomas, and screening characteristics, such as sensitivity of 
test, against empirical data.  
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Loeve (2000)   50yrs olds, 
US 
FSIGq3Y (till 74yrs) 
unhydrated FOBTq2Y (till 
80yrs) 
No screening Given the expert opinion-based assumptions, a program based 
on q5Y SIG screenings could result in a net savings of direct 
health care costs due to prevention of cancer treatment costs 
that compensate for the costs of screening, diagnostic follow-up, 
and surveillance. This result persists when costs and health 
effects are discounted at 3%. The 'break-even’ point, the time 
required for a screening program that terminates after 30 years 
and 44 years for a screening program that continues on 
indefinitely. However, net savings increase assumptions about 
natural history of CRC, costs of screening, surveillance, and 
diagnostics are considered. 
Lansdorp-
Vogelaar 
(2009a) 
Not stated 
(maybe 3rd 
party payer 
perspective) 
50-80yrs 
general 
population 
CTC with 20Y, 15Y, 10Y, 
5Y intervals 
(1) intensive referral: any 
suspected polyps  
(2)intermediate referral: 
suspected polyp>=6mm  
(3) minimal referral: 
suspected polyp >=10mm 
COL q20Y 
COLq15Y 
COLq10Y 
COLq5Y 
With equal costs ($662), COL dominated CTC screening. For 
CTC to gain similar LGY as COL q10Y, it should be offered q5Y 
with referral of polyps >=6mm. 
Eddy (1990) Not stated 50yr persons 
at average 
risk and 
persons at 
high risk 
(having a 1st 
degree 
relative with 
CRC), US 
FOBT (Hemoccult-II)q1Y 
plus ACBEq3Y 
FOBTq1Y plus 60cm 
FSIGq5Y  
FOBTq1Y plus COLq5Y 
FOBq1Y plus ACBEq1Y 
FOBTq1Y plus COLq3Y 
FOBTq1Y plus COLq1Y 
No screening Screening persons for 25 years, from the age of 50 to the age of 
75yrs should reduce the chance of developing or dying from CRC 
by 10% to 75%, depending on which screening tests are used 
and how often screening is done.  
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Lansdorp-
Vogelaar 
(2010) 
3rd party 
payer 
65yrs olds 
(varied, aged 
to 50 in 
sensitivity 
analysis) 
Stool DNAq3Y 
Stool DNAq5Y 
No screening 
HII; HS 
iFOBT 
SIGB; SIG 
HII + SIGB 
HII + SIG 
HS + SIGB 
HS + SIG 
HSq3Y + SIGB 
HSq3Y + SIG 
iFOBT + SIGB 
iFOBT + SIG 
iFOBTq3Y + 
SIGB 
iFOBTq3Y + 
SIG; COL 
Assuming a cost of $350 per test, strategies of stool DNA testing 
q3Y or q5Y yielded fewer life years and higher costs than the 
currently recommended CRC screening strategies. Screening 
with the stool DNA test would be cost-effective at a per-test cost 
of $40 to $60 for stool DNA testing q3Y, depending on the 
simulation model used. There were no levels of sensitivity and 
specificity for which stool DNA testing would be cost-effective at 
its current cost of $350 per test. Stool DNA testing q3Y would be 
cost-effective at a cost of $350 per test if the relative adherence 
to stool DNA testing were at least 50% better than that with other 
screening tests. 
McMahon 
(2001) 
re-analysis 
of existing 
studies 
(Eddy 1990, 
Glick 1998, 
OTA 1995) 
 US FOBT (Hemoccult-II)q1Y 
plus ACBEq3Y 
FOBTq1Y plus 60cm 
FSIGq5Y  
FOBTq1Y plus COLq5Y 
FOBq1Y plus ACBEq1Y 
FOBTq1Y plus COLq3Y 
FOBTq1Y plus COLq1Y 
No screening Strategies in which DCBE examination was performed emerged 
as optimal from all studies included. In average-risk individuals, 
screening with DCBE examination q3Y or q5Y with annual FOBT, 
had an ICER of less than $55,600 per life-years saved. However 
DCBE examination screening q3Y plus annual FOBT had an 
ICER of more than $100,000 per life-years saved. COL had an 
ICER of more than $100,000 per life years saved, was dominated 
by other screening strategies and offered less benefit than did 
DCBE. 
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Ness (2000) Societal 
perspective 
40 year old 
men and 
women in the 
US 
One-time COL at; 
45-49yrs 
50-54 
55-59 
60-64 
No screening It was determined that one-time COL screening in men age 60yr 
and in women age <65yr dominated never screening and 
screening at older ages. For both sexes, one-time COL screening 
between 50 and 54yrs was associated with a marginal cost-utility 
of less than $10,000 per QALY compared to screening between 
55 and 60yrs of age. One-time COL screening between 45 and 
49ys of age was either dominated (women) or associated with a 
marginal cost-utility of $69,000/QALY (men) compared to 
screening between 50 and 54yr of age. The marginal cost-utility 
of one-time COL screening was relatively insensitive to plausible 
changes in the cost of COL, the cost of CRC treatment, the 
sensitivity of COL for colorectal neoplasia, the utility values 
representing the morbidity associated with the CRC-related 
health states and the discount rate. 
Pickhardt 
(2008a) 
Not stated 60yrs 
asymptomatic 
polyps; 
diminutive 
(≤5mm), small 
(6-9mm), 
large 
(≥10mm), US 
CTC then COL CTC only Estimated 10Y CRC risk for unresected diminutive (0.08%), small 
(0.7%) and large polyps (15.7%). ICER of removing all diminutive 
$465,407 and small CTC-detected polyps $59,015 per life-years 
gained. Polypectomy for large CTC-detected polyps yielded a 
cost-saving of $151 per person screened.  
Pickhardt 
(2008b) 
not stated 60yrs 
asymptomatic 
people with 
small polyps 
(6- to 9-mm) 
detected at 
CTC 
screening, US 
CTCq3Y surveillance Immediate 
polypectomy 
Without any intervention, the estimated 5-year CRC death rate 
from 6- to 9-mm polyps in this concentrated cohort was 0.08%, 
which is a sevenfold decrease over the 0.56% CRC risk for the 
general unselected screening population. The death rate was 
further reduced to 0.03% with the CTC surveillance strategy and 
to 0.02% with immediate colonoscopy referral. However, for each 
additional cancer-related death prevented with immediate 
polypectomy versus CTC follow-up, 9,977 COL referrals would 
be needed, resulting in 10 additional perforations and an 
incremental cost-effectiveness ratio of $372,853. 
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Saini (2010) Not stated  
 
 
50yrs with 
newly 
diagnosed 
adenomas 
surveillance 
COL until 
85yrs, US 
COLq3Y HR, q10Y LR 
(3/10) 
3/5 
3/3 
No 
surveillance 
3/5 USD5743/QALY gained compared with no surveillance, 3/3 
strategy was dominated by 3/5 strategy. Assuming that the 
probability of advanced adenoma formation was 1.3% per year 
(based 0.5%), the incremental cost-effectiveness ratio (ICER) of 
the 3/5 strategy was <50000/QALY gained if the relative ratio of 
advanced adenoma formation was <2.4 (base 3.9). 
Sharp (2012) A healthcare 
payer 
perspective, 
Health 
Service 
Executive  
55-74yrs, 
Ireland 
1) gFOBYq2Y 55-74yrs, 
with reflex FIT 
2) FITq2Y 55-74yrs 
3) FSIG once-only at 
60yrs 
No screening All scenarios would be considered highly cost-effective compared 
to no screening. The lowest ICER vs no screening (ICER vs no 
screening €589 per QALY gained) was found for FSIG, followed 
by FIT (€1696) and gFOBT (€4428); gfFOBT was dominated. 
Compared with FSIG, FIT was associated with greater gains in 
QALYs and reductions in lifetime cancer incidence and mortality, 
but was more costly, required considerably more COL and 
resulted in more complications.  
Song (2004) Not stated; 
"indirect 
costs were 
not included" 
& "aimed to 
explore the 
potential role 
of F-DNA in 
a national 
strategy" 
50-80yrs 
average risk 
of developing 
CRC, US 
F-DNAq5Y 
COLq10Y 
FOBTq1Y 
FSIGq5Y 
FOBT combined with 
FSIG 
No screening Compared with no screening fDNA at a screening interval of 5Y 
decreased CRC incidence by 35% and CRC mortality by 54% and 
gained 4560 life-years per 100,000 persons at 47,700/LYG in the 
base-case. However, fDNA gained fewer LY and was more costly 
than conventional screening. The average number of COL per 
person was 3.8 with COL strategy and 0.8 with fDNA strategy. In 
most 1-way SA and Monte Carlo simulation iterations, fDNA 
remained reasonably cost-effective compared with no screening, 
but COL and FOBT dominated fDNA. Assuming fDNA testing 
sensitivities of 65% for CRC and 40% for large polyp, and 95% 
specificity, a screening interval of 2Y and a test cost of $195 would 
be required to make fDNA comparable with COL.  
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Parekh 
(2008) 
Not stated  US FecalDNAq3Y 
FOBTq1Y 
iFOBT 
COLq10Y 
  FOBT and iFOBT life-years gained (LYG) per person and cost less 
than no screening. Fecal DNA testing version 1.1 at $300 (the 
current PreGen Plus test) gained 5323 LYG/100 000 persons at 
$16 900/LYG and fecal DNA testing version 2 (enhanced test) 
gained 5795 LYG/100 000 persons at $15 700/LYG vs no 
screening. In the base-case and most sensitivity analyses, FOBY 
and feacal immunochemical testing were preferred to faecal DNA 
testing. Faecal DNA testing version 2 cost $100 000/LYG vs faecal 
immunochemical testing when per-cycle adherence with faecal 
immunochemical testing was 22%. Faecal immunochemical 
testing with excellence adherence was superior to COL every 10Y. 
Ladabaum 
(2004) 
National 
perspective 
Average 
risked US 
population  
50yrs for 50 
yrs time 
horizon 
CTCq10Y (test 
performance reported by 
Cotton et al) 
CTCq10Y (base-case) 
CTCq10Y(with test 
performance as reported 
by Pickhardt(2003) 
No screening 
COL  
In the best case considered (95%, 94%, and 87% sensitivity for 
CRC, polyps≥10mm, and polyps <10mm), CTC was nearly as 
effective as COL. However, if test costs were equal, total cost per 
person was 15% greater for CTC than COL, making COL 
dominant. When test cost for CTC was ≤60% of test cost for COL, 
the small benefit of COL vs CTC cost >$200,000/incremental life-
year. The greater the likelihood of being referred for COL after 
CTC, the greater the advantage of COL. with 75% screening 
adherence in the US, CTC and COL could decrease CRC 
incidence by 46%-54%, with COL requiring 6.9 million COL/year, 
and CTC, 3.2million COL/year, plus 5.4million CTC/year with CTC. 
Ladabaum 
(2006) 
not stated  US     As screening uptake increased, CRC incidence and mortality 
decreased, and annual costs related to CRC care and testing 
increased for younger persons, but decreased for older persons. 
Compared with current screening uptake of 40%, screening 75% 
of the US population aged 50 to 80 increased annual costs related 
to CRC care and testing from $3.5 billion to $5.0 billion for 50 to 
64 years old, but decreased annual costs form $5.9 billion to $5.6 
billion for those aged 65 years and older. Sensitivity analyses 
suggest that future costs for other diseases could offset CRC care 
savings in older Americans that are attributable to screening. 
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However, even without net cost savings for any age group, 
screening remained relatively cost-effective. 
Sonnenberg 
(2000) 
3rd party 
payer 
50yrs old 
general 
population, 
annual cycle 
till death, US 
FOBTq1Y  
FSIGq5Y 
COLq10Y 
No screening Compared to COL, FOBTq1Y costs less but saves fewer life-
years. A screening strategy based on FSIG q5Y or 10Y was less 
cost-effective than the other two screening methods. 
Tappenden  
(2007) 
NHS 50yrs and 
older, UK 
(1) FOBT biennial 50-
69yrs (2) FOBT biennial 
60-69yrs (3) FSIG once at 
55yrs (4)FSIG once at 
60yrs (5) FSIG once at 
60yrs, followed by FOBT 
61-70yrs 
No screening FSIG with or without FOBT may be cost-saving and may produce 
additional benefits compared with no screening. The marginal 
cost-effectiveness of FOBT options compared to no screening is 
estimated to be below GBP3000 per QALY gained. 
Wagner 
(1991) 
Not stated 65yrs old 
individuals 
until 85yrs or 
death, US 
1)FOBTq1Y and SIGq3Y 
2)FOBTq2Y and SIGq5Y 
3)FOBTq1Y and SIG at 
65yrs 
4)FOBT 
No screening A program of annual FOBT in the elderly would detect at least 17% 
of the expected cases of cancer and could cost $35 000 per year 
of life saved. Screening schedules that include periodic SIG would 
prevent more cases of cancer but could cost between $43 000 and 
$47 000 per year of life gained. These estimates are based on 
uncertain assumptions, but results were not extremely sensitive to 
further relaxation of the values of the most uncertain assumptions.  
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Theuer 
(2008) 
Not stated 50yr old 
Black, 
Latinos, 
Asians and 
white men 
and women, 
US 
Annual FOBT plus 
FSIGq5Y 
COLq10Y Age-specific CRC incidence rates were highest in black men and 
lowest in Latino women. Screening beginning at age 50 was most 
cost-effective in black men and least cost-effective in Latino 
women (measured in USD/LYS) using annual FOBT testing 
combined with FSIGq5Y and using COLq10Y. The cost-
effectiveness of a 35-yr screening program in black men beginning 
at age 45 was similar to the cost-effectiveness of screening white 
men and black women beginning at age 50 and more cost-
effective than screening nonblack women as well as Asian and 
Latino men beginning at age 50. 
Theuer 
(2001) 
Not stated 50yr old, US Annual FOBT plus 
SFIGq5Y 
COLq10Y Average annual age-specific CRC incidence rates were highest in 
blacks and lowest in Latinos.  
Vijan (2001) 3rd party 
payer (listed 
as one of 
limitations) 
50yrs, US Once- lifetime COL 
Twice-lifetime COL 
FOBT 
FOBT+FSIG 
FSIG 
COL 
With 100% compliance rate, twice-lifetime COL at 50yrs and 60yrs 
and FSIG with FOBT are most effective. Comp with primary 
screening tests and follow-up for polyps affect screening 
decisions. COL at 50 and 60yrs was the preferred test regardless 
of compliance with the primary screening test. However, if FU COL 
for polyps is less than 75%, then even once-lifetime COL was 
preferred over most combinations of FSIG and FOBT. 
Maciosek 
(2006) 
 Not stated Average-risk 
50yrs and 
older, US 
FOBTq1Y 
FSIGq5Y 
COLq10Y 
  If a birth cohort of 4 million were offered screening at 
recommended intervals, 31,500 deaths would be prevented and 
338,000 years of life would be gained over the lifetime of the birth 
cohort. In the current cross-section of people aged 50 and older, 
18,800 deaths could be prevented each year by offering all people 
in this group screening at recommended intervals. Only 58% of 
these deaths are currently being prevented. In year 2000 dollars, 
the cost effectiveness of offering patients aged 50 and older a 
choice of colorectal cancer screening options is $11,900 per year 
of life gained. 
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Vijan (2007) Not stated 50yrs till 80yrs 
(screening), 
modelled till 
100yrs, US 
2D CTC q5Y+COL 
2D CTC q10Y+COL 
3D CTC q5Y+COL 
3D CTC q10Y+COL 
No screening 
current 
practice 
(FOBT, COL, 
FSIG) 
COL dominates 2D CTC q5Y or q10Y. COL is weakly dominant 
over 3D CTC q5Y or q10Y. 3D CTC q5Y is more effective than 
COL q10Y, but costs an incremental $156000 per LYG. SA 
showed that 3D CTC q5Y is a dominant strategy of COL costs 
1.6times more than CTC. COL is a dominant strategy if the 
sensitivity of CTC for 1cn adenomas is 83% or lower. 
Walleser 
(2007) 
Government 
perspective, 
Australia   
People with a 
positive FOBT 
CTC COL CTC is less effective and more costly than COL; if CTC was more 
sensitive than COL, CTC was more effective, at higher cost. 
Wu (2008) 3rd party 
payer 
perspective 
general 
population 50-
75y, Taiwan 
Stool DNAq3Y 
Stool DNAq5Y 
Stool DNAq10Y 
No screening 
FOBYq1Y 
FSIGq5Y 
COLq10Y 
Stool DNA testing every 3,5 and 10 years can reduce CRC 
mortality by 22%, 15%, and 9%, respectively. The associated 
incremental costs were $9,794, $9,335, and $7,717, per  life-years 
saved when compared with no screening. Stool DNA testing 
strategies were the least cost-effective with the cost per stool DNA 
test, referral rate with diagnostic COL, prevalence of large 
adenoma, and the discount rate being the most influential 
parameters. 
Zauber 
(2010) 
Centre for 
Medicare 
and 
Medicaid 
Services 
(CMS) 
perspective 
on CTC 
US population 
65y-85y (50y 
in sensitivity 
analysis) 
14) CTC DoD 
15) CTC ACRIN 
1) Nothing 
2) Hemoccult 
II(HII) 
3) Hemoccult 
SENSA (HS) 
4) FIT 
5) SIGbiopsy   
6)SIG  
7) HII + SIGb 
8) HII + SIG  
9) HS + SIGb 
10) HS + SIG 
11) FIT + SIGb  
Annual high sensitive FOBTs (guaiac and FIT), FSIGq5Y with 
sensitive FOBTq1Y, and COL were reasonably cost-effective 
strategies for CRC. Hemoccult II only and FSIG only were not 
included in this set of acceptable tests. Similarly, with current 
levels of test costs based on diagnostic procedures, CTC was not 
a cost-effective choice. 
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12) FIT + SIG 
13) COL 
Knudsen 
(2010) 
Payer's 
perspective 
(CMS and 
modified 
societal 
excluding 
productivity 
cost) 
Average 
risked 65yr 
old 
individuals, 
US 
CTC DoDq5Y 
CTC NCTCq5Y 
1)H-IIq1Y 
2)Hemoccult 
SENSA (HS) 
q1Y 
3)iFOBTq1Y 
4)SIGq5Y 
5)SIGBiopsyq
5Y 
6) 1) + 4) 
7) 1) + 5) 
8) 2) + 4) 
9) 2)+ 5) 
10) 3) + 4) 
11) 3) + 5)  
12)COLq10Y 
13)no 
screening 
Assuming perfect adherence with all tests, the undiscounted 
number of life-years gained from CTC screening ranged from 143 
to 178 per 1000 65yr olds, which was slightly less than the number 
of life-years gained from 10-yearly COL (152-185 per 1000 65 yr-
olds) and comparable to that from 5-yearly SIG with annual FOBT 
(149-177 per 1000 65yrs-olds). If CTC screening was reimbursed 
at $488 per scan (slightly less than the reimbursement for a COL 
without polypectomy), it would be the most costly strategy. CTC 
screening could be cost-effective at $108-$205 per scan, 
depending on the microsimulation model used. Sensitivity 
analyses showed that if relative adherence to CTC screening was 
25% higher than adherence to other tests, it could be cost-effective 
if reimbursed at $488 per scan. 
Vanness 
(2011) 
US health 
sector 
perspective 
Average risk 
asymptomatic 
50yrs olds 
(screened 
until 80yrs & 
simulated to 
death) in the 
US 
FOBTq1Y + FISGq5Y 
FITq1Y + FSIGq5Y 
COLq10Y 
CTqC5Y (5 mm referral 
threshold) 
CTCq10Y  (5 mm referral 
threshold) 
Each strategy was run 
through the colorectal 
cancer Simulated 
population model for 
Incidence and Natural 
history (CRC-SPIN), 
  CTC at 5- and 10-year intervals was more costly and less effective 
than FOBT plus FSIB in all three models in both the 100% and 
50% adherence scenarios. COL also was more costly and less 
effective than FOBT plus FSIG, except in the CRC-SPIN model 
assuming 100% adherence (ICER $26,300/LYG). CTC at 5- and 
10-year screening intervals and COL were net beneficial over the 
10-year interval except in the MISCAN model when assuming 
100% adherence and WTP $50,000/LYG. 
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MISCAN, SimCRC 
models 
Subramanian 
(2009)  
3rd party 
payer, only 
direct 
medical 
costs 
Average risk 
50yrs, 
screening to 
80yrs 
preference 
(pref) and 
compliance 
(comp) 
incorporated, 
US 
FOBTq5Y 
FOBTq10Y 
FSIGq5Y 
FSGIq10Y 
COLq5Y 
COLq10Y comp at 45% 
(scenario 1) 
No CRC 
screening (2) 
Scenario (3) 
45% comp 
with 35% 
population 
never been 
screened 
Scenario (4) 
100% comp 
Improved comp is positively related to the reduction of CRC 
mortality. Achieving higher levels of compliance with screening or 
diagnosis recommendations such as targeted education and use 
of navigators to assist patients to increase adherence. 
Macafee 
(2008) 
Not 
specifically 
stated but 
top-down 
costs (direct 
costs) were 
considered 
60yr olds, 
modelled for 
50yrs for two 
timescale: 
2003 (early 
cohort) and 
2033 (late 
cohort), UK 
Unhydrated FOBT q2Y 
60-69yrs (2003 cohort) 
unhydrated FOBT q2Y 
60-69yrs (2033 cohort) 
No screening 
compared with 
corresponding 
cohort (early or 
late) 
Life expectancy was assumed to increase by 2.5 years per 
decade. There were 407 552 fewer people entering the model in 
the 2033 model due to a lower birth cohort, and population 
screening saw 30 345 fewer CRC-related deaths over the 50 years 
of the model. Screening the 2033 cohort would cost £96 million 
with cost savings of £43 million in terms of detection and treatment 
and 28 million GBP in palliative care costs. After 30 years of follow-
up, the cost per life year saved was £1544. An identical screening 
programme in an early cohort (2003) saw a cost per life year saved 
of £1651.  
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Telford 
(2010) 
3rd party 
paper 
50yrs average 
risk screening 
and 
surveillance 
until 75yrs 
old, Canada 
gFOBT low sensitivity 
(Se) q2Y 
gFOBT low Se q1Y 
gFOBT high Se 1Y 
gFOBT low Se q1Y plus 
SIGq5Y 
FITq1Y 
Fecal DNAq1Y 
DCBEq5Y 
CTCq5Y 
COLq10Y 
No screening current strategies reduced CRC incidence and mortality compared 
with no screening ICER CAD $9159 (gFOBT low Se q1Y), CAD 
$611(FITq1Y), CAD $6133 (COLq10Y) 
Di Bidino 
(2010) 
HC system 
perspective 
Average risk, 
Italy 
Arm 1 FOBT or FSIG or 
BE then COL for all 
positive results /COL/ 
CTC (Arm1) 
Arm2 FOBT 
Arm3 FSIG 
Arm4 BE 
Arm5 COL 
Arm6 CTC 
Arms 3, 4 and 6 showed strong dominance compared with Arm1, 
ICERs of Arm2 and Arm5 below threshold value of €35,000. 
Technology overlapping was not cost-effective 
Sonnenberg 
(2002) 
3rd party 
payer 
perspective 
50 yr olds 
hypothetical 
population, 
US 
COL once at 65 years 
COLq10Y from 50 years 
of age 
Not specified, 
possibly no 
screening 
Compared to no screening, the ICER of a single or repeated COL 
amounts to $2981 or to $10983 per LYG, respectively. A single 
COL saves most life years if done at the age of 60, but becomes 
most CE after the age of 70. Depending on the level of compliance, 
repeated COL save 2-3 times more lives than a screening program 
based on a single COL. 
Howard 
(2005) 
Not stated, 
US 
50 yr olds  
who are 
offered annual 
FOBT and 
follows them 
until death  
FOBT No screening 
same as 
Sonneberg 
(2000) 
The way in which participation rate is modelled, particularly 
assumptions made about the subsequent screening behaviour of 
non-participants (‘íf' and 'when' a non-participant attends for 
subsequent screening), affects the cost-effectiveness estimates 
for FOBT screening programmes. 100% participation in all 
screening gives USD per life-years saved of $9705. 
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Pickhardt 
(2007) 
Not stated People 50yrs 
with small (6-
9 mm) polyps 
detected at 
CTC 
screening, US 
CTC with no polyp size 
reporting threshold 
CTC with a 6-mm polyp 
size reporting threshold 
COL plus 
popypectomy 
FSIG  
No screening 
Compared with No screening; $4361(CTC with a 6-mm threshold), 
$7138 (CTC with no threshold), $7407(FSIG), $9180 (COL). 
Compared with COL, CTC with a 6-mm threshold resulted in a 
77.6% reduction in invasive endoscopic procedures and 1112 
fewer reported COL-related complications from perforation or 
bleeding. 
Hassan 
(2007) 
National 
level in Italy 
50yrs for 30 
yrs, US 
All q10Y; 
CTC screening  
COL 
FS 
No screening 65% initial adherence and a compliance with repeat examinations 
of 80%, COLq10Y appeared to be the most effective technique 
preventing 40.9% of CRC, whilst CTC resulted to be less effective 
than COL (38.2%), but more effective than FSIG (31.8%), 
corresponding to 3821, 3589, and 2945 LYS, respectively. 
 
Hassan 
(2008) 
Societal 50yrs and 
over, US 
CapEndo q10Y (capsule 
endocsopy; Pillcam 
Colon) 
COL q10Y 
no screening 
At baseline, the incremental cost-effectiveness (compared to no 
screening) of COL and CapEndo was $16,165 and $29,244 per 
life-years saved (LYS), respectively. When equal compliance was 
simulated, the COL program was more effective and less costly 
than a strategy based on CapEndo. When simulating an initial 
compliance to CapEndo 30% better than COL, CapEndo became 
more effective and more cost-effective option. A 20% better 
compliance was sufficient when a higher accuracy of CapEndo for 
polyps was assumed. A 6 mm threshold for polypectomy referral 
was associated with a substantial cost reduction in the CapEndo 
program with only a small loss of efficacy. 
Hassan 
(2009b) 
Societal 
perspective 
Hypothetical 
cohort aged 
50-100 yrs, 
US 
COLq10Y 
CTC q5Y 
FSIG q5Y 
BE q5Y 
 
 
Not stated 
 
In the reference-case analysis, COL was optimal test with the 
highest net benefit ($1945 per subject invited for screening 
compared with $1862, $1717, and $1653 for CTC, FISG, and BE, 
respectively). Results of PSA indicated that COL was the optimal 
choice in only 45% of the simulated scenarios, whereas CTC, 
FSIG, and BE were the optimal strategies in 23%, 16%, and 15% 
of the scenarios, respectively. Only two parameters were 
responsible for most of this uncertainty about the optimal test for 
CRC screening: the increase in adherence with less invasive tests 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
and CRC natural history. The expected societal monetary benefit 
of further research in these areas was estimated to be more than 
$15 billion. 
Flanagan(20
03) 
5% Hypothetical 
sample of 
7,001,322 
people 50-
74yrs with no 
history of 
CRC, Canada 
FOBTq2Y (Hemoccult II 
nonrehydrated) 
No screening Compared with no screening, the discounted ICER of biennial 
screening was $11,907. The ICNER of annual screening was 
$13,497. When the costs were increased, the ICER was $18,445 
with biennial screening and $19,893 with annual screening. 
Participation rate was an important determinant of the CE of the 
screening programme. When the participation rate was reduced 
from 67% to 50%, the biennial screening became less cost 
effective ($15,688). 
Frazier 
(2000) 
Not clearly 
stated  
50yrs average 
risk 
(screening 
surveillance 
till 85yrs), US 
rFOBT(rehydrated) 
uFOBT(unrehydrated) 
FSIG 
DCBE 
COL 
No screening FOBT rehydrated (annual) + FSIG plus COL (if polyp found) ICER 
USD92900/LYG compared with no screening among white men 
Hassan 
(2009a) 
Societal 60yrs 
postpolypecto
my 
surveillance, 
US  
at 1Y COL surveillance 
postpolypectomy  
No referral for 
COL after 
polypectomy 
"COL at1Y as compared with a no COL at 1Y postpolypectomy, 
was a relatively CE with an ICER of $66,136, which is well below 
the arbitrary threshold of $150,000" 
Helm (2000) Not stated, 
possibly 
societal 
perspective 
45-74 yrs 
general 
population in 
the US 
FOBT  No screening More than 1 million CRC could be expected to arise over 10 yr in 
the cohort of US residents eligible to enter a screening program in 
1997, and trial outcomes indicate that ≥60% of these cancers 
would be fatal. If the 60-67% compliance rate of the population-
based RCTs were achieved, a FOBT program would detect 30% 
of known CRCs and save 100,000 lives over 10 yr. Screening 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
would incur total costs of $3-4 billion over 10 yr, or $2,500 per life-
year saved. 
Heresbach 
(2010a) 
3rd party 
payer   
CTC offered 
at 50yrs, 
60yrs, 70yrs, 
US 
CTC without polyp size 
reporting  threshold (PL 
strategy) 
CTC with polyp size 
reporting threshold (TS) 
No screening ICER of PL and TS strategies were 12042 and 2765/life-years 
gained (LYG) associated to CRC prevention rates of 37.9 and 
36.5%. ICER of PL and TS strategies dropped to 9687 and 
1857/LYG when AA prevalence increased from 6.9 to 8.6% for 
male participants and 3.804.9% for female participants or to 9482 
and 2067/LYG when adenoma and AA annual recurrence rates 
dropped to 3.2 and 0.25%. ICER for PL and TS strategies 
decreased to 7947 and 954/LYG or when only two CTC performed 
at 50 and 60yrs. conversely ICER did not significantly change 
when varying population rate or accuracy of CTC. 
Sonnenberg 
(1999) 
3rd party 
payer 
50yrs average 
risk, US 
CTC q10Y 
MRC (magnetic 
resonance colonography) 
Polypectomy 
then; 
COL q10Y 
COL q3Y 
Under baseline conditions, screening by COL $20,930 per LYS, 
CTC $24,586 per life-years saved (LYS). ICER comparing CTC to 
no screening and COL to CTC were $11,484 and $10,408, 
respectively. Col screening remains more CE even if the sensitivity 
(Se) and specificity (Sp) of CTC both rise to 100%. For the two 
screening procedures to become similarly CE, CTC needs to be 
associated with an initial compliance rate 15-20% better or 
procedural costs 54% less than COL. 
Stone (2004) 3rd party 
payer 
Australian 
population at 
average risk, 
Australia 
CRC FOBTq2Y 55-69yrs 
olds 
Current 
practice 
(opportunistic 
screening) 
Base program 
extension to 
include; 
45-49, 50-54, 
70-74, 75+ 
We estimate a minimum of 'base program of screening those aged 
56 to 69 years could avert 250 deaths per annum (95% uncertainty 
interval 99-440), at a gross cost of $A55 million (95% UI $A46 
million to $A 96 million) and a gross incremental cost effectiveness 
ratio of $A 17,000/disability-adjusted life years (DALY; 95% UI $A 
13,000/DALY to $A 52,000/DALY). Extending the program to 
include 70 to 74 years olds is a more effective option (cheaper and 
higher health gain) than including the 50 to 54yr olds. 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
Regge (2009) Societal 
perspective  
Average risk 
50yrs, US 
CTC with CAD (software, 
computer aided detection)  
CTC without CAD as a 
2nd reader performed by 
radiologists with different 
level of experience. 
CTC 
FSIG 
COL 
No screening 
CAD CTC vs CTC, $8661/LYG (inexperience readers), 
$61354/LYG (experienced readers); COL vs CAD CTC $498 
668/LYG (experienced). For inexperienced readers CAD CTC was 
more clinically effective and CE than FSIG 
Wong (2004) Not stated 50-70 yrs of 
age, time 
horizone of 
50Y, 
Singapore 
gFOBT q1Y 
iFOBT q1Y 
DCBE q3Y 
FSIG q5Y 
COL q10Y 
No screening "Results are reported by giving the average cost and life 
expectancy for the subgroup within the population from the age of 
50-69 through to 70." FOBT is superior in terms of cost for LIS, 
SGD 162.11/LYS at 100% compliance. COL was most expensive 
strategy. 
Tsoi (2008) Possibly 
payer 
perspective 
50yrs average 
risk, China 
FOBT 
FOBT then COL 
FSIG q5Y 
COL then CS q3Y for 
polyps 
COL then FOBT q10Y for 
no-polyps 
No screening 
. 
Assume comp rate 90%, ICER for FOBT USD 6222/LYS and COL 
USD 7211/LYS. Even comp rate of FOBT were 50% and 30%, 
FOBT has the lowest ICER. 
Lansdorp-
Vogelaar 
(2009b) 
Not stated 40yrs old 
black and 
white men 
and women in 
the US 
COLq10Y 
COLq8Y 
individualized COL 
according to gender and 
race (white men 53-74yrs 
COLq7Y, black men 47-
75yrs COLq7yrs, white 
women 53-77yrs 
COLq8Y, black women 
47-75yrs COLq7Y) 
No screening The base-case strategy of no screening was the least expensive, 
yet least effective. The uniform 10Y COL strategy was dominated. 
The uniform 8Y COL and individualized strategies both increased 
life-expectancy by 0.0433-0.0435 years per individual at a cost of 
$15,565 per LYG. In the individualized strategy, African Americans 
began screening 6years earlier with a 1-year shorter interval 
compared with whites. The individualized policies were essentially 
the same for men and women, because the higher CRC risk in 
men is offset by their shorter life-expectancy. The results were 
robust for changes in model assumptions. 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
O'Leary 
(2004) 
Government-
funded 
health 
system 
50-64yrs, 
analysis over 
a 10-year time 
frame, 
Australia 
FSIG q10Y 
COL q10Y 
FOBT q1Y 
FOBT q2Y 
No screening COL averted the greatest No of cases of CRC (35%), followed by 
FSIG *25%), and annual (25%) and biennial (14%) FOBT. COL 
averted the greatest number of deaths from CRC (31%), followed 
by annual FOBT (28%), FSIG (21%) and biennial FOBT (19%). 
FSIG was the most efficient in terms of cost per LYS (A$ 16,801), 
followed by COL (A$ 19,285), biennial (A$ 41,183), and annual 
(A$ 46,900) FOBT. 
Park (2005) Korean NHI 50yrs average 
risk in NHI, 
Korea 
COLq5Y; COLq3Y 
COLq10Y; COLat50 
SIGq3Y; SIGq5Y 
SIGq10Y; SIGat55 
SIGq5Y+DCBEq5Y 
FOBTq2Y; FOBTq1Y 
DCBEq10Y; DCBEq5Y 
DCBEq3Y 
No screening With the NHI did not cover the screening and compliance was 
30%, non-dominated strategies were COLq5Y and COLq3Y. In all 
scenarios of various compliance rates with raised coverage of the 
NHI and increased reimbursement of OCL, COLq10Y, COLq5Y 
and COLq3Y were non-dominated strategies, and COLq10Y had 
lower or minimal incremental medical cost and financial burden on 
the NHI than the strategy of no screening. These results were 
stable with sensitivity analyses. 
Sobhani 
(2011) 
Payer - 
health care 
system 
people 
without 
symptoms, 
France 
iFOBTq2Y 
MagStream 1xsample 
gFOBTq2Y 
OC-SENSOR 1x sample 
OC-SEONSOR 2x 
samples 
OC-SENSOR 3xsamples 
  The results suggest that a 3-sample iFOBT with 50 ng/mL as a 
positive cutoff is cost-effective. It provides more asymptomatic 
cancer detection without significantly increasing normal COL 
van Rossum 
(2011) 
3rd party 
payer 
50-75yrs 
Dutch 
population 
time horizon 
10 years, The 
Netherlands 
iFOBT once 
gFOBT once 
No screening iFOBT dominated the alternatives: after one round of iFOBT 
screening, a hypothetical persone would on average gain 0.003 
life-years and save the health care system 27 Euro compared with 
gFOBT and 0.003 LY and 72 Euro compared with no screening. 
Overall, in 4,460,265 Dutch aged 50-75yrs, after one round iFOBT 
screening, 13,400 LY and 320 million Euro would have been saved 
compared with no screening. iFOBT also dominated in sensitivity 
analyses, varying uncertainty surrounding important effect and 
cost parameters.  
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Author  Perspective Population  Intervention(s) Comparators Reported results  
Wang (2012) Not stated 50-80yrs 
Chinese 
individuals, 
China 
Repeat COL Single COL 
No screening 
Assuming a first-time compliance rate of 90%, repeat screening 
COL and single COL can reduce the incidence of CRC by 65.8% 
and 67.2% respectively. The incremental cost-effectiveness ratio 
for single COL (49 Renminbi Yuan [RMB]) was much lower than 
that for repeat screening COL (474 RMB). Single COL was a more 
cost-effective strategy, which was not sensitivity to the compliance 
rate of COL and the cost of advanced CRC. 
Whyte (2012) NHS 50-100yrs, UK gFOBT at 60-69 q2Y 
gFOBT at 60-74 q2Y 
iFOBT at 60, 65, 70yrs 
iFOBT at 60-69yrs 
iFOBT at 60-74yrs q2Y 
FSIG age 55yrs; FSIG 55, 
65yrs; FSIG 55yrs and 
gFOBT q2Y 66-74yrs; 
FSIG 55yrs and  iFOBT 
60,65,70; FISG 55yrs, 
and iFOBT 60-74 q2Y; 
FSIG 55yrs, and iFOBT 
56-74 q2Y 
No screening The model suggests that screening strategies involving FSIG or 
iFOBT (immunochemical FOBT) may produce additional benefits 
compared with fhe current policy of FOBTq2Y for 60-74yrs. The 
age at which a single FSIG screenn results in the greatest QALY 
gain was 55, with similar gains for ages between 52 and 58. 
Strategies which combined FSIG and iFOBT showed further 
benefits and improved economic outcomes. 
Wilschut 
(2011a) 
Not stated Age to start 
screening 
(45,50,55,60), 
stop screening 
age (70,75,80) 
in Netherlands 
(N=30000) 
Different FIT cut off level of 
50, 75, 100, 150, 200 
ng/mL Hb. For each cutoff 
level, screening strategies 
were assessed with 
various age ranges and 
screen intervals 
See 
intervention(s) 
At all cost levels, FIT screening between age 55 and 75 yrs using 
FIT at 50 ng/mL, for example, was €3900/LYG. 
FIT screening is more cost-effective at a cutoff level of 50 ngmL 
than at higher cutoff levels - which is considerably lower than the 
values used in current practice. 
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Author  Perspective Population  Intervention(s) Comparators Reported results  
Wilschut 
(2012b) 
Not stated 45-80yrs 
Dutch 
population - 
attendance 
rate, costs, 
positivity, and 
detection 
rates from two 
Dutch 
implementatio
n trials were 
analysed, the 
Netherlands 
FIT at varying Hb cutoff 
levels under different 
capacities 
gFOBT When COL capacity was unlimited, the optimal screening strategy 
was to administer an annual FIT with a 50 ng/mL Hb cutoff level in 
individuals aged 45-80yrs and to offer COL surveillance to all 
individuals with adenomas. When Col capacity was decreasing, 
the optimal screening adaptation was to first increase the FIT Hb 
cutoff value to 200 ng Hb per mL and narrow the age range of 50-
75yrs, to restrict COL surveillance, and finally to further decrease 
the number of screening rounds. FIT screening was always more 
cost-effective compared with gFIBT. Doubling COL capacity 
increased the benefits of FIT screening up to 100%. 
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APPENDICES TO CHAPTER 4 
Table A4.1 Search strategy for MEDLINE  
Database: Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed 
Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) <1946 to Present> 
Platform used: OvidSP 
Date run: 30 October 2015 
Search Strategy: 
1 Economics/ or exp "Costs and Cost Analysis"/ or exp Economics, Hospital/ or 
exp Economics, Medical/ or Economics, Nursing/ or Economics, 
Pharmaceutical/ or Budgets/ or exp Models, Economic/ or Markov Chains/ or 
Monte Carlo Method/ or Decision Trees/  
2 (econom$ or cba or cea or cua or markov$ or (monte adj carlo) or (decision adj2 
(tree$ or analys$)) or (cost or costs or costing$ or costly or costed) or (price$ or 
pricing$) or budget$ or expenditure$ or (value adj2 (money or monetary)) or 
(pharmacoeconomic$ or (pharmaco adj economic$))).ti,ab.  
3 1 or 2  
4 "Value of Life"/  
5 Quality-Adjusted Life Years/  
6 quality adjusted life year.tw.  
7 (qaly$ or qald$ or qale$ or qtime$).tw.  
8 disability adjusted life.tw. 
9 daly$.tw.  
10 Health Status Indicators/  
11 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or 
shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty 
six).tw. 
12 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or 
short form six).tw.  
13 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or 
shortform twelve or short form twelve).tw.  
14 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or 
shortform sixteen or short form sixteen).tw.  
15 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or 
shortform twenty or short form twenty).tw.  
16 (euroqol or euro qol or eq5d or eq 5d).tw.  
17 (qol or hql or hqol or hrqol).tw.  
18 (hye or hyes).tw.  
19 health$ year$ equivalent$.tw.  
20 utilit$.tw.  
21 (hui or hui$1 or hui$2 or hui$3).tw.  
22 disutili$.tw.  
23 rosser.tw.  
24 quality of wellbeing.tw.  
25 quality of well-being.tw.  
26 qwb.tw.  
27 willingness to pay.tw.  
28 standard gamble$.tw.  
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29 time trade off.tw.  
30 time tradeoff.tw.  
31 tto.tw.  
32 mapping.tw. 
33 mapped.tw.  
34 crosswalk.tw.  
35 transfer$ to utilit$.tw. 
36 or/4-35  
37 ((colorectal or colon$ or rectal or rectum$) and (cancer$ or tumor$ or tumor$ or 
neoplasm$ or carcinoma$ or adenoma$)).tw.  
38 Colorectal Neoplasms/ or Colonic Neoplasms/ or rectal neoplasms/  
39 crc.tw.  
40 37 or 38 or 39  
41 36 and 40  
42 3 and 41  
43 limit 42 to humans 
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Table A4.2 Search strategy for mapping studies - MEDLINE 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to Present> 
Platform used: OvidSP. Date run: 30 October 2015 
Search strategy 
1 ((colorectal or colon$ or rectal or rectum$) and (cancer$ or tumor$ or tumor$ or 
neoplasm$ or carcinoma$ or adenoma$)).tw.  
2 Colorectal Neoplasms/ or Colonic Neoplasms/ or rectal neoplasms/  
3 crc.tw.  
4 or/1-3  
5 mapping$.tw.  
6 mapped$.tw.  
7 (crosswalk$ or cross walk$).tw.  
8 transfer$ to utilit$.tw.  
9 (euroqol or euro qol or eq5d or eq 5d).tw.  
10 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or 
shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty 
six).tw.  
11 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short 
form six).tw.  
12 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform 
twelve or short form twelve).tw.  
13 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or 
shortform sixteen or short form sixteen).tw.  
14 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform 
twenty or short form twenty).tw.  
15 or/5-14  
16 4 and 15  
17 limit 16 to humans  
18 remove duplicates from 17  
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Table A4.3 Study selection criteria 
Studies were 
excluded if  
 the title/abstract were irrelevant to HRQoL or CRC-related 
HSUVs  
 conference abstracts with no full publication 
 Psychometric validation studies or description of health 
states without interval properties rather than valuation of 
health states 
 values were previously reported in other included studies 
 unspecified/ not clearly specified health states relating to 
CRC 
 primary mapping function is not reported in studies 
Studies were 
included if 
 
CRC-related HSUVs which were had not been reported previously 
which were 
 preference-based generic measure such as EQ-5D, HUI3, 
and SF-6D 
 or directly valued health state descriptions  
 or mapping to generic preference-based measures based 
on direct statistical association mapping  
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Andersson  
(2013) 
EQ-5D Pre-4 weeks-6 months(m)-12m 
Lap 0.77-0.642-0.775-0.794 
Open 0.749-0.626-0.757-0.787 
Pre: preoperative; Lap: laparoscopic surgery; Open: open surgery 
Re-expressed on a 0-1 scale 
Augestad  
(2013) 
EQ-5D  mean EQ-5D (SD);  baseline-12m-
24m 
Surgeon-led 0.83(0.16) - 0.85(0.20) - 
0.90(0.14) 
GP-led 0.79(0.22) - 0.87(0.18) -  0.89 
(0.13) 
SD standard deviation 
m months 
Bennett  
(2011) 
EQ-5D  1st line EQ-5D baseline mean (SD)  
P+FOLFOX4 0.778 (0.247): 
FOLFOX4 0.756 (0,244) 
2nd line EQ-5D baseline mean (SD) 
P+FOLFIRI 0.769 (0.230); FOLFIRI 
0.762 (0.252) 
P panitumumab 
FOLFIRI fluorouracil, leucovorin and irinotecan 
FOLFOX fluorouracil, leucovorin and oxaliplatin 
Best (2010) TTO CRC patients/community members; 
Remission 0.83/0.82 
adjuvant, no neuropathy 0.61/0.60 
adjuvant, mild neuropathy 0.61/0.51 
adjuvant, moderate neuropathy 
0.53/0.46 
adjuvant, severe neuropathy 
0.48/0.34 
metastatic, stable 0.40/0.51  
metastatic, progressive 0.37/0.21  
  
Boyd  
(1990) 
SG with colostomy 0.915  
without colostomy 0.804  
HSUVs re-expressed on a 0-1 scale 
Carter (2014) EQ-5D Capecitabine 0.07939 
Capeditabine plus Bevacizumab 
0.7839 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Dominitz 
(1997) 
TTO 20Y your current health - 20Y with 
CRC - 20Y with a colostomy (IQR) 
Unscreened 
0.95(0.85-1.00) - 0.80 (0.65-0.95) - 
0.80 (0.50-0.95) 
Screening  
0.95 (0.90-1.00)-0.80 (0.73-0.95)-0.75 
(0.75-0.93)  
VA#380 
1.00 (0.90-1.00)-0.85 (0.70-0.95)-0.79 
(0.50-0.95) 
CRC 
0.90 (0.70-0.95)-0.83 (0.70-1.00)-0.90 
(0.64-1.00) 
Y years 
VA#380 patients enrolled in VA Cooperative Studies Program #380, a colonoscopic screening program 
IQR interquartile range (25th and 75th percentile) 
Doornebosche 
(2007) 
EQ-5D TEM 0.81   
TME 0.76  
Control 0.76   
control (healthy, sex- and age-matched control group) 
TEM transanal endoscopic microsurgery (TEM); TME total mesorectal excision (TME) 
Re-expressed on a 0-1 scale 
Doornebosche 
(2008) 
EQ-5D Control 0.86 
Pre-operative 0.84 
Post-operative 0.89 
control (healthy, sex- and age-matched control group) 
Re-expressed on a 0-1 scale 
Smith (2006) TTO Current patients 0.84 (SD 0.24)  
Former patients  0.64 (0.35)   
Community member 0.63 (0.36) 
SD standard deviation 
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Dranitsaris 
(2011a)  
TTO mean (95% CI); [m] time in health 
state in months 
#1 [10m] 0.73 (0.67-0.80) 
#2 [28m] 0.83 (0.78-0.89) 
#3 [8m] 0.72 (0.65-0.78)  
#4 [4m] 0.68 (0.58-0.78) 
#5 [6m] 0.80 (0.74-0.86)  
#6 [33m] 0.89 (0.86-0.92) 
#7 [11m] 0.78 (0.73-0.83)  
#8 [2m] 0.74 (0.63-0.85) 
#9 [10m] 0.85 (0.80-0.91)  
#10 [28m] 0.87 (0.81-0.92)  
#11 [8m] 0.60 (0.73-0.86)  
#12 [4m] 0.70 (0.62-0.78) 
#13 [6m] 0.89 (0.83-0.96)  
#14 [32m] 0.94 (0.90-0.97) 
#15 [11m] 0.88 (0.84-0.91)  
#16 [2m] 0.82 (0.72-0.93) 
FOLFOX: Oxaliplatin + infusional 5 fluorouracil (5-FU); FOLFIRI: Irinotecan + infusional 5 fluorouracil (5-
FU); BSC best supportive care; [m] time in health state in months 
#1 Stopped FOLFOX + the 'new drug'' after 2 cycles due to side effects (SEs) and was then treated with 
FOLFIRI for 4 cycles. There was disease progression. The patient (pt) received BSC and died 6 months 
(m) late; #2 Stopped FOLFOX + the 'new drug' after 2 cycles due to SEs and was then treated with 
FOLFIRI. There was a response to FOLFIRI and the pt went on to receive 8 cycles. Upon progression, 
the pt received BSC and died 22m later; #3 Stopped FOLFOX + the 'new drug' after 2 cycles due to SEs 
and was then treated with FOLFIRI. There was a response to FOLFIRI and the pnt went on to receive 8 
cycles. Upon progression, the pt received BSC and died 2m later; #4 Stopped FOLFOX + the 'new drug' 
after 2 cycles due to SEs and was then treated with FOLFIRI for 2 cycles. However, the pt died due to 
cancer progression within the first 2m; #5 Tolerated SEs but had disease progression after 4 cycles of 
FOLFOX + the 'new drug'. The pt was then treated with FOLFIRI for 4 cycles but the disease did not 
respond. The pt received BSC and died 2m later; #6 Tolerated SEs and responded FOLFOX + the 'new 
drug'. The pt went on to receive a total of 17 cycles of first line therapy. Upon progression, the pt went 
on to receive 6 cycles of FOLFIRI. Upon progression, the pt received BSC and died 21m later; #7 
Tolerated SEs and responded FOLFOX + the 'new drug'. The pt went on to receive a total of 17 cycles 
of first line therapy. Upon progression, the pt went on to receive 2 cycles of FOLFIRI but died 2m later; 
#8 Tolerated SEs and but had disease progression after 2 cycles of FOLFOX + the 'new drug'. The pt 
died to the cancer 1m later; #9 Stopped FOLFOX after 2 cycles due to SEs and was then treated with 
FOLFIRI for 4 cycles. There was disease progression. The pt received BSC and died 6m later; #10 
Stopped FOLFOX after 2 cycles due to SEs and was then treated with FOLFIRI for 4 cycles. There was 
disease progression. The pt received BSC and died 6m later; #11 Stopped FOLFOX after 2 cycles due 
to SEs and was then treated with FOLFIRI. There was a response to FOLFIRI and the pt went on to 
receive 8 cycles. Upon progression, the patient received BSC and died 2m later; #12 Stopped 
FOLFORX after 2 cycles due to SEs and was then treated with FOLFIRI for 2 cycles. However, the pt 
died due to cancer progression within the first 2m; #13 Tolerated SEs but had diseases progression 
after 4 cycles of FOLFOX. The pt was then treated with FOLFIRI for 4 cycles but the disease did not 
respond. The pt received BSC and died 2m later; #14 Tolerated SEs and responded FOLFOX. The pt 
went on to receive a total of 15 cycles of first line therapy. Upon progression, the pt went on to receive 6 
cycles of FOLFIRI. Upon progression, the patient was offered BSC and died 21m later; #15 Tolerated 
SEs and responded FOLFOX. The pt went on to receive a total of 15 cycles of first line therapy. Upon 
progression, the pt went on to receive 2 cycles of FOLFIRI but died 2m later; #16 Tolerated SEs and but 
had had disease progression after 2 cycles of FOLFOX. The pt died due to cancer progression 1m later. 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Dranitsaris 
(2011b)  
TTO  mean (95% CI); [m] time in health 
state in months 
#1 [10m] 0.74 (0.65-0.83)  
#2[28m] 0.80 (0.73-0.87)  
#3 [8m] 0.67 (0.61-0.73) 
#4 [4m] 0.74 0(.65-0.84)  
#5[6m]  0.82 (0.76-0.89)  
#6 [29m] 0.81 (0.77-0.86)  
#7[11m]  0.83 (0.79-0.87)  
#8 [2m] 0.75 (0.63-0.86)  
#9 [10m] 0.82 (0.75-0.82)  
#10 [28m] 0.81 (0.76-0.86) 
#11 [8m] 0.72 (0.66-0.79)  
#12 [4m] 0.75 (0.66-0.84) 
#13 [6m] 0.84 (0.76-0.92)  
#14 [32m] 0.91 (0.88-0.94) 
#15 [11m] 0.84 (0.79-0.90)  
#16 [2m]  0.75 (0.63-0.86) 
FOLFOX: Oxaliplatin+infusional 5 fluorouracil (5-FU); FOLFIRI; Irinotecan+infusional 5 fluorouracil (5-
FU); BSC best supportive care; [m] time in health state in months 
#1 Stopped FOLFOX+newTX after 2 cycles due to side effects(SE) and then treated with FOLFIRI for 4 
cycles. There was disease progression, the patient (pt) received BSC and died 6 months (m) later; #2 
Stopped FOLFOX+newTx after 2 cycles due to SE and was then treated with FOLFIRI. There was a 
response to FOLFIRI and pt went on to recieve 8 cycles. Upon progression, BSC and died 22m later; #3 
Stopped FOLFOX+newTx after 2 cycles due to SE and was then treated with FOLFIRI. There was a 
response to FOLFIRI and pt went on to receive 8 cycles. Upon progression, pt received BSC and died 
2m later; #4 Stopped FOLFOX+new Tx after 2 cycles due to SE and was then treated with FOLFIRI for 
2 cycles. However, pt died due to cancer progression within the first 2m; #5 Tolerated SE but had 
disease progression after 4 cycles of FOLFOX+newTx. Pt was then treated with FOLFIRI for 4 cycles 
but the disease did not respond. Pt received BSC and died 2m later; #6 Tolerated SE and responded 
FOLFOX+newTx. Pt went on to receive a total of 17 cycles of 1st line therapy. Upon progression, pt 
went on to receive 6 cycles of FOLFIRI but died 2m later; #7 Tolerated SE and responded 
FOLFOX+newTx. Pt went on to receive a total of 17 cycles of 1st line therapy. Upon progression, pt 
went on to receive 2 cycles of FOLFIRI but died 2m later; #8 Tolerated SE but disease progression after 
2 cycles of FOLFOX+ newTx. Pt died due to the cancer 1m later; #9 Stopped FOLFOX after 2 cycles 
due to side effects(SE) and then treated with FOLFIRI for 4 cycles. There was disease progression, the 
pt received BSC and died 6 months (m) later; #10 Stopped FOLFOX after 2 cycles due to SE and was 
then treated with FOLFIRI. There was a response to FOLFIRI and pt went on to receive 8 cycles. Upon 
progression, the Pt received BSC and died 22m later; #11 Stopped FOLFOX after 2 cycles due to SE 
and was then treated with FOLFIRI. There was a response to FOLFIRI and pt went on to receive 8 
cycles. Upon progression, pt received BSC and died 2m later; #12 Stopped FOLFOX after 2 cycles due 
to SE and was then treated with FOLFIRI for 2 cycles. However, pt died due to cancer progression 
within the first 2m; #13 Tolerated SE but had disease progression after 4 cycles of FOLFOX. Pt was 
then treated with FOLFIRI for 4 cycles but the disease did not respond. Pt received BSC and died 2m 
later; #14 Tolerated SE and responded FOLFOX. Pt went on to receive a total of 15 cycles of 1st line 
therapy. Upon progression, Pt went on to receive 6 cyclr of FOLFIRI. Upon progression, the pt was 
offered BSC and died 2m later; #15 Tolerated SE, responded FOLFOX. Pt went on to receive a total of 
15 cycles of 1st line therapy. Upon progression, pt went on to receive 2 cycles of FOLFIRI but died 2m 
later; #16 Tolerated SE but disease progression after 2 cycles of FOLFOX. Pt died due to the cancer 
1m later 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Dranitsaris 
(2012a)  
TTO  #1 [10m] 0.53 (0.46-0.60) 
#2 [28m] 0.65 (0.57-0.87) 
#3 [8m] 0.67 (0.58-0.76) 
#4 [4m] 0.52 (0.42-0.62) 
#5 [6m] 0.61 (0.55-0.68)  
#6 [29m] 0.69 (0.61-0.76) 
#7 [11m] 0.81 (0.74-0.89)  
#8 [2m] 0.84 (0.75-0.94) 
#9 [10m] 0.54 (0.47-0.62);  
#10 [28m] 0.66 (0.59-0.74)  
#11 [8m] 0.68 (0.59-0.77)  
#12 [4m] 0.53 (0.43--.63) 
#13 [6m] 0.61 (0.55-0.68)  
#14 [32m] 0.65 (0.72-0.87) 
#15 [11m] 0.80 (0.72-0.87)  
#16 [2m] 0.84 (0.75-0.94) 
FOLFOX: Oxaliplatin + infusional 5 fluorouracil (5-FU); FOLFIRI: Irinotecan + infusional 5 fluorouracil (5-
FU); BSC best supportive care; Side effects (SEe); [m] time in health state in months 
#1 Stopped FOLFOX + the 'new drub' after 2 cycles due to SEs and was then treated with FOLFIRI for 
4 cycles. There was disease progression. The patient (pt) received BSC and died 6 months (m) later; #2 
Stopped FOLFOX + the 'new drug' after 2 cycles due to SEs and was then treated with FOLFIRI. There 
was a response to FOLFIRI and the pt went on to receive 8 cycles. Upon progression, the pt received 
BSC and died 22m later; #3 Stopped FOLFOX + the 'new drug' after two cycles due to SEs and was 
then treated with FOLFIRI. There was a response to FOLFIRI and the pt went on to receive 8 cycles. 
Upon progression, the pt received BSC and died 2m later; #4 Stopped FOLFOX + the 'new drug' after 2 
cycles due to SEs and was then treated with FOLFIRI for 2 cycles. However, the pt died due to cancer 
progression within the first 2m; #5 Tolerated SEs but had disease progression after 4 cycles of FOLFOX 
+ the 'new drug'. The pt was then treated with FOLFIRI for 4 cycles but the disease did not respond. 
The pt received BSC and died 2m later; #6 Tolerated SEs and responded FOLFOX + the 'new drug'. 
The pt went on to receive a total of 17 cycles of first line therapy. Upon progression, the pt went on to 
receive 6 cycles of FOLFIRI. Upon progression, the pt received BSC and died 21m later; #7 Tolerated 
SEs and responded FOLFOX + the 'new drug'. The pt went on to receive a total of 17 cycles of first line 
therapy. Upon progression, the pt went on to receive 2 cycles of FOLFIRI but died 2m later; #8 
Tolerated SEs but had disease progression after 2 cycles of FOLFOX + the 'new drug'. The pt died due 
to the cancer 1m later; #9 Stopped FOLFOX after 2 cycles due to SEs and was then treated with 
FOLFIRI for 4 cycles. There was disease progression. The pt received BSC and died 6m later; 10 
Stopped FOLFOX after 2 cycles due to SEs and was then treated with FOLFIRI. There was a response 
to FOLFIRI and the pt went on to receive 8 cycles. Upon progression, the pt received BSC and died 
22m later; #11 Stopped FOLFOX after 2 cycles due to SEs and was then treated with FOLFIRI. There 
was a response to FOLFIRI and the pt went to on to receive 8 cycles. Upon progression, the pt received 
BSC and died 2m later; #12 Stopped FOLFOX after 2 cycles due to SEs and was then treated with 
FOLFIRI for 2 cycles. However, the pt died due to cancer progression within the first 2m; #13 Tolerated 
SEs but had disease progression after 4 cycles of FOLFOX. The pt was then treated with FOLFIRI for 4 
cycles but the disease did not respond. The pt received BSC and died 2m later; #14 Tolerated SEs and 
responded FOLFOX. The pt went onto receive a total of 15 cycles of first line therapy. Upon 
progression, the pt went on to receive 2 cycles of FOLFIRI. Upon progression, the pt was offered BSC 
and died 21m later; #15 Tolerated SEs and responded FOLFOX. The pt went on to receive a total of 15 
cycles of first line therapy. Upon progression, the pt went on to receive two cycles of FOLFIRI but died 
2m later; #16 Tolerated SEs but had disease progression after 2 cycles of FOLFOX. The pt died due to 
cancer progression 1m later. 
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Dranitsaris 
(2012b)  
TTO  #1 [10m] 0.61 (0.54-0.68) 
#2 [28m] 0.63 (0.55-0.72) 
#3 [8m] 0.65 (0.57-0.73) 
#4 [4m] 0.47 (0.37-0.88) 
#5 [6m] 0.61 (0.51-0.72) 
#6 [29m] 0.72 (0.63-0.81) 
#7 [11m] 0.69 (0.62-0.76) 
#8 [2m] 0.44(0.32-0.56) 
#9 [10m] 0.64 (0.57-0.70) 
#10 [28m] 0.63 (0.55-0.72) 
#11  [8m] 0.69 (0.62-0.76) 
#12 [4m] 0.49 (0.38-0.60) 
#13 [6m] 0.62 (0.51-0.72) 
#14 [32m] 0.68 (0.56-0.80) 
#15 [11m] 0.71 (0.64-0.78) 
#16 [2m] 0.44 (0.32-0.56) 
FOLFOX: Oxaliplatin + infusional 5 fluorouracil (5-FU); FOLFIRI: Irinotecan + infusional 5 fluorouracil (5-
FU); BSC best supportive care; Side effects (SEs) 
#1 Stopped FOLFOX + the 'new drug' after 2 cycles due to SEs and was then treated with FOLFIRI for 
4 cycles. There was disease progression. The patient (pt) received BSC and died 6 months (m) later; #2 
Stopped FOLFOX + the 'new drug' after 2 cycles due to SEs and was then treated with FOLFIRI. There 
was a response to FOLFIRI and the pt went on to receive 8 cycles. Upon progression, the pt received 
BSC and died 22m later; #3 Stopped FOLFOX + the 'new drug' after two cycles due to SEs and was 
then treated with FOLFIRI. There was a response to FOLFIRI and the pt went on to receive 8 cycles. 
Upon progression, the pt received BSC and died 2m later; #4 Stopped FOLFOX + the 'new drug' after 2 
cycles due to SEs and was then treated with FOLFIRI for 2 cycles. However, the pt died due to cancer 
progression within the first 2m; #5 Tolerated SEs but had disease progression after 4 cycles of FOLFOX 
+ the 'new drug'. The pt was then treated with FOLFIRI for 4 cycles but the disease did not respond. 
The pt received BSC and died 2m later; #6 Tolerated SEs and responded FOLFOX + the 'new drug'. 
The pt went on to receive a total of 17 cycles of first line therapy. Upon progression, the pt went on to 
receive 6 cycles of FOLFIRI. Upon progression, the pt received BSC and died 21m later; #7 Tolerated 
SEs and responded FOLFOX + the 'new drug'. The pt went on to receive a total of 17 cycles of first line 
therapy. Upon progression, the pt went on to receive 2 cycles of FOLFIRI but died 2m later; #8 
Tolerated SEs but had disease progression after 2 cycles of FOLFOX + the 'new drug'. The pt died due 
to the cancer 1m later; #9 Stopped FOLFOX after 2 cycles due to SEs and was then treated with 
FOLFIRI for 4 cycles. There was disease progression. The pt received BSC and died 6m later; #10 
Stopped FOLFOX after 2 cycles due to SEs and was then treated with FOLFIRI. There was a response 
to FOLFIRI and the pt went on to receive 8 cycles. Upon progression, the pt received BSC and died 
22m later; #11 Stopped FOLFOX after 2 cycles due to SEs and was then treated with FOLFIRI. There 
was a response to FOLFIRI and the pt went to on to receive 8 cycles. Upon progression, the pt received 
BSC and died 2m later; #12 Stopped FOLFOX after 2 cycles due to SEs and was then treated with 
FOLFIRI for 2 cycles. However, the pt died due to cancer progression within the first 2m; #13 Tolerated 
SEs but had disease progression after 4 cycles of FOLFOX. The pt was then treated with FOLFIRI for 4 
cycles but the disease did not respond. The pt received BSC and died 2m later; #14 Tolerated SEs and 
responded FOLFOX. The pt went onto receive a total of 15 cycles of first line therapy. Upon 
progression, the pt went on to receive 2 cycles of FOLFIRI. Upon progression, the pt was offered BSC 
and died 21m later; #15 Tolerated SEs and responded FOLFOX. The pt went on to receive a total of 15 
cycles of first line therapy. Upon progression, the pt went on to receive two cycles of FOLFIRI but died 
2m later; #16 Tolerated SEs but had disease progression after 2 cycles of FOLFOX. The pt died due to 
cancer progression 1m later. 
 
 
261 
 
Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Farkkila 
(2013) 
EQ-5D Primary treatment 0.760  
Rehabilitation 0.835  
Remission 0.850  
Metastatic disease 0.820  
Palliative care 0.643  
All patients 0.813  
  
Grosslink 
(2006) 
EQ-5D [Note: HSUVs were estimated from 
Figure 1] 
LRA 0.77 (range 0.72-0.83) 
CPA 0.84 (0.80-0.89) 
APR 0.80(0.75-0.86) 
LRA low colo-rectal anastomosis 
CPA colo-anal J-pouch anastomosis 
APR abdominoperitoneal resection 
Haapamaki 
(2011) 
EQ-5D Mean EQ-5D 0.71 (SD 0.18) SD standard deviation 
Hamashima 
(2002) 
EQ-5D Without stoma 0.870  
With stoma 0.836 
  
Hornbrook 
(2011) 
SF-6D Wth stoma 0.69 
Without stoma 0.73 
  
Kapidzic 
(2012) 
EQ-5D FIT negative 0.85 FIT positive 0.82 
(0.17) 
FS negative 0.85 (0.17) FS positive 
0.80 (0.24) 
*Negative FIT 0.85 (0.19) *4-12 
months (m) 0.85 (0.17)  
*13-24 m 0.85 (0.17) *25 m or more 
0.89 (0.17) 
**FIT positive 0.82 (0.20) **4-12m 
0.84 (0.20) 
**13-24m 0.81 (0.23) **25m or more 
(0.82 (0.19) 
Negative FS after positive FIT 0.81 
(0.21) 
Positive FS after positive FIT 0.82 
(0.22) 
 
FIT faecal immunochemical test  
FS flexible sigmoidoscopy 
 *Mean scale scores of responders with a negative test results for the whole group and per whole group 
and per time period passed between participation 
** Mean scale scores of responders with a positive test result for the whole group and per time period 
passed between participation 
***Mean scale scores of responders with a positive test result (FIT) by result of the FS 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Miller (2000) SG Healthcare providers; patients (±SD) 
Disease recurrence  
0.69±0.24; 0.72±0.22 
Surgical resection  
0.69±0.24; 0.83±0.18 
Pain and complications  
0.50±0.29; 0.78±0.27 
SD standard deviation 
Mittman 
(2009) 
HUI3 Cetuximab+BSC; BSC 
baseline 0.72;  0.71  
Week4 0.71;  0.68 
Week8 0.73;  0.66 
Week16 0.73; 0.63  
Week24 0.77; 0.70  
BSC best supportive care 
TOX days with≥ grade 3 adverse events 
TWIST time without symptoms or toxicity 
REL relapse period until death or end of follow-up 
Ness (1999) SG Participant's current health 0.84 
State A 0.74  
State BC 0.67  
State D 0.59 
State E 0.50 
State FG 0.25 
State A: stage I rectal or stage I/II colon cancer treated with resection only; State B: Stage III colon 
cancer treated with resection and chemotherapy without significant side effects; State C: Stage III colon 
cancer treated with resection and chemotherapy (chemoTx) with significant SE;  State D: stage II/III 
rectal cancer treated with resection/chemoTx/radiationTx; State E: stage II/III rectal cancer treated with 
resection/chemoTx/radiationTx/permanent ostomy; State F: stage IV metastatic/unresectable disease 
without ostomy; State G: stage IV metastatic/unresectable disease with ostomy 
Norum (1997) EQ-5D EuroQoL median 0.78 (range 0.33-
1.00) 
  
Odom (2011) EQ-5D Panitumumab plus BSC;  BSC alone 
(SD) 
Overall 0.72 (0.24); 0.68 (0.25) 
Wild-type KRAS 0.73 (0.24); 0.68 
(0.23) 
Mutant KRAS 0.71 (0.25); 0.68 (0.26) 
BSC best supportive care  
KRAS Kirsten rat sarcoma viral oncogene homolog 
SD standard deviation 
Petrou (1997) SG  Partial response 1.0 
Stable disease 0.95 
Progressive disease 0.575 
Terminal disease 0.1 
HSUVs re-expressed on a 0-1 scale 
Ramsey 
(2000) 
HUI3  mean 0.85 (SD 0.15)  
stage I 0.84 (0.17)  
stage II 0.86 (0.14) 
stage III 0.85 (0.14)  
stage IV 0.84 (0.12) 
SD standard deviation 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Ramsey 
(2002) 
HUI3 Stage I 0.83 (SD 0.11)  
Stage II 0.86 (0.13) 
Stage III 0.87 (0.08)  
Stage IV 0.81 (0.11) 
SD standard deviation 
Schwandner 
(2013) 
EQ-5D Pre-SNS 0.42 
Post-SNS 0.74 
SNS sacral nerve stimulation 
Sharma 
(2007) 
EQ-5D Pre-operative 0.8614 (SD 0.16) 
Post-operative 0.9009 (0.13) 
SD standard deviation 
Shiroiwa 
(2009) 
TTO a) chemotherapy (95% CI)  
XELOX without AEs 0.59 (0.55-0.64) 
FOLFOX without AEs 0.53 (0.49-
0.57) 
b) AEs Febrile neutropenia 0.39 
(0.36-0.42); Nausea/vomiting 0.38 
(0.35-0.42); Diarrhoea 0.42 (0.39-
0.45); Hand-foot syndrome 0.39 
(0.36-0.42); Fatigue 0.45 (0.41-0.48); 
Peripheral neuropathy 0.45 (0.41-
0.48); Stomatitis 0.42 (0.39-0.45) 
AE adverse event 
CI confidence interval 
XELOX capecitabine plus oxaliplatin 
FOLFOX4 5-fluorouracil/folic acid and oxaliplatin 
Smith (1993) TTO   Utility weight [QALY] 
No recurrence 1.0 [11Y*1=11.0]  
Recurrence 1.0 [2.25Y*1=2.25] 
Good chemotherapy scenario: 
No recurrence 0.93 [14.2Y*0.93=13.2]  
Recurrence 0.93 [1.45Y*0.93=1.35] 
Medium chemotherapy scenario: 
No recurrence 0.88 [14.2Y*0.88=12.5]  
Recurrence 0.88 [1.45Y*0.88=1.28]   
Bad chemotherapy scenario: 
No recurrence 0.80 [14.2Y*0.80=11.4] 
Recurrence 0.80 [1.45Y*0.80=1.16] 
QALY quality-adjusted life year 
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van den Brink 
(2004) 
EQ-5D PRT + TME 
Randomisation to PRT or S 0.78 PRT 
to S 0.70 
R0 S to DC 0.11  
DC to 4.5m 0.77 (NS) -  0.71 (RS) - 
0.83 (DS) - 0.74 (PS) 
4.5 to 9m 0.85 (NS) - 0.86 (RS) - 0.78 
(DS) - 0.79 (PS) 
 >9months 0.86 (NS - 0.86 (RS) - 
0.80 (DS) - 0.85 (PS) 
R1 S to DC 0.09  
DC to 4.5m 0.88 (NS) - 0.73 (RS) - 
0.77 (DS) -0.80 (PS) 
4.5 to 9m 0.86 (NS) - 0.82 (RS) - 0.81 
(DS) - 0.88 (PS) 
>9m 0.89 (NS) - 0.89 (RS) - 0.75 (DS) 
- 0.88 (PS) 
R2 0.73 
0.67 (local) Distance (0.70) local and 
distant (0.48) 
TME 
Randomisation to PRT or S 0.78 
R0 S to DC 0.21  
DC to 4.5m 0.89 (NS) -  0.785(RS) - 
0.79 (DS) - 0.80 (PS) 
4.5 to 9m 0.90 (NS) - 0.80 (RS) - 0.76 
(DS) - 0.85 (PS) 
 >9m 0.86 (NS - 0.86 (RS) - 0.80 (DS) 
- 0.85 (PS) 
R1 S to DC 0.17  
DC to 4.5m 0.63 (NS) - 0.69 (RS) - 
0.76 (DS) -0.88 (PS) 
4.5 to 9m 0.85 (NS) - 1.0 (RS) - 0.84 
(DS) - 0.86 (PS) 
>9m 0.89 (NS) - 0.89 (RS) - 0.75 (DS) 
- 0.88 (PS) 
R2 0.80 Recurrence  
0.80 (local) Distance (0.64) local and 
distant (0.45) 
PRT preoperative radiotherapy 
TME total mesorectal excision  
DC discharge 
m month 
NS no stoma: RS removed diverting stoma 
DS diverting stoma; PS permanent stoma 
R0, R1 and R2 patients with microscopically negative, positive, or incomplete  local resection or distant 
metastases at surgery, respectively 
S surgery 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Wang (2011) EQ-5D Panitumumab plus BSC vs BSC [Q-
TWiST] 
TOX  0.6008 vs 0.4409 
TWiST 0.7678 vs 0.6630 
REL 0.6318 vs 0.6407 
BSC best supportive care 
TOX days with≥ grade 3 AEs 
AE adverse event 
TWiST time without symptoms or toxicity 
Q-TWiST quality-adjusted TWiST 
REL relapse period until death or end of follow-up  
Wiering (2010) EQ-5D No health states were defined, 
aggregated QALY for a 3 year follow-
up  
CWU 1.78 (range 0.30-2.76) FDG-
PET 1.68 (0.10-2.76) 
mean difference (95% CI) 0.10 (-
0.10/0.39) 
QALY quality-adjusted life year 
CWU conventional diagnostic work-up 
PDG-PET [F-18]-Fluorodeosyglucose-positron emission tomography 
Wiering (2011) EQ-5D Disease-free 0.78 (SD 0.23) 
Non-curative  0.67 (0.31) 
Recurrence 0.74 (0.25) 
Recurrence with CTx - without CTx 
0.82 (0.17) - 0.68 (0.28) 
CTx chemotherapy 
Wilson (2006) EQ-5D EQ-5D baseline 0.79 (0.21) 
With tumor factors 
Site: colon 0.824 rectal 0.761  
Urgency: elective 0.792 acute 0.741 
Dukes: A+B 0.786 C+D 0.806 
With treatment factors 
RTx: not given 0.791 given0.750 
Stoma: absent 0.831 present 0.726 
Wx: absent 0.799 present 0.699 
Other complications: absent 0.781 
present 0.812 
CTx: not given 0.774 given 0.816 
Constipation and diarrhoea 
Constipation: absent 0.794 mild 0.784 
moderate/severe 0.706 
diarrhoea: absent 0.81 mild 0.827 
moderate/severe 0.585  
 
*HSUVs re-expressed on a 0-1 scale 
CTx chemotherapy 
RTx radiotherapy 
Wx wound infection 
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Table A4.5 Summary of studies reporting HSUVs in CRC 
Author (year) Measured 
by  
Reported CRC-related utility values  Abbreviations/Keys 
Syngal (1998) SG mean (range min-max) 
subtotal colectomy 0.95 (0.85-1.0) 
Localized or regional CRC 0.94 (0.90-
1.0) 
Proctocolectomy 0.89 (0.65-1.0) 
Distant CRC 0.56 (0.30-0.70) 
Syngal (1998) 
Wong (2012) FACT-C 
and FACT-
G mapped 
onto SF-
6D 
SF6D mean score (±SD) 0.825 (± 
0.136)   
SD standard deviation 
Wong (2013b) FACT-C 
and FACT-
G mapped 
onto SF-
6D 
LR 0.871 (SD ±0.12) 
HR 0.832 (SD±0.12) 
Stage I 0.831 (±0.14)  
Stage II 0.858 (±0.12) 
Stage III 0.817 (±0.13)  
Stage IV 0.732 (±0.15) 
SD standard deviation 
LR low-risk polyp 
HR high-risk polyp 
Wong (2014) SF-6D 
SF12 to 
SF6D 
FACT-C to 
SF-6D 
Baseline; follow-up 6 months (±SD) 
SF6D Direct  0.826(±0.133); 
0.807(±0.157) 
From SF12 to SF-6D 0.815(±0.156); 
0.834(±0.172) 
FACT-C mapped to SF6D 
0.824(±0.105); 0.825(±0.139) 
 
SD standard deviation 
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Table A4.6 Summary of mapping studies  
Measuring health Disease or 
patient group 
(number) 
Mapping model 
 
Reference 
From To  
FACT-G 
FACT-C 
SF-6D Patients with LR 
& HR polyps, 
stage I II and III 
CRC (n=552) 
OLS Wong (2012) 
[226] 
FACT-G EQ-5D Cancer patients 
(n=558) 
CLAD 
OLS 
Cheung (2009) 
[235] 
FACT-G  
FACT-C 
SF-6D  OLS Wong (2013b) 
[190] 
FACT-C SF-6D  OLS (Wong 2012) 
[226] 
Wong (2014) 
[224] 
FACT-G EQ-5D Cancer patients 
(n=472) 
Used existing 
mapping models 
(Wong 2012, 
Cheung 2009, 
Kind 2005)[226, 
235, 292] 
Pickard (2012) 
[198] 
EORTC 
QLQ C-30 
EQ-5D  OLS Kim (2012) 
[229] 
SF-36 EQ-5D   Kim (2014) 
[230] 
FACT-C EQ-5D   Pickard (2012) 
[198] 
SF-36 SF-6D   Lee (2013) [222] 
FACT-C SF-6D  OLS (Wong 2012) 
[226] 
Yang (2014) 
[225] 
CLAD censored least absolute deviation; CRC colorectal cancer; FACT-C Functional 
Assessment of Cancer Therapy-Cancer; FACT-G Functional Assessment of Cancer 
Therapy-General; HR high-risk LR low-risk; OLS ordinary least squares 
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APPENDICES TO CHAPTER 5 
Figure A5.1 Reporting form CRCS, NHI (2009) 
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Figure 5.2 Validation – probability of alive over time in No COL surveillance 
and general population in Korea 
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Table A5.1 Steps taken for further search of economic evidence in Korea 
Table A5.1.1 Key words, search strategy and selection criteria 
Key words colorectal cancer, screening, polyp, adenoma, cost-effectiveness and 
cost-utility 비용-효용 분석; 건강상태; 효용; 대장암, 질보정수명, 검진, 
용종 
Searched 
databases 
National Assembly Library (www.nanet.go.kr), Korean Medical 
Database (www.kmbase.medric.or.kr), Korean Association of Medical 
Journal Edition (www.koreamed.org), National Digital Science Library 
(www.ndsl.kr), Korea Institute of Science and Technology Information 
(www.kisti.re.kr), Korean Studies information (www.kstudy.com), 
Korean Medicine Information System (www.kiom.re.kr), Research 
Information Sharing Service (www.riss.kr). Relevant conference 
proceedings and abstracts were checked for a full publication and 
included if relevant. The search was extended to grey literature in 
order to capture relevant reports commissioned by governmental 
agencies such as MoHW (www.mw.go.kr), NCC (www.ncc.re.kr), 
NHIS (www.nhis.or.kr), National Evidence-based Healthcare 
Collaborating Agency (NECA) (www.neca.re.kr), HIRA 
(www.hira.or.kr). Supplementary searches including grey literature 
was conducted in order to identify relevant studies and evidence in a 
Korean setting. 
Selection 
criteria 
Inclusion and exclusion criteria were adopted from Jeong and Cairns 
(2013). Full economic evaluations considered costs and health 
outcomes of relevant types of intervention with outcomes expressed 
in cost per quality-adjusted life-year (QALY) or cost per life-year 
gained. Burden of disease studies or non-comparative costing studies 
were included. The population considered was adults with confirmed 
colorectal adenoma/polyp who are otherwise healthy with no personal 
or familial history of CRC. Follow-up strategies and screening 
strategies based on the best available evidence on the screening 
modalities were considered, including current practice and no 
intervention. Clinical investigation or therapeutic interventions for 
suspected CRC or conditions other than colorectal adenoma/polyp 
were not considered. Any studies which did not assess costs and 
related health outcomes in line with the research questions were 
excluded. 
 
 
 
271 
 
Table A5.1.2 Quality assessment of cost-effectiveness studies in Korea 
 Park 
(2004) 
Han 
(2004) 
Kim 
(2004) 
Jeong 
(2008) 
Park  
(2010) 
1 Was the research question stated?  Yes Yes Yes Yes Yes 
2 Was the economic importance of the research question stated?  Yes Yes Yes Yes Yes 
3 Was/were the viewpoint(s) of the analysis clearly stated and justified?  Yes No No No Yes 
4 Was a rationale reported for the choice of the alternative programmes or interventions 
compared?  
Yes Yes Yes Yes Yes 
5 Were the alternatives being compared clearly described?  Yes Yes Yes Yes Yes 
6 Was the form of economic evaluation stated?  Yes Yes No No Yes 
7 Was the choice of form of economic evaluation justified in relation to the questions 
addressed?  
Yes Yes No No Yes 
8 Was/were the source(s) of effectiveness estimates used stated?  No Yes Yes Yes Yes 
9 Were details of the design and results of the effectiveness study given (if based on a single 
study)?  
No No No Yes No 
10 Were details of the methods of synthesis or meta-analysis of estimates given (if based on 
an overview of a number of effectiveness studies)?  
No No No Yes No 
11 Was/were the primary outcome measure(s) for the economic evaluation clearly stated?  Yes Yes No Yes Yes 
12 Were the methods used to value health states and other benefits stated?  No No No No No 
13 Were the details of the subjects from whom valuations were obtained given?  No No No No No 
14. Were productivity changes (if included) reported separately?  No No No No No 
15 Was the relevance of productivity changes to the study question discussed?  No No No No No 
16 Were quantities of resources reported separately from their unit cost?  No No No No No 
17 Were the methods for the estimation of quantities and unit costs described? Yes Yes No No No 
18 Were currency and price data recorded?  Yes Yes Yes  Yes Yes 
19 Were details of price adjustments for inflation or currency conversion given?  No No No No No 
20 Were details of any model used given?  Yes Yes No Yes No 
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 Park 
(2004) 
Han 
(2004) 
Kim 
(2004) 
Jeong 
(2008) 
Park  
(2010) 
21 Was there a justification for the choice of model used & the key parameters on which it was 
based?  
Yes Yes No No No 
22 Was the time horizon of cost and benefits stated?  Yes No No No No 
23 Was the discount rate stated/justified?  Yes/No Yes/No No/No No/No No 
24 Was an explanation given if cost or benefits were not discounted?  NA NA No No No 
25 Were the details of statistical test(s) and confidence intervals given for stochastic data?  No No No No No 
26 Was the approach to sensitivity analysis described?  Yes Yes No Yes Yes 
27 Was the choice of variables for sensitivity analysis justified?  No Yes No No Yes 
28 Were the ranges over which the parameters were varied stated?  Yes Yes No Yes Yes 
29 Were appropriate comparisons made when conducting the incremental analysis? Yes Yes No Yes Yes 
30 Was an incremental analysis reported?  Yes No No Yes Yes 
31 Were major outcomes presented in a disaggregated as well as aggregated form?  No No No No No 
32 Was the answer to the study question given?  Yes Yes No No Yes 
33 Did conclusions follow from the data reported? Yes Yes No Yes Yes 
34 Were conclusions accompanied by the appropriate caveats?  Yes No No No No 
35 Were generalisability issues addressed? No No No No No 
NA not applicable 
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Table A5.2 Quality assessment: Whyte (2012) [96] 
1. Was the research question stated?  Y 
2. Was the economic importance of the research question stated?  Y 
3. Was/were the viewpoint(s) of the analysis clearly stated and justified?  Y 
4. Was a rationale reported for the choice of the alternative programmes or 
interventions compared?  
Y 
5. Were the alternatives being compared clearly described?  Y 
6. Was the form of economic evaluation stated?  Y 
7. Was the choice of form of economic evaluation justified in relation to the 
questions addressed?  
Y 
8. Was/were the source(s) of effectiveness estimates used stated?  Y 
9. Were details of the design and results of the effectiveness study given (if 
based on a single study)?  
NA 
10. Were details of the methods of synthesis or meta-analysis of estimates given 
(if based on an overview of a number of effectiveness studies)?  
Y 
11. Were the primary outcome measure(s) for the economic evaluation clearly 
stated?  
Y 
12 Were the methods used to value health states and other benefits stated?  Y 
13. Were the details of the subjects from whom valuations were obtained given?  Y 
14. Were productivity changes (if included) reported separately?  NA 
15. Was the relevance of productivity changes to the study question discussed?  NA 
16. Were quantities of resources reported separately from their unit cost?  N 
17. Were the methods for the estimation of quantities and unit costs described? Y  
18. Were currency and price data recorded?  Y 
19. Were details of price adjustments for inflation or currency conversion given?  N 
20. Were details of any model used given?  Y 
21. Was there a justification for the choice of model used & the key parameters 
on which it was based?  
Y 
22. Was the time horizon of cost and benefits stated?  Y 
23. Was the discount rate stated/justified?  Y 
24. Was an explanation given if cost or benefits were not discounted?  NA 
25. Were the details of statistical test(s) and confidence intervals given for 
stochastic data?  
Y 
26. Was the approach to sensitivity analysis described?  Y 
27. Was the choice of variables for sensitivity analysis justified?  Y 
28. Were the ranges over which the parameters were varied stated?  Y 
29. Were appropriate comparisons made when conducting the incremental 
analysis? 
Y 
30. Was an incremental analysis reported?  Y 
31. Were major outcomes presented in a disaggregated as well as aggregated 
form?  
Y 
32. Was the answer to the study question given?  Y 
33. Did conclusions follow from the data reported? Y 
34. Were conclusions accompanied by the appropriate caveats?  Y 
35 Were generalisability issues addressed? P 
N no; NA not applicable; P partly; Y yes 
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Table A5.3 Comparison of CRC stage using different classification system 
(KAMS 2012, Ruh 2016, Walters 2013) [91-93] 
CRC stage   T N M SEER Dukes Estimated 
CRC stages, 
CRC cohort 
0 Tis N0 M0 LOC 0 - DA 
I T1 N0 M0 LOC 1 A DA 
I T2 N0 M0 LOC 1 A DA 
IIA T3 N0 M0 REG 2 B DB 
IIB T4a N0 M0 REG 2 B DB 
IIC T4b N0 M0 REG 2 B DB 
IIIA T1-2 N1/N1c M0 REG 3 C DC 
 T1 N2a M0 DIS 3 C DC 
IIIB T3-4a N1/N1c M0 REG 4/5 C DC 
 T2-T3 N2a M0 REG 5 C DC 
 T1-T2 N2b M0 REG 5 C DC 
IIIC T4a N2a M0 REG 5 C DC 
 T3-T4a N2b M0 DIS 7 C DC 
 T4b N1-N2 M0 DIS 7 C DC 
IVA Any T Any N M1a DIS 7 - DD 
IVB Any T Any N M1b DIS 7 - DD 
CRC colorectal cancer; CRCS colorectal cancer screening; DA Dukes A; DB Dukes’ B; 
DC Dukes’ C; DD stage D CRC; DIS distant cancer; LOC localised cancer; M distant 
metastasis; M0 no distant metastasis; M1 distant metastasis; M1a metastasis confined 
to one organ or site (for example, liver, lung, ovary, nonregional node); M1b metastases 
in more than one organ/site or the peritoneum T primary tumour; ; N regional lymph 
nodes; N0 no regional lymph node metastasis; N1 metastasis in 1-3 regional lymph 
nodes; N1a Metastasis in one regional lymph node; N1b metastasis in 2–3 regional 
lymph nodes; N1c tumuor deposit(s) in the subserosa, mesentery, or nonperitonealized 
pericolic or perirectal tissues without regional nodal metastasis; N2 metastasis in 4 or 
more regional lymph nodes; N2a metastasis in 4–6 regional lymph nodes; N2b 
metastasis in 7 or more regional lymph nodes; NCC National Cancer Centre; NCSP 
National Cancer Screening Programme; REG regional cancer; SEER Surveillance, 
Epidemiology, and End Results; Tis carcinoma in situ; T1 tumour invades submucosa; 
T2 tumour invades muscularis propria; T3 tumour invades through the muscularis 
propria into the pericolorectal tissues; T4 tumour penetrates to the surface of the 
visceral peritoneum or directly invades or in adherent to other organs or structures 
SEER code 0 In situ ; 1 Localized only ; 2 Regional by direct extension only ; 3 Regional 
lymph nodes involved only; 4 Regional by BOTH direct extension AND lymph node 
involvement ; 5 Regional, NOS (Not Otherwise Specified); 7 Distant site(s)/node(s) 
involved; 9 Unknown if extension or metastasis (unstaged, unknown, or unspecified); 
Death certification only case 
 
  
 
 
275 
 
Table A5.4 Fixed transition probabilities 
Table A5.4.1 Adenoma recurrence (subgroup of CRC cohort, n=132,422) 
From To Incidence Follow up  
AF_LRpp LR at year 1 85 8832 
AF_LRpp LR at year 2+ 282 8547 
AF_HRpp LR at year 1 6 1172 
AF_HRpp LR at year 2+ 17 1162 
AF_LRpp AF at year 1 8746 8832 
AF_LRpp AF at year 2+ 8256 8547 
AF_HRpp AF at year 1 1162 1172 
AF_HRpp AF at year 2+ 1138 1162 
AF adenoma free; AF_LRpp year1 adenoma free post-polypectomy of low-risk 
adenomas at year 1; AF_LRpp year 2+ adenoma free post-polypectomy of low-risk 
adenomas at year 2 or more years; AF_HRpp year 1 adenoma free post-polypectomy of 
high-risk adenomas at year 1; AF_HRpp year 2+ adenoma free post-polypectomy of 
high-risk adenomas 2 or more years; HR high-risk; LR low-risk  
 
Table A5.4.2 Fixed annual transition probabilities (CRC cohort, Whyte 2012) 
  AF LR HR DA DB DC DD CRC 
death 
AF (LRpp) yr1 # 0.0096 0 0 0 0 0  0 
AF (LRpp) 
yr2+ 
# 0.0330 0 0 0 0 0  0 
AF (HRpp) yr1 # 0.0051 0 0 0 0 0  0 
AF (HRpp) 
yr2+ 
# 0.0146 0 0 0  0  0  0 
LR 0 # 0.008  0  0  0  0  0 
HR 0 0 # 0.0250  0  0  0  0 
DA  0  0  0 # 0.5100  0  0  0 
DB 0 0 0  0 # 0.6900  0 0.0100 
DC 0 0 0  0  0 # 0.7100 0.0602 
DD 0 0 0 0 0 0 # 0.3867 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk 
adenomas at year 1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk 
adenomas at year 2 or more years; AF(HRpp) year 1 adenoma free post-polypectomy 
of high-risk adenomas at year 1; AF(HRpp) year 2+ adenoma free post-polypectomy 
of high-risk adenomas 2 or more years; CRC colorectal cancer; CRC death death due 
to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; DC Duke’s C CRC; DD Dukes’ D CRC; 
HR high-risk; LR low-risk; # 1 minus other states  
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Table A5.4.3 Fixed 3-monthly transition probabilities (CRC cohort, Whyte 2012) 
  AF LR HR DA DB DC DD CRC 
death 
AF (LRpp) yr1 # 0.0024 0 0 0 0 0  0 
AF (LRpp) 
yr2+ 
# 0.0082 0 0 0 0 0  0 
AF (HRpp) yr1 # 0.0013 0 0 0 0 0  0 
AF (HRpp) 
yr2+ 
# 0.0037 0 0 0  0  0  0 
LR 0 # 0.0020 0 0  0  0  0 
HR 0 0 # 0.0063  0  0  0  0 
DA  0  0  0 # 0.1633  0  0  0 
DB  0  0  0  0 # 0.2538  0 0.0025 
DC 0 0  0  0  0 # 0.2662 0.0154 
DD 0 0  0  0  0  0 # 0.1151 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk 
adenomas at year 1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk 
adenomas at year 2 or more years; AF(HRpp) year 1 adenoma free post-polypectomy 
of high-risk adenomas at year 1; AF(HRpp) year 2+ adenoma free post-polypectomy 
of high-risk adenomas 2 or more years; CRC colorectal cancer; CRC death death due 
to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; DC Duke’s C CRC; DD Dukes’ D CRC; 
HR high-risk; LR low-risk; # 1 minus other states 
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Table 5.5 Steps taken to make the economic model probabilistic [271] 
Table A5.5.1 Posterior distribution parameters (yearly) 
  AF LR HR DA DB DC DD CRC 
death 
AF 
(LRyr1) 
99.03 0.96 0 0 0 0 0 0 
AF 
(LRyr2+) 
96.6 3.3 0 0 0 0 0 0 
AF 
(HRyr1) 
99.15 0.51 0 0 0 0 0 0 
AF 
(HRyr2+) 
97.93 1.46 0 0 0 0 0 0 
LR 0 99.2 0.8 0 0 0 0 0 
HR 0 0 97.5 2.5 0 0 0 0 
DA 0 0 0 49.0 51.0 0 0 0 
DB 0 0 0 0 30.0 69.12 0 1.0 
DC 0 0 0 0 0 22.98 71.0 6.02 
DD 0 0 0 0 0 0 61.33 38.67 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk 
adenomas at year 1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk 
adenomas at year 2 or more years; AF(HRpp) year 1 adenoma free post-polypectomy 
of high-risk adenomas at year 1; AF(HRpp) year 2+ adenoma free post-polypectomy 
of high-risk adenomas 2 or more years; CRC colorectal cancer; CRC death death due 
to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; DC Duke’s C CRC; DD Dukes’ D CRC; 
HR high-risk; LR low-risk  
 
Table A5.5.2 Posterior distribution probabilities (yearly) 
  AF LR HR DA DB DC DD CRC 
death 
AF 
(LRyr1) 
0.9904 0.0096 0 0 0 0 0 0 
AF 
(LRyr2+) 
0.9670 0.0330 0 0 0 0 0 0 
AF 
(HRyr1) 
0.9949 0.0051 0 0 0 0 0 0 
AF 
(HRyr2+) 
0.9853 0.0147 0 0 0 0 0 0 
LR 0 0.992 0.008 0 0 0 0 0 
HR 0 0 0.975 0.025 0 0 0 0 
DA 0 0 0 0.49 0.51 0 0 0 
DB 0 0 0 0 0.3 0.69 0 0.01 
DC 0 0 0 0 0 0.2298 0.71 0.0602 
DD 0 0 0 0 0 0 0.6133 0.3867 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk 
adenomas at year 1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk 
adenomas at year 2 or more years; AF(HRpp) year 1 adenoma free post-polypectomy 
of high-risk adenomas at year 1; AF(HRpp) year 2+ adenoma free post-polypectomy 
of high-risk adenomas 2 or more years; CRC colorectal cancer; CRC death death due 
to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; DC Duke’s C CRC; DD Dukes’ D CRC; 
HR high-risk; LR low-risk  
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Table A5.5.3 Random Dirichlet probabilities (yearly) 
  AF LR HR DA DB DC DD CRC 
death 
AF (LRpp) 
year 1 
# 0.00960 0 0 0 0 0 0 
AF (LRpp) 
year2+ 
# 0.03303 0 0 0 0 0 0 
AF (HRpp) 
year1 
# 0.00512 0 0 0 0 0 0 
AF (HRpp) 
year2+ 
# 0.01469 0 0 0 0 0 0 
LR 0 0.99200 0.0080 0 0 0 0 0 
HR 0 0 # 0.0250 0 0 0 0 
DA 0 0 0 # 0.5100 0 0 0 
DB 0 0 0 0 # 0.6900 0 0.0100 
DC 0 0 0 0 0 # 0.7100 0.0602 
DD 0 0 0 0 0 0 # 0.3867 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk adenomas at 
year 1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk adenomas at year 2 or 
more years; AF(HRpp) year 1 adenoma free post-polypectomy of high-risk adenomas at year 1; 
AF(HRpp) year 2+ adenoma free post-polypectomy of high-risk adenomas 2 or more yearst; 
CRC colorectal cancer; CRC death death due to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; 
DC Duke’s C CRC; DD Dukes’ D CRC; HR high-risk; LR low-risk; Other death deaths due to all 
other causes; # 1 minus other states  
 
Table A5.5.4 Transition probabilities of adenoma-carcinoma (3-monthly) 
  AF LR HR DA DB DC DD CRC 
death 
AF (LRpp) 
year 1 
# 0.0024
1 
0  0  0  0  0  0  
AF (LRpp) 
year2+ 
# 0.0083
6 
0  0  0  0  0  0  
AF (HRpp) 
year1 
# 0.0012
8 
0  0  0  0  0  0  
AF (HRpp) 
year2+ 
# 0.0036
9 
0  0  0  0  0  0  
LR 0 # 0.002  0 0  0  0  0  
HR 0 0 # 0.0063 0  0  0  0  
DA 0 0 0  # 0.1633  0 0  0  
DB  0  0 0  0  # 0.2538 0  0.0025 
DC 0 0 0  0  0  # 0.2662 0.0154 
DD 0 0 0  0  0  0  # 0.1151 
AF adenoma free; AF(LRpp) year1 adenoma free post-polypectomy of low-risk adenomas at year 
1; AF(LRpp) year 2+ adenoma free post-polypectomy of low-risk adenomas at year 2 or more 
years; AF(HRpp) year 1 adenoma free post-polypectomy of high-risk adenomas at year 1; 
AF(HRpp) year 2+ adenoma free post-polypectomy of high-risk adenomas 2 or more years; CRC 
colorectal cancer; CRC death death due to CRC; DA Dukes’ A CRC; DB Dukes’ B CRC; DC 
Duke’s C CRC; DD Dukes’ D CRC; HR high-risk; LR low-risk; Other death deaths due to all other 
causes; # 1 minus other states  
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Appendix Table A5.6 Steps taken to identify HSUVs of CRC in a Korean 
context  
Table A5.6.1 Further search for HSUVs in a Korean context 
Key words Health state utility value; colorectal cancer; quality-adjusted life year 
(QALY); economic evaluation; 비용-효용 분석; 건강상태; 효용; 
대장암, 질보정수명 
Searched 
databases 
National Assembly Library (www.nanet.go.kr), Korean Medical 
Database (www.kmbase.medric.or.kr), Korean Association of 
Medical Journal Edition (www.koreamed.org), National Digital 
Science Library (www.ndsl.kr), Korea Institute of Science and 
Technology Information (www.kisti.re.kr), Korean Studies information 
(www.kstudy.com), Korean Medicine Information System 
(www.kiom.re.kr), Research Information Sharing Service 
(www.riss.kr). The search was extended to grey literature in order to 
capture relevant reports commissioned by governmental agencies 
such as MoHW (www.mw.go.kr), National Cancer Centre (NCC) 
(www.ncc.re.kr), NHIS (www.nhis.or.kr), National Evidence-based 
Healthcare Collaborating Agency (NECA) (www.neca.re.kr), Health 
Insurance Review & Assessment (HIRA) (www.hira.or.kr)  
Selection 
criteria 
Relevant conference proceedings and abstracts were checked for a 
full publication and included if relevant. Full text was acquired for the 
remaining studies (including those which had insufficient details, 
such as no abstract). Studies were included if they contained CRC-
related HSUVs which had not been previously reported, be they 
generic PBMs or directly valued CRC-related health state 
descriptions, or mapping to generic PBMs based on direct statistical 
association mapping  
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Table A5.6.2 Studies identified for full-text review 
1 Min, H. and J. Kim, Health-related Quality of Life of Patients with Rectal Cancer. 
J Korean Soc Coloproctol, 2009. 25(2): p. 100-106. 
2 Kim, J., et al., 항암화학요법으로 인한 말초신경병증을 경험하는 대장암 환자의 
삶의 질. 종양간호학회지 Journal of Korean oncology nursing, 2011. 11(3): p. 254-
262. 
3 Jeong, J., et al., Related Factors to Quality of Life among Hospitalized Cancer 
Patients Undergoing Chemotherapy. Asian Oncology Nursing, 2012. 12(1): p. 84-
91. 
4 Jeong, G., K. Kim, and Y. Kwak, 대장암 환자 증상군의 중증도에 따른 삶의 
질 Quality of Life in Colorectal Cancer Patients according to the Severity of 
Symptom Clusters Classification. Asian Oncology Nursing, 2014. 14(2): p. 74-83. 
5 Byun, H.S., et al., 입원 암환자의 피로와 삶의 질. 한국호스피스 & 완화의료학회지 
Korean journal of hospice and palliative care, 2010. 13(2): p. 98-108. 
6 Choi, H.J., J. Park, and J.H. Lee, 대장암 환자의 증상경험과 극복력이 삶의 질에 
미치는 효과. Asian Oncology Nursing, 2012. 12(1): p. 61-68. 
7 Kim, J.H., 장루 복원술을 시행한 대장암 환자의 삶의 질 영향 요인 Quality of life 
and related factors in colorectal cancer patinets with stoma reversal in Graduate 
School of Nursing. 2014, Hallym University: Korea. p. 61. 
8 Kim, S.H., et al., Deriving a mapping algorithm for converting SF-36 scores to EQ-
5D utility score in a Korean population. Health and Quality of Life Outcomes, 
2014. 12(1): p. 1-10. 
9 Kim, S.H., et al., Validity and reliability of the EQ-5D for cancer patients in Korea. 
Support Care Cancer, 2012a. 20(12): p. 3155-60. 
10 Kim, S.H., et al., Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of 
cancer patients. Health Qual Life Outcomes, 2012b. 10: p. 151. 
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Table A5.6.3 Ordinary least square regression model (Kim 2012b)  
    B Standard 
error 
P value 
Intercept _cons 0.53897 0.03507 <0.0001 
Global health status global 0.00092 0.00018 <0.0001 
5 functional scales F_       
Physical F_phy 0.00223 0.00027 <0.0001 
Role F_role 0.00065 0.00019 0.001 
Emotional F_emo 0.00038 0.00021 0.071 
Eognitive F_cog 0.00015 0.00021 0.474 
Social F_soc 0.0002 0.00017 0.234 
3 symptom scales S_       
fatigue S_fat 0.00042 0.00027 0.111 
nausea or vomitting S_nau -0.00005 0.00015 0.737 
pain S_pain -0.00123 0.00017 <0.0001 
6 single items         
Dyspnea dysp -0.00024 0.00015 0.102 
Insomnia inso -0.00009 0.00013 0.494 
Appetite loss apploss -0.00001 0.00014 0.943 
Constipation consti -0.00004 0.00012 0.72 
Diarroea diarr 0.00005 0.00013 0.72 
Financial difficulties fdiff 0.00005 0.00012 0.673 
 
 
Table A5.6.4 Summary statistics and mapped HSUVs  
Characteristics Mean (±SD), 
frequency (%) 
Mapped 
HSUVs 
Reference 
Sample size N=93 (male n=53, 
57%) 
NA Kim JH (2011) [286] 
Age 55.75 (±9.07) NA Kim JH (2011) [286] 
CRC stage I 0 (0.0) 0.662 Assumption 
CRC stage II 7 (7.5%) 0.662 Kim JH (2011), Kim SH 
(2012b) [229, 286] 
CRC stage III 22 (23.7%) 0.668 Kim JH (2011), Kim SH 
(2012b) [229, 286] 
CRC stage IV 64 (68.8%) 0.667 Kim JH (2011), Kim SH 
(2012b) [229, 286] 
CRC colorectal cancer; HSUV health state utility value; NA not applicable; SD standard 
deviation 
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Table A5.7 Resources associated with COL and CRC in the NHI 
Table A5.7.1 Summary of unit costs of COL surveillance and CRC diagnosis 
(Unit: KRW; KRW 1,000=GBP 0.56) 
Description Reimbursement NHI 
(2015) 
COL  74,240  
Bowel preparation for COL 8,400  
Biopsy during COL 12,740  
Pathology 
1-3 pieces  
4-6 pieces  
7-9 pieces  
10-12 pieces  
13 and more  
 
20,390  
27,470  
34,560  
42,530  
49,620  
Outpatient clinic visits for consultation (initial and 3 
follow-up visits) 
9,479  
Histopathology 40,437 
Routine blood tests, complete blood count with platelet, 
chemistry and CEA 
16,255 
Colonoscopy in case of incomplete previous 
colonoscopy 
74,240 
Intravenous contrast-enhanced abdomen and pelvis 
CT 
 
Chest x-ray  
Chest CT for lung metastasis  
PET-CT when metastasis is suspected 260,135 
Abdomen (MRI)  277,018 
Bone scan 76,062 
Ultrasound sonography 44,120 
CEA carcinoembryonic antigen; COL colonoscopy; CRC colorectal cancer; CT 
computed tomography; GBP Great British Pound; KRW Korean Won; MRI magnetic 
resonance imaging; PET position emission tomography 
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Table A5.7.2 Summary of recommended chemotherapy agents for CRC  
Primary chemotherapy agents Indications Reference  
Fluorouracil + leucovorin Clinician’s judgement HIRA (2014) 
Fluorouracil + cisplatin Clinician’s judgement HIRA (2014) 
Fluorouracil + leucovorin + cicplatin Clinician’s judgement HIRA (2014) 
Fluorouracil + leucovorin + 
carboplatin 
Clinician’s judgement HIRA (2014) 
Tegafur + uracil + leurovorin (oral) Clinician’s judgement HIRA (2014) 
leurovorin (oral) Clinician’s judgement HIRA (2014) 
Tegarfut + uracil + leucovorin (oral) 
+ cisplatin 
Clinician’s judgement  HIRA (2014) 
leucovorin (oral) + cisplatin Clinician’s judgement HIRA (2014) 
Mitomycin C Clinician’s judgement HIRA (2014) 
Mitomycin C  + leucovorin (oral) Clinician’s judgement HIRA (2014) 
Mitomycin C + tegarfur + uracil + 
leucovorin (oral) 
Clinician’s judgement HIRA (2014) 
Cisplatin Clinician’s judgement HIRA (2014) 
Etoposide (intravenous or oral)  Clinician’s judgement HIRA (2014) 
Secondary chemotherapy agents   HIRA (2014) 
Neoadjuvant   HIRA (2014) 
Capecitabine + radiotherapy CRC Stages II & III HIRA (2014) 
Oxaliplatin + leucovorin + infusional 
flourouracil (FOLFOX) 
CRC stage II (post-operative) 
CRC stage III 
HIRA (2014) 
Capecitabine  CRC stage II (post-operative) 
CRC stage III 
HIRA (2014) 
Oxaliplatin + capecitabine  CRC stage III  HIRA (2014) 
Palliative  
Irinotecan + leucovorin fluorouracil 
(infusion)(FOLFIRI) + bevacizumab 
Metastasis HIRA (2014) 
Irinotecan + leucovirin + fluoroucil 
(infusion) (FOLFIRI) + cetuximab 
EGFR positive, KRAS wild-
type metastatic CRC 
HIRA (2014) 
Irinotecan + leucovorin + 
fluorouracil (infusion) (FOLFIRI) + 
bevacizumab 
Metastasis HIRA (2014) 
Oxaliplatin + leucovorin + fluoroucil 
(infusion) (FOLFOX) + 
bevacizumab 
Metastasis HIRA (2014) 
CRC colorectal cancer; EGFR epidermal growth factor receptor; KRAS mutations in 
the Kirsten Ras gene 
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Table A5.8 Annual average OOP payments between people with and without cancer in Korea (Seo 2013) [284] 
 (Unit: KRW; KRW 1,000=GBP 0.56) 
  2009 2010 2011 
  Average SD % Average SD % Average SD % 
Without 
cancer 
Emergency 4,841 34,899 1.3 5,610 58,922 1.4 4,696 33,066 1.1 
Hospital stay 96,508 603,044 25.8 102,047 641,365 25.0 117,756 970,279 26.4 
Outpatient clinic 215,545 581,167 57.5 233,240 614,434 57.2 251,483 620,185 56.3 
Pharmacy 
prescription 
55,534 133,473 14.8 62,807 146,481 15.4 68,147 161,528 15.3 
Carers costs 2,314 77,940 0.6 4,065 125,738 1.0 4,605 128,241 1.0 
Total 374,742  100 407,769  100 446,687  100 
Cancer  Emergency 13,904 77,874 0.8 15,697 110,287 0.9 15,537 57,254 0.8 
Hospital stay 924,635 1,853,974 54.4 899,139 1,860,753 49,9 1,134,263 2,185,250 55.3 
Outpatient clinic 597,448 775,403 35.1 690,775 972,270 38.3 697,575 918,968 34.0 
Pharmacy 
prescription 
152,288 276,796 9.0 175,817 383,616 9.7 185,790 401,160 9.0 
Carers costs 12,245 142,681 0.7 22,195 200,763 1.2 16,962 185,672 0.8 
 1,700,520  100 1,803,623  100 2,050,127  100 
GBP Great British pound; KRW Korean Won; OOP out-of-pocket payment; SD standard deviation
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Table A5.9 Description of SEER and the partial adoption of SEER in CRCS 
SEER Description Reported SEER 
codes in CRCS  
CRC stages in 
the model 
0 In situ Not specified Dukes’ A 
1 Localised only 1 Dukes’ A 
2 Regional by direct extension only 2 Dukes’ B 
Dukes’ C 
3 Regional lymph nodes involved 
only 
Not specified  
4 Regional by BOTH direct 
extension AND lymph node 
involvement 
Not specified  
5 Regional, NOS (Not Otherwise 
Specified) 
Not specified  
7 Distant site(s)/node(s) involved 7 Dukes’ D 
9 Unknown if extension or 
metastasis (unknown, or 
unspecified) 
9  
SEER Surveillance, Epidemiology and End Results; CRC colorectal cancer; CRCS 
colorectal cancer screening 
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Table A5.10 Summary of recommended chemotherapy agents for CRC [282] 
Primary chemotherapy agents Indications 
Fluorouracil + leucovorin Clinician’s judgement 
Fluorouracil + cisplatin Clinician’s judgement 
Fluorouracil + leucovorin + cicplatin Clinician’s judgement 
Fluorouracil + leucovorin + carboplatin Clinician’s judgement 
Tegafur + uracil + leurovorin (oral) Clinician’s judgement 
leurovorin (oral) Clinician’s judgement 
Tegarfut + uracil + leucovorin (oral) + cisplatin Clinician’s judgement  
leucovorin (oral) + cisplatin Clinician’s judgement 
Mitomycin C Clinician’s judgement 
Mitomycin C  + leucovorin (oral) Clinician’s judgement 
Mitomycin C + tegarfur + uracil + leucovorin (oral) Clinician’s judgement 
Cisplatin Clinician’s judgement 
Etoposide (intravenous or oral)  Clinician’s judgement 
Secondary chemotherapy agents   
Neoadjuvant   
Capecitabine + radiotherapy CRC Stages II & III 
Oxaliplatin + leucovorin + infusional flourouracil 
(FOLFOX) 
CRC stage II (post-operative) 
CRC stage III 
Capecitabine  CRC stage II (post-operative) 
CRC stage III 
Oxaliplatin + capecitabine  CRC stage III  
Palliative 
Irinotecan + leucovorin fluorouracil 
(infusion)(FOLFIRI) + bevacizumab 
Metastasis 
Irinotecan + leucovirin + fluoroucil (infusion) 
(FOLFIRI) + cetuximab 
EGFR positive, KRAS wild-
type metastatic CRC 
Irinotecan + leucovorin + fluorouracil (infusion) 
(FOLFIRI) + bevacizumab 
Metastasis 
Oxaliplatin + leucovorin + fluoroucil (infusion) 
(FOLFOX) + bevacizumab 
Metastasis 
CRC colorectal cancer; EGFR epidermal growth factor receptor; KRAS mutations in the 
Kirsten Ras gene 
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Table A5.11 Summary costs of chemotherapy, CRC treatment (source: CRC 
cohort) 
(Unit: KRW; KRW 1,000=GBP 0.56) 
NHI Code Description Average  
cost 
KK 153, KK154  Chemotherapy Administration-Continuous 
Intravenous 
4,170  
HE427, HE 427001, 
HE427006, HE427007, 
HE427300, HE427306, 
HE427307 
Abdomen MRI (limited) in deciding 
therapeutic range and location of 
radiotherapy 
86,605  
 
Q2671, Q2672, Q2673, 
Q2679, Q2680, Q2921-
Q2927  
Surgeries relevant to CRC treatment: total 
colectomy, colectomy – segmental 
resection, rectal and sigmoid resection, 
intestinal anastomosis, hemi-colectomy, 
colectomy with proximal colostomy and 
distal stump, Colonoscopic operation of 
colonic tumor-mucosal resection and 
submucosal resection 
373,038 
L01010101 Intravenous general anaesthesia 62,159 
CRC colorectal cancer; KRW Korean Won; GBP Great British pound; MRI magnetic 
resonance imaging 
 
 
Table A5.12 Costs of radiation therapy for CRC (CRC cohort) 
(Unit: KRW; KRW 1,000=GBP 0.56) 
Codes Description Average cost 
HD051-HD056 Teletherapy 28,378 
HD057-HD059 Rotational irradiation 38,845 
HD061 3-dimensional conformal therapy 152,490 
HD071-HD073 Unsealed sources 36,265 
HD080-HD088 Brachytherapy 2,097,480 
HD091-HD092 Total body irradiation 233,060 
HD093 Total skin electron beam therapy 403,665 
HD110 Fractionated stereotactic radiotherapy 547,915 
HD111, 
HD112, HD212 
Body stereotactic radiosurgery 529,565 
HD121 Proton therapy 513,235 
HZ271 Intensity modulated radiation therapy 297,645 
KRW Korean Won; GBP Great British pound 
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Table A5.13 Validation of model - probability of being alive from age 50-100  
Age No COL 
surveillance 
KONS (2015) Age No COL 
surveillance 
KONS (2015) 
  1.0000 1.0000 62.75 0.9369 0.9358 
50 0.9992 0.9992 63.00 0.9349 0.9339 
50.25 0.9984 0.9984 63.25 0.9330 0.9320 
50.50 0.9976 0.9976 63.50 0.9311 0.9301 
50.75 0.9969 0.9968 63.75 0.9292 0.9281 
51.00 0.9960 0.9959 64.00 0.9271 0.9260 
51.25 0.9952 0.9951 64.25 0.9250 0.9239 
51.50 0.9943 0.9942 64.50 0.9230 0.9219 
51.75 0.9935 0.9933 64.75 0.9209 0.9196 
52.00 0.9925 0.9924 65.00 0.9186 0.9174 
52.25 0.9916 0.9915 65.25 0.9164 0.9151 
52.50 0.9907 0.9906 65.50 0.9141 0.9129 
52.75 0.9898 0.9896 65.75 0.9118 0.9104 
53.00 0.9888 0.9886 66.00 0.9093 0.9079 
53.25 0.9879 0.9877 66.25 0.9068 0.9055 
53.50 0.9869 0.9867 66.50 0.9043 0.9030 
53.75 0.9859 0.9857 66.75 0.9019 0.9003 
54.00 0.9849 0.9846 67.00 0.8991 0.8975 
54.25 0.9839 0.9836 67.25 0.8964 0.8948 
54.50 0.9828 0.9826 67.50 0.8936 0.8921 
54.75 0.9818 0.9815 67.75 0.8909 0.8891 
55.00 0.9807 0.9804 68.00 0.8879 0.8861 
55.25 0.9796 0.9793 68.25 0.8849 0.8832 
55.50 0.9786 0.9782 68.50 0.8819 0.8802 
55.75 0.9775 0.9771 68.75 0.8789 0.8769 
56.00 0.9763 0.9759 69.00 0.8756 0.8737 
56.25 0.9752 0.9748 69.25 0.8723 0.8704 
56.50 0.9740 0.9736 69.50 0.8690 0.8672 
56.75 0.9729 0.9724 69.75 0.8658 0.8636 
57.00 0.9716 0.9712 70.00 0.8621 0.8600 
57.25 0.9704 0.9699 70.25 0.8585 0.8565 
57.50 0.9692 0.9687 70.50 0.8550 0.8530 
57.75 0.9679 0.9674 70.75 0.8514 0.8490 
58.00 0.9666 0.9661 71.00 0.8474 0.8451 
58.25 0.9653 0.9648 71.25 0.8434 0.8412 
58.50 0.9640 0.9634 71.50 0.8395 0.8373 
58.75 0.9627 0.9620 71.75 0.8356 0.8329 
59.00 0.9612 0.9606 72.00 0.8312 0.8286 
59.25 0.9598 0.9591 72.25 0.8269 0.8243 
59.50 0.9584 0.9577 72.50 0.8225 0.8201 
59.75 0.9569 0.9562 72.75 0.8182 0.8154 
60.00 0.9554 0.9546 73.00 0.8135 0.8107 
60.25 0.9538 0.9531 73.25 0.8087 0.8060 
60.50 0.9523 0.9515 73.50 0.8040 0.8013 
60.75 0.9507 0.9499 73.75 0.7994 0.7962 
61.00 0.9491 0.9482 74.00 0.7942 0.7911 
61.25 0.9474 0.9465 74.25 0.7890 0.7860 
61.50 0.9457 0.9449 74.50 0.7839 0.7810 
61.75 0.9440 0.9431 74.75 0.7788 0.7754 
62.00 0.9422 0.9413 75.00 0.7732 0.7699 
62.50 0.9387 0.9377 75.25 0.7677 0.7644 
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Age No COL 
surveillance 
KONS (2015) Age No COL 
surveillance 
KONS (2015) 
75.50 0.7621 0.7589 87.75 0.3482 0.3408 
75.75 0.7566 0.7529 88.00 0.3379 0.3308 
76.00 0.7506 0.7469 88.25 0.3278 0.3210 
76.25 0.7445 0.7410 88.50 0.3181 0.3115 
76.50 0.7385 0.7351 88.75 0.3087 0.3014 
76.75 0.7326 0.7285 89.00 0.2986 0.2917 
77.00 0.7260 0.7220 89.25 0.2889 0.2822 
77.25 0.7195 0.7156 89.50 0.2795 0.2731 
77.50 0.7130 0.7092 89.75 0.2704 0.2634 
77.75 0.7066 0.7021 90.00 0.2608 0.2541 
78.00 0.6995 0.6951 90.25 0.2515 0.2451 
78.25 0.6924 0.6881 90.50 0.2425 0.2364 
78.50 0.6854 0.6813 90.75 0.2339 0.2273 
78.75 0.6785 0.6736 91.00 0.2248 0.2185 
79.00 0.6708 0.6661 91.25 0.2161 0.2101 
79.25 0.6633 0.6586 91.50 0.2077 0.2020 
79.50 0.6558 0.6512 91.75 0.1997 0.1935 
79.75 0.6483 0.6431 92.00 0.1913 0.1854 
80.00 0.6402 0.6350 92.25 0.1832 0.1776 
80.25 0.6321 0.6271 92.50 0.1755 0.1701 
80.50 0.6241 0.6192 92.75 0.1681 0.1624 
80.75 0.6162 0.6105 93.00 0.1604 0.1550 
81.00 0.6075 0.6020 93.25 0.1531 0.1480 
81.25 0.5989 0.5935 93.50 0.1461 0.1413 
81.50 0.5904 0.5852 93.75 0.1394 0.1343 
81.75 0.5821 0.5760 94.00 0.1326 0.1277 
82.00 0.5729 0.5669 94.25 0.1260 0.1215 
82.25 0.5638 0.5580 94.50 0.1198 0.1155 
82.50 0.5549 0.5493 94.75 0.1139 0.1094 
82.75 0.5461 0.5396 95.00 0.1079 0.1036 
83.00 0.5364 0.5301 95.25 0.1022 0.0981 
83.25 0.5269 0.5208 95.50 0.0967 0.0930 
83.50 0.5176 0.5116 95.75 0.0916 0.0877 
83.75 0.5084 0.5015 96.00 0.0864 0.0827 
84.00 0.4983 0.4916 96.25 0.0815 0.0780 
84.25 0.4883 0.4818 96.50 0.0768 0.0736 
84.50 0.4786 0.4723 96.75 0.0725 0.0691 
84.75 0.4691 0.4619 97.00 0.0680 0.0649 
85.00 0.4587 0.4518 97.25 0.0639 0.0610 
85.25 0.4486 0.4418 97.50 0.0600 0.0573 
85.50 0.4386 0.4321 97.75 0.0563 0.0536 
85.75 0.4289 0.4216 98.00 0.0527 0.0501 
86.00 0.4185 0.4114 98.25 0.0493 0.0469 
86.25 0.4082 0.4014 98.50 0.0461 0.0438 
86.50 0.3982 0.3916 98.75 0.0431 0.0408 
86.75 0.3885 0.3811 99.00 0.0401 0.0380 
87.00 0.3780 0.3709 99.25 0.0373 0.0354 
87.25 0.3678 0.3609 99.50 0.0347 0.0329 
87.50 0.3579 0.3512 99.75 0.0323 0.0307 
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Tables A5.14 Full results of sensitivity analyses 
Table A5.14.1 Discount at 0% 
  Cost QALY inc Cost inc QALY ICER  
No_COL  2818 10.86598       
0LR3HR 5750 10.92539 2932 0.05941 49346 
0LR2HR 5991 10.92534 241 -0.00005 Dominated by 0LR3HR 
0LR1HR 6250 10.92532 259 -0.00002 Dominated by 0LR3HR 
5LR3HR 41907 10.85894 35657 -0.06638 Dominated by 0LR3HR 
5LR2HR 42113 10.85884 206 -0.00010 Dominated by 0LR3HR 
5LR1HR 42330 10.85884 217 0.00000 Dominated by 0LR3HR 
3LR3HR 49695 10.85652 7365 -0.00232 Dominated by 0LR3HR 
3LR1HR 50021 10.85646 325 -0.00006 Dominated by 0LR3HR 
1LR1HR 57542 10.85571 7521 -0.00075 Dominated by 0LR3HR 
 
Table 5.14.2 Discount at 3.5% 
  Cost QALY inc Cost inc QALY ICER  
No_COL  6533 16.270694       
0LR3HR 9325 16.418176 2793 0.1475 18935 
0LR2HR 9463 16.418116 138 -0.0001 Dominated by 0LR2HR 
0LR1HR 9607 16.418076 144 0.0000 Dominated by 0LR2HR 
5LR3HR 54894 16.254645 45287 -0.1634 Dominated by 0LR2HR 
5LR2HR 54927 16.254502 33 -0.0001 Dominated by 0LR2HR 
5LR1HR 55007 16.254498 80 0.0000 Dominated by 0LR2HR 
3LR3HR 58554 16.250703 3547 -0.0038 Dominated by 0LR2HR 
3LR1HR 58573 16.250631 19 -0.0001 Dominated by 0LR2HR 
1LR1HR 60600 16.249637 2027 -0.0010 Dominated by 0LR2HR 
 
Table A5.14.3 Discount at 7% 
  Cost QALY inc Cost inc QALY ICER  
No_COL  2818 10.86598       
0LR3HR 5750 10.92539 2932 0.05941 49346 
0LR2HR 5991 10.92534 241 -0.00005 Dominated by 0LR3HR 
0LR1HR 6250 10.92532 259 -0.00002 Dominated by 0LR3HR 
5LR3HR 41907 10.85894 35657 -0.06638 Dominated by 0LR3HR 
5LR2HR 42113 10.85884 206 -0.00010 Dominated by 0LR3HR 
5LR1HR 42330 10.85884 217 0.00000 Dominated by 0LR3HR 
3LR3HR 49695 10.85652 7365 -0.00232 Dominated by 0LR3HR 
3LR1HR 50021 10.85646 325 -0.00006 Dominated by 0LR3HR 
1LR1HR 57542 10.85571 7521 -0.00075 Dominated by 0LR3HR 
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Table A5.14.4 Transition probability (TP) LR year 1 (0.0024) is assumed to be 
same as TP at year 2 (0.0084) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4587 13.55879       
0LR3HR 7487 13.66083 2900 0.10204 28419 
0LR2HR 7672 13.66073 185 -0.00009 Dominated by 0LR3HR 
0LR1HR 7867 13.66067 195 -0.00006 Dominated by 0LR3HR 
5LR3HR 49234 13.58028 41367 -0.08039 Dominated by 0LR3HR 
5LR2HR 49354 13.57960 120 -0.00069 Dominated by 0LR3HR 
5LR1HR 49494 13.57954 140 -0.00005 Dominated by 0LR3HR 
3LR3HR 55072 13.56890 5578 -0.01064 Dominated by 0LR3HR 
3LR1HR 55224 13.56834 153 -0.00056 Dominated by 0LR3HR 
1LR1HR 59813 13.55279 4588 -0.01555 Dominated by 0LR3HR 
 
Table A5.14.5 Transition probability (TP) HR year 1 (0.0012) is assumed to be 
same as TP at year 2 (0.0037) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4495 13.490150       
0LR3HR 7407 13.588586 2912 0.09844 29585 
0LR2HR 7592 13.588540 185 -0.00005 Dominated by 0LR3HR 
0LR1HR 7788 13.588518 196 -0.00002 Dominated by 
0LR3HR 
5LR3HR 48754 13.479301 40966 -0.10922 Dominated by 0LR3HR 
5LR2HR 48879 13.479172 125 -0.00013 Dominated by 0LR3HR 
5LR1HR 49021 13.479170 142 0.00000 Dominated by 0LR3HR 
3LR3HR 54543 13.476035 5522 -0.00313 Dominated by 0LR3HR 
3LR1HR 54707 13.475961 165 -0.00007 Dominated by 0LR3HR 
1LR1HR 59307 13.475026 4600 -0.00094 Dominated by 0LR3HR 
 
Table A5.14.6 Transition probability (TP) LR year 1 (0.0024) is assumed to be 
(0.026) (Whyte 2012) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4859 13.76103       
0LR3HR 7742 13.87326 2883 0.11223 25,689 
0LR2HR 7927 13.87306 185 -0.00019 Dominated by 0LR3HR 
0LR1HR 8122 13.87289 195 -0.00017 Dominated by 0LR3HR 
5LR3HR 50749 13.88482 42627 0.01193  3,718,969 
5LR2HR 50878 13.88249 129 -0.00234 Dominated by 5LR3HR 
5LR1HR 51014 13.88228 136 -0.00020 Dominated by 5LR3HR 
3LR3HR 56752 13.85115 5739 -0.03113 Dominated by 5LR3HR 
3LR1HR 56883 13.84915 131 -0.00200 Dominated by 5LR3HR 
1LR1HR 61447 13.79156 4564 -0.05760 Dominated by 5LR3HR 
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Table A5.14.7 Transition probability (TP) HR year 1 (0.0012) is assumed to be 
(0.0026) (Whyte 2012) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4545 13.527115       
0LR3HR 7516 13.626158 2971 0.09904 29,999 
0LR2HR 7702 13.626154 186 0.00000 Dominated by 0LR3HR 
0LR1HR 7903 13.626185 201 0.00003 Dominated by 
0LR3HR 
5LR3HR 49156 13.518268 41253 -0.10792 Dominated by 0LR3HR 
5LR2HR 49348 13.518020 192 -0.00025 Dominated by 0LR3HR 
5LR1HR 49495 13.518040 146 0.00002 Dominated by 0LR3HR 
3LR3HR 54978 13.513839 5483 -0.00420 Dominated by 0LR3HR 
3LR1HR 55182 13.513676 204 -0.00016 Dominated by 0LR3HR 
1LR1HR 59802 13.511995 4621 -0.00168 Dominated by 0LR3HR 
 
Table A5.14.8 Risk stratification – number of adenomas 
  Cost QALY inc Cost inc QALY ICER  
No_COL  5041 13.487691       
0LR3HR 7784 13.595716 2742 0.108025 25,386 
0LR2HR 7967 13.595641 183 -0.000075 Dominated by 0LR3HR 
0LR1HR 8161 13.595591 194 -0.000050 Dominated by 0LR3HR 
5LR3HR 49787 13.475612 41626 -0.119980 Dominated by 0LR3HR 
5LR2HR 49817 13.475443 30 -0.000169 Dominated by 0LR3HR 
5LR1HR 49945 13.475438 128 -0.000005 Dominated by 0LR3HR 
3LR3HR 55531 13.472028 5586 -0.003410 Dominated by 0LR3HR 
3LR1HR 55578 13.471939 47 -0.000089 Dominated by 0LR3HR 
1LR1HR 59779 13.470993 4202 -0.000947 Dominated by 0LR3HR 
 
Table A5.14.9 LR:HR proportion 500:500 
  Cost QALY inc Cost inc QALY ICER  
No_COL  3511 13.4834       
0LR3HR 16219 13.5369 12708 0.05356 237,256 
0LR2HR 16958 13.5367 739 -0.00021 Dominated by 0LR3HR 
0LR1HR 17739 13.5366 781 -0.00011 Dominated by 0LR3HR 
5LR3HR 41522 13.4739 23783 -0.06270 Dominated by 0LR3HR 
5LR2HR 41650 13.4735 128 -0.00043 Dominated by 0LR3HR 
5LR1HR 42365 13.4735 715 0.00000 Dominated by 0LR3HR 
3LR3HR 44915 13.4720 2550 -0.00153 Dominated by 0LR3HR 
3LR1HR 45698 13.4717 783 -0.00027 Dominated by 0LR3HR 
1LR1HR 48507 13.4712 2809 -0.00050 Dominated by 0LR3HR 
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Table A5.14.10 LR:HR=0:1000 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4489 13.48613       
0LR3HR 7395 13.58451 2906 0.0984 29,538 
0LR2HR 7580 13.58445 185 -0.0001 Dominated by 0LR3HR 
0LR1HR 7775 13.58443 195 0.0000 Dominated by 0LR3HR 
5LR3HR 48710 13.47507 40935 -0.1094 Dominated by 0LR3HR 
5LR2HR 48827 13.47495 117 -0.0001 Dominated by 0LR3HR 
5LR1HR 48969 13.47495 142 0.0000 Dominated by 0LR3HR 
3LR3HR 54495 13.47193 5526 -0.0030 Dominated by 0LR3HR 
3LR1HR 54656 13.47187 160 -0.0001 Dominated by 0LR3HR 
1LR1HR 59253 13.47101 4598 -0.0009 Dominated by 0LR3HR 
 
Table A5.14.11 Mapped HSUVs (Kim SH, 2011) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4378 13.480859       
0LR3HR 7293 13.558066 2915 0.07721 37,753 
0LR2HR 7478 13.558018 185 -0.00005 Dominated by 0LR3HR 
0LR1HR 7673 13.557997 195 -0.00002 Dominated by 0LR3HR 
5LR3HR 48505 13.473773 40833 -0.08422 Dominated by 0LR3HR 
5LR2HR 48621 13.473685 115 -0.00009 Dominated by 0LR3HR 
5LR1HR 48764 13.473682 143 0.00000 Dominated by 0LR3HR 
3LR3HR 54306 13.471626 -4870 0.00062 Dominated by 0LR3HR 
3LR1HR 54469 13.471574 5705 -0.00211 Dominated by 0LR3HR 
1LR1HR 59176 13.471004 4707 -0.00057 Dominated by 0LR3HR 
 
 
 
Table A5.14.12 Alternative HSUVs (Ness, 1999) 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4378 13.475123       
0LR3HR 7293 13.511077 2915 0.03595 81,070 
0LR2HR 7478 13.511038 185 -0.00004 Dominated by 0LR3HR 
0LR1HR 7673 13.511028 195 -0.00001 Dominated by 0LR3HR 
5LR3HR 48505 13.473932 40833 -0.03710 Dominated by 0LR3HR 
5LR2HR 48621 13.473840 115 -0.00009 Dominated by 0LR3HR 
5LR1HR 48764 13.473837 143 0.00000 Dominated by 0LR3HR 
3LR3HR 54306 13.471699 5542 -0.00214 Dominated by 0LR3HR 
3LR1HR 54469 13.471645 163 -0.00005 Dominated by 0LR3HR 
1LR1HR 59176 13.471008 4707 -0.00064 Dominated by 0LR3HR 
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Table A5.14.13 Alternative HSUVs – cancer-free, LR and HR 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4378 13.4858     
0LR3HR 7293 24.3986 2915 0.003 1,142,623 
0LR2HR 7478 24.3961 185 0.003 Dominated by 0LR3HR 
0LR1HR 7673 24.3929 195 9.356 Dominated by 0LR3HR 
5LR3HR 48505 15.0371 40833 0.038 Dominated by 0LR3HR 
5LR2HR 48621 14.9988 115 0.001 Dominated by 0LR3HR 
5LR1HR 48764 14.9978 143 0.914 Dominated by 0LR3HR 
3LR3HR 54306 14.1067 5542 0.548 Dominated by 0LR3HR 
3LR1HR 54469 14.0838 163 14.084 Dominated by 0LR3HR 
1LR1HR 59176 13.5586 4707 13.559 Dominated by 0LR3HR 
 
 
Table A5.14.14 COL reimbursement KRW 5,680,000 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4378 13.48582    
0LR3HR 157871 13.58154 153493 0.095721 1,603,549 
0LR2HR 166063 13.58149 8192 -0.000052 Dominated by 0LR3HR 
0LR1HR 174725 13.58146 8662 -0.000026 Dominated by 0LR3HR 
5LR3HR 2133515 13.47495 1958790 -0.106509 Dominated by 0LR3HR 
5LR2HR 2138833 13.47483 5319 -0.000118 Dominated by 0LR3HR 
5LR1HR 2145156 13.47483 6323 -0.000003 Dominated by 0LR3HR 
3LR3HR 2396549 13.47192 -216808 0.000898 Dominated by 0LR3HR 
3LR1HR 2403858 13.47185 258702 -0.002980 Dominated by 0LR3HR 
1LR1HR 2613357 13.47102 209499 -0.000832 Dominated by 0LR3HR 
 
 
Table A5.14.15 COL reimbursement KRW 1,650,000 
 
 Cost QALY inc Cost inc QALY ICER  
No_COL  4377.96 13.48582       
0LR3HR 49969.83 13.58154 45592 0.095721 476,300 
0LR2HR 52423.96 13.58149 2454 -0.000052 Dominated by 0LR3HR 
0LR1HR 55018.97 13.58146 2595 -0.000026 Dominated by 0LR3HR 
5LR3HR 639441.65 13.47495 584423 -0.106509 Dominated by 0LR3HR 
5LR2HR 641031.67 13.47483 1590 -0.000118 Dominated by 0LR3HR 
5LR1HR 642926.17 13.47483 1895 -0.000003 Dominated by 0LR3HR 
3LR3HR 718147.80 13.47192 -64938 0.000898 Dominated by 0LR3HR 
3LR1HR 720336.13 13.47185 77410 -0.002980 Dominated by 0LR3HR 
1LR1HR 783085.54 13.47102 62749 -0.000832 Dominated by 0LR3HR 
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Table A5.14.16 COL age 50-75 
  Cost QALY inc Cost inc QALY ICER  
No_COL  4378 13.48582 0 0   
0LR3HR 7293 13.58154 2915 0.09572 30,451 
0LR2HR 7478 13.58149 185 -0.00005 Dominated by 0LR3HR 
0LR1HR 7673 13.58146 195 -0.00003 Dominated by 0LR3HR 
5LR3HR 48368 13.47503 40695 -0.10643 Dominated by 0LR3HR 
5LR2HR 48489 13.47491 122 -0.00012 Dominated by 0LR3HR 
5LR1HR 48633 13.47491 143 0.00000 Dominated by 0LR3HR 
3LR3HR 54303 13.47192 5670 -0.00299 Dominated by 0LR3HR 
3LR1HR 54466 13.47185 164 -0.00007 Dominated by 0LR3HR 
1LR1HR 59176 13.47102 4709 -0.00083 Dominated by 0LR3HR 
 
Table A5.14.17 COL age 40-80 
  Cost QALY inc Cost inc QALY ICER  
No_COL  6270 14.871115       
0LR3HR 8949 15.025109 2679 0.154 17,396 
0LR2HR 9127 15.025042 178 0.000 Dominated by 0LR3HR 
0LR1HR 9315 15.024999 188 0.000 Dominated by 0LR3HR 
5LR3HR 49528 14.855246 40213 -0.170 Dominated by 0LR3HR 
5LR2HR 49626 14.855110 98 0.000 Dominated by 0LR3HR 
5LR1HR 49760 14.855107 135 0.000 Dominated by 0LR3HR 
3LR3HR 54851 14.851740 5091 -0.003 Dominated by 0LR3HR 
3LR1HR 54994 14.851669 143 0.000 Dominated by 0LR3HR 
1LR1HR 59319 14.850738 4325 -0.001 Dominated by 0LR3HR 
 
Table A5.14.87 Non-risk based strategy compared to No_COL  
  Cost QALY inc Cost inc QALY ICER  
No_COL  4489 13.486132      Dominant 
3LR3HR 54495 13.471932 50006 -0.01420 Dominated by No_COL 
1LR1HR 59253 13.471011 4758 -0.00092 Dominated by No_COL 
 
 
Table A5.14.19 Risk-based strategies compared to no_COL  
  Cost QALY inc Cost inc QALY   
No_COL  4489 13.486132       
0LR3HR 7395 13.584507 2906 0.09838 29538 
0LR2HR 7580 13.584454 185 -0.00005 Dominated by 0LR3HR 
0LR1HR 7775 13.584427 195 -0.00003 Dominated by 0LR3HR 
5LR3HR 48710 13.475073 40935 -0.10935 Dominated by 0LR3HR 
5LR2HR 48827 13.474953 117 -0.00012 Dominated by 0LR3HR 
5LR1HR 48969 13.474950 142 0.00000 Dominated by 0LR3HR 
3LR3HR 54495 13.471932 5526 -0.00302 Dominated by 0LR3HR 
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Table A5.15 Quality assessment: cost-utility analysis of COL surveillance 
in CRCS, NHI Korea  
1. Was the research question stated?  Y 
2. Was the economic importance of the research question stated?  Y 
3. Was/were the viewpoint(s) of the analysis clearly stated and justified?  Y 
4. Was a rationale reported for the choice of the alternative programmes or 
interventions compared?  
Y 
5. Were the alternatives being compared clearly described?  Y 
6. Was the form of economic evaluation stated?  Y 
7. Was the choice of form of economic evaluation justified in relation to the 
questions addressed?  
Y 
8. Was/were the source(s) of effectiveness estimates used stated?  Y 
9. Were details of the design and results of the effectiveness study given (if based 
on a single study)?  
NA 
10. Were details of the methods of synthesis or meta-analysis of estimates given 
(if based on an overview of a number of effectiveness studies)?  
NA 
11. Were the primary outcome measure(s) for the economic evaluation clearly 
stated?  
Y 
12 Were the methods used to value health states and other benefits stated?  Y 
13. Were the details of the subjects from whom valuations were obtained given?  Y 
14. Were productivity changes (if included) reported separately?  NA 
15. Was the relevance of productivity changes to the study question discussed?  NA 
16. Were quantities of resources reported separately from their unit cost?  N 
17. Were the methods for the estimation of quantities and unit costs described? Y  
18. Were currency and price data recorded?  Y 
19. Were details of price adjustments for inflation or currency conversion given?  NA 
20. Were details of any model used given?  Y 
21. Was there a justification for the choice of model used & the key parameters on 
which it was based?  
Y 
22. Was the time horizon of cost and benefits stated?  Y 
23. Was the discount rate stated/justified?  Y 
24. Was an explanation given if cost or benefits were not discounted?  NA 
25. Were the details of statistical test(s) and confidence intervals given for 
stochastic data?  
Y 
26. Was the approach to sensitivity analysis described?  Y 
27. Was the choice of variables for sensitivity analysis justified?  Y 
28. Were the ranges over which the parameters were varied stated?  Y 
29. Were appropriate comparisons made when conducting the incremental 
analysis? 
Y 
30. Was an incremental analysis reported?  Y 
31. Were major outcomes presented in a disaggregated as well as aggregated 
form?  
Y 
32. Was the answer to the study question given?  Y 
33. Did conclusions follow from the data reported? Y 
34. Were conclusions accompanied by the appropriate caveats?  Y 
35 Were generalisability issues addressed? P 
N no; NA not applicable; P partly; Y yes 
